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IntroduCtIon and  




Although consistently ranked number one in the European Health Consumer 
Indexsince 20081, the Dutch Health Care System is seen as one of the most ex-
pensive healthcare systems in Europe 2,3. In the past, countless attempts to reduce 
healthcare costs have been tried, like enforcing practices guidelines, capitation of 
hospital’s budgets or making patients consumers. So far, none had much impact. 
Perhaps one of the reasons for the lack of success of these earlier fixes is the failure 
to define the overall goal: improving value for patients 4. As defined by Michael 
Porter, value means the health outcomes achieved that matter to patients relative 
to the cost of achieving those outcomes. Moving from volume and profitability of 
services provided, to a high-value health care delivery system might be accom-
plished by following the six components of Michael Porters value agenda. First, 
health care providers should organize into Integrated Practice Units (IPUs). In an 
IPU, a dedicated team made up of both clinical and nonclinical personnel provides 
the full care cycle for the patient’s condition. Second, clinical outcomes and costs 
should be measured at patient level. Third, health care providers and payers should 
move from ‘fee for services’ systems to ‘bundled payments for care cycles’. Fourth, 
services should be provided at the right location for each service line and therefore 
hospitals should work together to integrate care delivery across separate facili-
ties. Fifth, superior health care providers for particular medical conditions need to 
serve more patients and extend their reach through strategic expansion. Six, the 
preceding five components are powerfully enabled by a supporting information 
technology platform (Figure 1) 4.
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Figure 1. The Value Agenda by professor M.E. Porter
Source M.E. Porter et al. The strategy that will fi x health care. Harvard Business Review 2013.
Measuring clinical outcomes for every pati ent
Despite the important societal and economic role the health care system fulfi lls, it 
sti ll lags behind when it comes to standardized reporti ng processes. In the past, data 
to compare the performance of diff erent health care providers were scarce. With 
Sweden as a pioneer, several nati on-wide clinical registries (audits) have been initi -
ated in the Western world, like the English Lothian and Borders large bowel cancer 
project and the United States Nati onal Surgical Quality Improvement Program, all 
leading to demonstrable improvement in clinical outcomes and smaller variati on 
between providers 5-7. With the introducti on of the Dutch Surgical Colorectal Audit 
(DSCA) in 2009, robust quality informati on became available, enabling monitoring, 
evaluati on, and improvement of surgical colorectal cancer care in the Netherlands. 
12
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The DSCA dataset covers 3 aspects: case-mix variables (e.g., age, sex, and comor-
bidity) necessary for hospital comparison; process variables (e.g., wait times, 
multidisciplinary team meetings, complete colonoscopy); and outcomes of care 
(e.g., mortality, length of hospital stay, number of lymph nodes, and complications 
like anastomotic leakage, pneumonia, or reinterventions) all measured at patient 
level. Since the introduction of the DSCA, guideline compliance for diagnostics, 
preoperative multidisciplinary meetings and standardized reporting increased and 
post-operative morbidity and mortality declined 8,9. Besides from facilitating the 
improvement in outcomes, population-based databases provide important clinical 
data for research as well, especially from patients often not eligible for RCTs 10.
Colorectal cancer
Colorectal cancer is among the top three leading cancers in terms of new cases as 
well as cancer related mortality in Europe and the United States of America 11,12. 
Most colorectal carcinomas develop through an adenoma - carcinoma sequence, 
therefore underlining the need for early detection of adenomatous polyps, e.g. by 
national screening programs or colonoscopy in high-risk patients. In the Nether-
lands between 8000-10000 procedures for primary colorectal cancer are performed 
each year. The cancer and nearby tissue is removed and either an anastomosis 
(Figure 2 or a stoma is constructed (or both, which can be more likely in the case 
of rectal cancer). The two major approaches for colorectal cancer surgery are open 
abdominal surgery, usually performed through a midline incision, or laparoscopic 
surgery. Between 2009 and 2015, laparoscopic approach in the Netherlands in-
creased from 35% to 70% for colon cancer resections and from 35% to 85% for 
rectal cancers resections 13. Although colorectal cancer resections are commonly 
performed, they are still associated with a disproportional share of complications 
in general surgery 14, with mortality and morbidity rates ranging up to 1.2-4.8% and 
15-25% respectively 13. 
13
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OUTLINE OF THIS THESIS
The Dutch Value Based Health Care study
In 2012 a pilot study combined the detailed clinical data of the DSCA with cost-price 
information for six hospitals. Results of this pilot study led to the initiation of the 
Dutch Value Based Health Care (DVBHC)-study. The purpose of the DVBHC-study 
was to investigate possible relations between quality and costs of colorectal cancer 
surgery. Twenty-nine hospitals were approached for participation and analyses 
were performed from a scientific perspective. Translation of patient level resource 
utilization into costs for each hospital was provided by Performation (Bilthoven, 
The Netherlands), a healthcare consultancy firm providing patient level costing 
(using time-driving activity-based costing) 15. The dataset of the Dutch Value Based 
Health Care study was used for chapters 3, 4, 5, 7, 8 and 9.
Surgical auditing and hospital costs
Recent literature suggests that focus in health care should shift from reducing costs 
to improving quality; where quality of health care improves, cost reduction will 
follow 16. Surgical auditing could facilitate this process, since availability of key data 
on processes and outcomes is one of the cornerstones for quality improvement. 
However quality improvement by surgical auditing had been described earlier, 
it’s relation to cost reduction is poorly investigated. A systematic review of the 
Figure 2. Colon cancer resection
Before and after a colon resection with construction of a primary anastomosis (image retrieved from the 
National Cancer Institute, Rockville, Maryland, United States of America).
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relationship between surgical auditing and cost-evaluation is reported in chapter 
2 17 of this thesis.
The DSCA identified significant reduction in mortality and severe complications after 
its initiation in 2009 8. To explore the effect of a nation-wide quality improvement 
initiative on healthcare costs, the DVBHC-database was analyzed to investigate 
whether the quality improvement between 2010 and 2012 for the participating 29 
hospitals was accompanied by cost-reduction as well. Moreover, identification of 
‘best performing hospitals’ was explored by looking at quality and costs at hospital 
level. The results are reported in chapter 3 18. 
Colorectal cancer surgery is commonly performed however it is associated with a 
disproportionate share of adverse events in general surgery 14. Since adverse events 
are associated with extra hospital costs it seems important to explicitly discuss the 
costs of complications and the risk factors for high-costs after colorectal surgery. 
Obviously, a decline in complication rates after colorectal surgery will be of most 
benefit to the patients, however one might argue that a business case for quality 
improvement can be made as well. Both items are reported in chapter 4 19. 
Laparoscopic techniques and hospital costs 
During the last two decades, laparoscopic resection has developed as a commonly 
accepted surgical procedure for colorectal cancer. However, there have been ques-
tions regarding the cost-efficacy, mostly because of prolonged operation time and 
higher costs of operation materials (e.g. disposables) 20,21. The DVBHC-database 
was used to compare actual 90-day hospital costs between elective open and 
laparoscopic colon and rectal cancer resection. Analyses were performed by using 
sub-group analyses based on operative risk and reported in chapter 5 22. 
The Jeroen Bosch Hospital (Den Bosch, The Netherlands) is one of the Dutch pio-
neers in performing single port laparoscopy (SPL) for colorectal cancer and Jeroen 
Bosch Hospital’s surgeons started using SPL in 2011. Since SPL is a relatively new 
technique, little is known about is effect on hospital costs. In chapter 6 23 we de-
scribe clinical and financial outcomes between SPL and conventional laparoscopy 
for colorectal cancer performed at the Jeroen Bosch Hospital. 
15
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High-risk patients and hospital costs
Frail patients are at high risk for developing complications after major surgery 
and therefore detailed performance information of those patients is of interest 
for healthcare providers. Moreover, due to increasing health care costs, discussion 
regarding increased hospital costs when operating high-risk and/or frail patients 
is rising. To facilitate this discussion, we analyzed hospital costs of two specific 
sub-groups suffering from high complication rates. Firstly, the impact of obesity 
on hospital costs is reported in chapter 7 24. Since evidence from general surgery 
suggest that there seems to be a so-called “obesity paradox” (lower mortality 
rates after surgery for pre-obese and mildly obese patients as compared to normal 
weight patients) 25, this was also investigated in this study. Secondly, hospital costs 
of the oldest old colorectal cancer patients (age 85 and older) were analyzed and 
the results are reported in chapter 8 26.
Reimbursement and quality improvement
The current reimbursement system in the Netherlands is not contributing to any 
improvement in value of care. At the moment, colorectal cancer reimbursement is 
partly based on length of hospital stay (with a cut-off at day 28). Although not very 
likely because of the integrity of healthcare providers, it might even provide a per-
verse stimulant (e.g., complications will result in longer hospital stay and therefore 
result in a higher reimbursement). As suggested by Michael Porter, reimbursement 
in healthcare should be tied to overall care for the patient and should include 
severity adjustments and (long-term) care guarantees that hold the provider re-
sponsible for avoidable complications 27. Based on the subgroup analyses showed 
in chapter 5 22, an alternative reimbursement system for colorectal cancer surgery 
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Surgical auditing has been developed in order to benchmark and to facilitate qual-
ity improvement. The aim of this review is to determine if auditing combined with 
systematic feedback of information on process and outcomes of care results in 
lower costs of surgical care.
Method
A systematic search of published literature before 21-08-2013 was conducted in 
Pubmed, Embase, Web of Science, and Cochrane Library. Articles were selected if 
they met the inclusion criteria of describing a surgical audit with cost-evaluation.
Results
The systematic search resulted in 3608 papers. Six studies were identified as rel-
evant, all showing a positive effect of surgical auditing on quality of healthcare and 
therefore cost savings was reported. Cost reductions ranging from $16 to $356 per 
patient were seen in audits evaluating general or vascular procedures. The highest 
potential cost reduction was described in a colorectal surgical audit (up to $1,986 
per patient).
Conclusions
All six identified articles in this review describe a reduction in complications and 
thereby a reduction in costs due to surgical auditing. Surgical auditing may be of 
greater value when high-risk procedures are evaluated, since prevention of adverse 
events in these procedures might be of greater clinical and therefore of greater 
financial impact.
Implication of key findings
This systematic review shows that surgical auditing can function as a quality instru-
ment and therefore as a tool to reduce costs. Since evidence is scarce so far, further 
studies should be performed to investigate if surgical auditing has positive effects 
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to turn the rising healthcare costs around. In the future, incorporating (actual) cost 
analyses and patient-related outcome measures would increase the audits’ value 




By acknowledging the importance of reliable and valid quality information in health-
care, in the last decades, surgical audits have been initiated in several countries. 
Surgical auditing is a quality instrument that collects detailed clinical data from 
health care providers, which is used to improve quality of care by timely feedback 
to clinicians about their (case-mix adjusted) results and facilitate benchmarking 
between participating hospitals 1. Moreover, surgical auditing provide useful infor-
mation of patients usually not eligible for clinical trials and are therefore of great 
value for all day practice 2.  With Sweden as a pioneer 3, countries like the United 
Kingdom (Lothian and Borders large bowel cancer project) 4, the United States 
(National Surgical Quality Improvement Program) 5 and the Netherlands (Dutch 
Surgical Colorectal Audit) 6 developed and implemented nationwide surgical audits 
as well.
As raised by Michael E. Porter, the overall goal in health care should be maximizing 
value for patients. Value is defined as ‘the health outcomes achieved that mat-
ter to patients, relative to costs of achieving those outcomes’ 7,8. One of the six 
components of Porter’s Value Based Health Care is ‘measurement of outcomes and 
costs for every patient’. As emphasized by Larsson et al. 3, measurement of out-
comes by surgical audits perfectly facilitates this process of improving healthcare. 
With auditing, results are systematically measured and therefore might improve 
outcomes 9,10. 
Despite its important societal and economical position, the healthcare industry 
has been lagging behind regarding the availability of key data on process and 
outcomes of care, when compared to other industries where product evaluation 
is standardly embedded in the production process. Most often, focus is on patient 
care and quality of care instead of costs and cost reduction. Especially in the era 
of rapidly increasing healthcare costs, evaluation of treatments and its costs might 
be highly prioritized in order to reduce costs and provide good value healthcare. 
In the literature so far, many articles have been published describing a relationship 
between surgical auditing and quality improvement. However, surgical auditing in 
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combination with cost evaluation is described less often. Therefore, this systematic 
review aims to evaluate the effects of surgical auditing on hospital costs.
METHODS
Search strategy
A systematic search of published literature before 21-08-2013 was conducted in 
Pubmed, Embase, Web of Science, and Cochrane Library. A specialized librarian 
of our institution constructed the search. No MeSH terms for studies related to 
‘audit’, as in quality instrument that collects detailed clinical data from health care 
providers and ‘costs’, as in financial expenditure were available. Therefore, the 
search strategy included a variety of search terms describing ‘audit’ and ‘costs’ 
in order to prevent exclusion of relevant articles. Search terms on auditing (e.g., 
‘audit’, ‘outcome and process assessment’, ‘NSQIP’, ‘benchmark’, ‘outcome regis-
try’) and search terms on costs (e.g., ‘finance’, ‘economic’, ‘costs’) were combined 
with search terms on surgery (e.g., ‘surgery’, ‘surgeon’), see appendix 1 for the 
complete search.  Meeting abstracts, duplicates and non-English-language studies 
were excluded. 
Selection of studies
Three authors (J. G., A. v. B., M. W.) defined the inclusion criteria. Articles were 
included if they met the following criteria: (1) at least one process or outcome 
indicator was measured or an audit was described which had been established 
to monitor and evaluate quality of care, (2) the indicator or audit focused on 
patient care within the surgical department, (3) the indicator or surgical audit 
itself described cost evaluation over time. Two investigators (J. G., A. v. B.) inde-
pendently reviewed each title and, if applicable, the abstract was reviewed. The 
articles included after screening title and abstract, were evaluated by reading 
the complete manuscript. Disagreements on selection of a study were solved by 
deliberation between the two investigators or by consulting a third reviewer (M. 
24
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W.). For additional relevant articles, reference lists and citations of the included 
studies were verified.
Calculations
All costs are stated in U.S. dollars and inflated to 2013 using the Consumer Price 
Index11, unless otherwise described. In the case of foreign currency the currency 
was first converted to U.S. dollars using the yearly average currency exchanges 
rate 12. If applicable, the effect on costs per patient due to surgical auditing was 




The systematic search revealed a total of 5,505 citations. After excluding duplicates 
and meeting abstracts, 3,608 articles were eligible for evaluation. Main reason for 
exclusion criteria was studies revealing clinical pathways or population-based stud-
ies instead of audits with regular feedback and benchmark. Furthermore, studies 
not showing any information on costs were excluded.
Twenty-nine articles met the inclusion criteria on title and abstract. However, 16 
articles were excluded after reading the manuscript because no surgical audit was 
described (inclusion criterion one). Although all remaining 13 articles described 
an audit in a surgical setting (inclusion criterion two), another seven articles were 
excluded since they did not show any data on cost reduction over time (inclusion 
criterion three). Some of those articles theorize about cost reduction or costs effec-
tiveness due to surgical auditing, but do not describe actual financial calculations 
10,13-15. 
A total of six articles met the predefined inclusion criteria 16-21. The reference lists of 
these six studies revealed no new articles. The study selection is shown in Figure 1. 
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Auditi ng and costs
All six studies describe a relati onship between surgical auditi ng and cost reducti on. 
However, three studies based their analyses on non-original clinical data 19-21 and 
were therefore analyzed separately (Table 1).
Figure 1. Selecti on process 




Englesbe et al.20 described the potential for payers to participate in quality im-
provement programs by supporting 80 % of data collection costs and all of the 
coordinating center costs. If a reduction of surgical complications (general and 
vascular surgery) by 3 % per year was established by the Michigan Surgical Quality 
Collaborative (MSQC); the payer would save $2.81 million (2007: $2.5 million) on 
the program after 3 years. Gordon et al. 21 estimated the potential cost savings 
for colorectal surgery in Australian hospitals. Savings were attributed to a surgi-
cal self-audit system by combining existing literature on colorectal cancer surgery 
complications and effectiveness of surgical audit with financial data. A potential of 
$24.7 million (2009: AU $30.3 million) could be saved for colorectal cancer surgery 
in Australian hospitals each year by implementing surgical self-auditing. The third 
Table 1. Included articles using non-original clinical data
First author Englesbe Gordon Larsson
Year of publication 2007 2010 2013






‘effectiveness of surgical 
audits’









Setting 15 United States hospitals Australian hospitals Swedish hospitals
Start Audit 2005 Not applicable 1979
Estimated clinical 
outcome**
3% complication reduction 
based on earlier published 
data 
50% reduction of 
adverse events based 
on literature
Reduction of 750 hip 
revisions a year as 




$833,333) per year for 15 
hospitals***
$24 million (2009: 
AU$ 30,3 million) per 
year for all Australian 
hospitals
$14.5 million (2011: $14 




$18 (2007: $16)*** $1,986 (2009: AU$ 
2,436)
Not described
* Clinical data retrieved from American College of Surgeons - National Surgical Quality Improvement Pro-
gram, ** outcomes are estimations since these articles did not use original data, ***analysis based on 
financial data in article.
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identified article by Larsson et al. 19 analyzed the potential of disease registries 
to improve healthcare in five different countries. Only for the Swedish Hip Ar-
htroplasty Register financial analyses were performed. Based on registry data (no 
details specified), an estimation was made that Sweden avoided 7,500 hip revisions 
between 2000 and 2009, if Sweden’s revision burden had been as high as that 
of the United States in the same period. Given costs of $19,159 (2011: $18,500) 
per revision (financial analyses not further specified) Larsson et al. estimated that 
$14,499 million (2009: $14 million) could be avoided per year in revision costs for 
hip surgery.
Original clinical data
The other three articles, based on original data, were published in the last 4 years 
and retrieved their clinical data from the American College of Surgeons—National 
Quality Improvement Program (ACS-NSQIP) (Table 2) 16-18. 
For the financial analyses, one study referred to another article 20 describing a stan-
dardized price per complication 16. Another study used standardized complication 
prices based on the ACS-NSQIP Return Of Investment (ROI) calculator 18. The third 
article used ‘real costs’ using the hospital accounting database 17. 
The article from Henke et al.16 was from the same study group as Englesbe et al.20. 
Patient variables of vascular procedures (provided by ACS-NSQIP) for the original 
16 hospitals of the MSQC were used. Costs of one major complication were derived 
from the earlier article by Englesbe et al. 20 having a fixed price of $8,287. Between 
the first two years and the third year, a 2 % reduction in complication rate was 
achieved, leading to an average cost reduction of $186 (2008: $172) per patient. 
Hollenbeak et al.17 described an improvement in cost-effectiveness with longer 
duration in participation in the auditing program, for both general and vascular 
procedures in an academic setting. Where they report a cost of $27,658 (2009: 
$25,471) to avoid one postoperative event 1 year after initiation of the program, 
these expenditures declined to 28.7 % ($7,947 (2009: $7,319)) of the initial costs 
2 years after the initiation. By multiplying the savings of avoiding one postopera-
tive event in their studied population ($9829 (2009: $9,052)) with the reduction in 
postoperative events (3.63 %), the program saved an average of $356 (2009: $328) 
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Table 2. Included articles using original clinical data
Article characteristics   
First author Henke Hollenbeak Guillamondegui
Year of publication 2010 2011 2012
Audit characteristics   
Name MSQC* ACS-NSQIP TSQC*
Procedures 
analysed
Vascular surgeries General and vascular 
surgeries
General and vascular 
surgeries
Setting 16 U.S. hospitals 1 U.S. academic hospital 10 U.S. hospitals
Start Audit 2005 Jul. 2007 May 2008
Control period Apr. 2005 - Mar. 2007 Study 1: Jul. 2007 - Dec. 
2007 Study 2: Jul. 2007 - 
Jun. 2008
Jan. 2009 - Dec. 2009
Audit period Apr. 2007 - Mar. 2008 Study 1: Jul. 2008 - Dec. 
2008 Study 2: Jul. 2008 - 
Jun. 2009
Jan. 2010 - Dec. 2010
Summary QI 
program
Timely feedback of 
data and comparison 
between institutions
Not specified (start of QI 
program in July 2008) 
Sharing surgical process 
and out-come data 
between hospitals
Clinical characteristics   
Study 
size
Control 2,453 patients Study 1: 699 patients Study 
2: 1,230 patients
14,205 patients





2% decrease in overall 
morbidity. 
Not described Significant reduction in: 
SSI, >48 ventilator hours, 
graft/host/flap failure, 
RF, wound disruption
Financial characteristics   







No Yes (2009: $138,821 a year) Yes (ROI calculator)
Financial analyses Extrapolated cost savings 
from complication rates 
(earlier study)
Costs-to-charges 
methodology, audit group 
included NSQIP fee 
Complication rate 




$186 (2008: $172) $356 (2009: $328)** $238 (2009: $219)**
Abbreviations: MSQC= Michigan Surgical Quality Consortium, ACS-NSQIP= American College of Surgeons 
- National Surgical Quality Improvement Program, TSQC= Tennessee Surgical Quality Consortium, U.S.= 
United States, QI= quality improvement, ROI= Return On Investment, SSI= surgical side infection, RF= 
renal failure.
* Clinical data retrieved from ACS-NSQIP, **calculation based on financial data in article.
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per patient. Costs of the audit itself [$150,740 (2009: $138,821)], for example the 
NSQIP license fee and salary for a clinical nurse reviewer, were taken into account. 
The study of Guillamondegui et al. 18 described improved clinical outcomes between 
the first and second year after implementation of a regional surgical quality collab-
orative of ten hospitals (the Tennessee Surgical Quality Collaborative). The reduc-
tion in complications of general and vascular procedures was translated to costs 
with the use of the ACS-NSQIP ROI calculator. The ROI calculator calculates costs 
of complications and includes costs for enrollment and participation in NSQIP. Net 
cost avoided between the first and second year was $2,276,911 (2011: $2,198,543) 
per 10,000 surgical cases. The authors outline that although the mechanisms for 
these changes are likely multifactorial, the Tennessee Surgical Quality Collabora-
tive established communication, process improvement, and discussion among the 
members.
DISCUSSION
In this systematic review, a relationship between surgical auditing and reduced 
healthcare costs was identified. Though frequently assumed in the literature, 
only six articles actually described this relationship. All identified studies suggest 
that besides quality improvement, surgical auditing has the potential to reduce 
in-hospital costs. 
With the continuous rise of healthcare costs, healthcare providers, insurance com-
panies, governments, and patients demand for information and transparency on 
performance of hospitals. Surgical audits facilitate this process and, most impor-
tant, surgical auditing might lead to improved outcomes for patients. Whether this 
involves orthopedic surgery 22, colorectal surgery 6, vascular surgery 16 or general 
surgery 9,10,17,18, all show an association with  improved clinical outcome. Because of 
the cost- and time-consuming exercise of data collection 23, the use of surgical au-
diting as a quality instrument will catalyze only when it proves to be cost-effective. 
Four of the identified articles 17,18,20,21 incorporated costs of the audit itself in their 
calculations and therefore analyzed the actual cost-effectiveness of surgical audits. 
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These four studies showed larger reduction in costs (due to quality improvement) 
compared to the audit-participation-costs, and therefore overall cost reduction 
was established.
Notable variation was seen in the amount of cost reduction per patient between 
the reported studies. Four articles using data from the ACS-NSQIP 16-18,20 described 
savings in a small spectrum ranging from $18 (2007: $16) 20 to $356 (2009: $328) 
17 per patient. All these studies were based on vascular or general surgical proce-
dures, however separate financial analyses for low- or high-risk procedures were 
not made. Gordon et al. 21 described the highest (potential) cost reduction, reach-
ing up to $1,986 (2009 AU$2,436) per patient. However the reported reduction 
of complications by 50 % accomplished with ‘self-auditing’, might overestimate 
clinical reality 6. A factor that attributed to the high reduction in costs in this study 
might be the selection of colorectal cancer patients. In high-risk procedures, like 
colorectal cancer resections, the prevention of adverse events, such as anastomotic 
leakage, might be of greater clinical 24 and financial impact. 
Remarkable, Hollenbeak et al. 17 found further cost reduction when audits were 
used for a longer period. This is also seen in the study by van Leersum et al. describ-
ing the first three years of the Dutch Surgical Colorectal Audit (DSCA). Between 
the first and the second year of the DSCA, the improvement in quality seemed 
to be less distinct then between the second and third year 6. Hollenbeak et al.17 
explained the improved cost effectiveness after a longer duration of participation 
by the later onset of the effect of improvement activities. Whether results further 
improve with even longer duration of a surgical audit should be addressed in future 
studies.
The exact mechanism of cost reduction by surgical auditing is sometimes hard to 
identify. As seen in the literature, occurrence of complications goes hand in hand 
with increased hospital costs 25,26, for example due to prolonged length of hospital 
stay, prolonged intensive care stay and increased reoperations. The cornerstone of 
surgical auditing is collecting performance data and providing (benchmarked) feed-
back tot surgeons, leading to identification of existing problems in the care process. 
Knowledge of performances can facilitate quality improvement of the participating 
hospitals, resulting in fewer complications 6 and therefore fewer costs. 
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A note of caution should be made in ascribing improved quality of care (or cost 
reduction) to surgical auditing, since possible occurrences of secular trends not 
registered in the audit could influence outcomes as well 17,27. Also continuous 
development of new surgical techniques might have beneficial effect on its own. 
For example, the development of laparoscopic techniques may result in lower 
complication rates, shorter length of hospital stay, and therefore lower costs 28. 
Quality improvements initiatives in individual hospitals (introduced independently 
from the surgical audit) might have led to overestimation of auditing results. Also 
participation in a registry might have some kind of Hawthorne-effect as addressed 
by Guillamondegui et al. 18. Nevertheless, without availability of key data on out-
comes, health care organizations are flying blind in deciding what should be targets 
for quality improvement initiatives or in deciding which ‘peer-hospitals’ could serve 
as best practice hospitals, and therefore underlying the need of audits.
An opportunity to improve insight in the value of healthcare is the introduction 
of more accurate cost calculations when evaluating care processes. Hollenbeak et 
al. 17 analyzed costs for each admission, though insights in these calculations were 
not given. Also, the use of the ACS NSQIP ROI calculator 18 or Diagnose Related 
Groups (DRG) instrument 21 is a proxy of costs of complications, and actual costs 
undoubtedly vary between hospitals. Henke et al. 16, Englesbe et al. 20 and Larsson 
et al. 19 used a fixed price for complications by referring to earlier published articles 
but detailed descriptions were not given. 
As suggested by Porter et al., calculating true medical costs would give a more ac-
curate financial perspective 7 and allows to determine the value of care. and allows 
one to determine the value of care. To do so, healthcare providers must measure 
costs at medical condition level and for the complete cycle of care. Therefore, actual 
costs should be used instead of declaration data. Calculating actual costs requires 
understanding of the resources used in patient’s care, including staff, equipment, 
medication, facilities, and support costs (IT, maintenance). The methodology Porter 
recommends to calculate the costs is time-driven activity-based costing (TD-ABC) 
29,30: actual costs are calculated by identifying all clinical services in a healthcare 
organization and assigning both direct and indirect costs to each clinical service. 
Using time estimates, or actual data when available (for example in the operation 
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room), for each service allows to specifically allocate all costs. This methodology 
is not commonly used in healthcare, and therefore not mentioned in literature. 
Articles describing an accurate translation of resource utilization into costs are 
scarce 31,32. In general, cost-based studies often use DRGs 21 or insurance claim data 
33,34 to indicate expenditures. These methods do not seem to provide an accurate 
economic perspective either, since DRGs do not represent ‘real costs’ but mainly 
depend on the classification system used 35,36. Moreover, since no uniformity or 
transparency of costs registration in various hospitals exists, most of these ‘real 
cost’ studies are limited to single-center settings 17,31,32. If used in a multi-center 
setting, these costs are often retrieved from a single hospital’s accounting system 
and extrapolated to the other participating institutions 37. 
Limitations
No specific MeSH terms related to ‘audit’ and ‘costs’ were used. Using these two 
terms would result in a broad spectrum of articles describing audit as in ‘any ret-
rospective database’ or costs as in ‘non-financial costs’. Restriction of the search 
(e.g., using ‘financial costs’ instead of‘costs’) consequently increases the potential 
of missing relevant literature. Therefore, the search strategy included a variety 
of search terms describing ‘audit’ and ‘costs’ (see appendix 1). This resulted in 
many articles describing clinical pathways or population-based studies without a 
feedback mechanism, which were excluded for this reason (exclusion criterium 1). 
Because we did not find any new related articles by checking references and cita-
tions of the six included studies, the search terms seem to be adequate. Though 
we used broad search terms, we only identified six articles as relevant. The three 
studies using original clinical data retrieved their data from 27 hospitals. Therefore, 
caution should be taken in generalization of our findings since results found in 
these hospitals may not be representative at other institutions. Finally, a major 
limitation of the investigated studies is the potential occurrence of publication and 
selection bias. Studies showing negative outcomes of surgical auditing might less 
likely to be submitted by the authors. Also the included studies were not designed 
as randomized controlled trials, therefore unattended selection bias might be 
introduced since the interventions (the audits themselves) were not allocated 
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randomly to patients. The results of this systematic review should be interpreted 
having this limitation in mind.
Future perspectives 
We were surprised by the lack of evidence for cost evaluation of surgical auditing. As 
addressed by Porter, measuring clinical outcomes and costs at patient level should 
be embedded in the quality improvement process of healthcare 7. In addition, the 
authors believe that combining clinical outcomes with patient reported outcome 
measures (PROMs) would provide an even stronger tool. Benchmarking hospitals 
on quality, costs, and PROMs could identify ‘best practices’ on all three dimensions, 
which will lead to higher quality of care with the use of fewer resources and less 
costs.
Although we only identified articles focused on hospital related costs, registries 
that cover the complete patient cycle should provide better insights. Long-term 
complications can be identified which might cover ‘hidden’ long-term costs. For 
example, in colorectal cancer surgery, the creation of a defunctioning stoma 
shortens length of hospital stay during the initial operation and lowers short-term 
complications 38. However, next to the impact on quality of life a stoma has, it 
also has serious long-term financial implications. Patients have a life time need for 
colostomy pouches and a constant risk for long-term complications 39 which are 
seen in up to fifty percent of the patients within ten year follow up 40. Increasing 
quality and reducing costs is the fundamental base of ‘value based health care’ 
7. Therefore, covering short- as well as long-term outcomes should be aimed for 
all health care evaluations. While surgical auditing has become more integrated 
in common practice, its effectiveness on costs needs to be evaluated as well, and 





Ideally, the overall quality improvement related to surgical auditing should be judged 
with the assessment of its costs. In literature, only six articles 16-21 have been pub-
lished so far, describing cost reduction due to auditing. Potential higher cost reduc-
tion is seen when the surgical audit is focused on high-risk procedures only, such 
as colorectal cancer surgery. Auditing could perfectly facilitate the decision- making 
process for reducing costs, as addressed by Porter et al. and Larsson et al.19,41. None-
theless, further studies should be performed to confirm whether surgical auditing 
has sustainable (long-term) effects in confining the rise in healthcare costs.
RECOMMENDATIONS 
In future, widespread introduction and continuous use of surgical auditing is re-
quired to evaluate and improve quality of medical care for patients. The main focus 
should be evaluation of high-risk procedures since prevention of adverse events in 
these procedures will have greater clinical and financial impact compared to low-risk 
procedures. Moreover, when financial outcomes are incorporated in the audit, cal-
culating those financial outcomes should be based on actual costs, for example using 
time-driven activity-based costing. In the future, covering the complete cycle of care 
and incorporating cost analyses and patient-related outcome measures would in-
crease the audits’ value and provide a complete overview of the value of healthcare. 
Further studies describing the audit’s value should include all of the above-men-
tioned elements, in order to provide more robust evidence for further implementa-
tion of auditing.
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Appendix 1. Pubmed, Embase, Web of Science and Cochrane search terms.
PubMed: 
Limits activated: English.
(“finance”[TIAB] OR “finances”[TIAB] OR “financial”[TIAB] OR “economics”[TIAB] 
OR “economic”[TIAB] OR “economics”[Majr] OR ((“costs”[TIAB] OR “cost”[TIAB]) 
AND (“reduction”[TIAB] OR “improvement”[TIAB] OR “health care”[TIAB] OR 
“healthcare”[TIAB] OR “hospital”[TIAB])) OR “euro”[TIAB] OR “dollar”[TIAB] 
OR “pound”[TIAB] OR “euros”[TIAB] OR “dollars”[TIAB] OR “pounds”[TIAB] OR 
“pound”[TIAB]OR €[tiab] OR $[tiab] OR £[tiab]) 
AND 
(“surgery”[Subheading] OR “Surgical Procedures, Operative”[Majr] OR 
“Surgery”[tiab] OR “Surgical”[tiab] OR “Surgeon”[tiab] OR “Surgery Department, 
Hospital”[Majr] OR “Specialties, Surgical”[Majr:noexp]) 
AND 
(“Outcome and Process Assessment (Health Care)”[Majr] OR “audits”[tw] OR 
“auditing”[tw] OR “audit”[tw] OR “Clinical Audit”[Mesh:noexp] OR “Medical 
Audit”[Mesh] OR “Outcome Assessment”[tiab] OR “Process Assessment”[tiab] OR 
“Quality Assurance, Health Care”[Majr] OR “Quality Assurance”[tiab] OR “Qual-
ity Management”[tiab] OR “Quality Assessment”[tiab] OR “benchmark”[tiab] OR 
“benchmarks”[tiab] OR “benchmarking”[tiab] OR “NSQIP”[text word] OR “National 
Surgical Quality Improvement Program”[text word] OR “outcome registry”[TIAB] 
OR “Outcome and Process Assessment”[TIAB] OR “Quality of Health Care”[TIAB] 
OR “Quality of Healthcare”[TIAB] OR “Quality Control”[Majr])
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Recent literature suggests that focus in health care should shift from reducing costs 
to improving quality; where quality of health care improves, cost reduction will fol-
low. Our primary aim was to investigate whether improving the quality of surgical 
colorectal cancer care, by using a national quality improvement initiative, leads to 
a reduction of hospital costs.
Study design
This was a retrospective analysis of clinical and financial outcomes after colorectal 
cancer surgery in 29 Dutch hospitals (9,913 patients). Detailed clinical data were 
obtained from the 2010 to 2012 population-based Dutch Surgical Colorectal Audit. 
Patient-level costs were measured uniformly in all participating hospitals and based 
on time-driven, activity-based costing. Odds ratios (OR) and relative differences 
(RD) were risk adjusted for hospitals and differences in patient characteristics.
Results 
Over 3 consecutive years, severe complications and mortality declined by 20% 
(risk-adjusted OR 0.739, 95% CI 0.653 to 0.836, p < 0.001), and 29% (risk-adjusted 
OR 0.757, 95% CI 0.571 to 1.003, p = 0.05), respectively. Simultaneously, costs dur-
ing primary admission decreased 9% (risk-adjusted RD -7%, 95% CI -10% to -5%, p < 
0.001) without an increase in costs within the first 90 days after discharge (RD -2%, 
95% CI -10% to 6%, p = 0.65). An inverse relationship (at hospital level) between 
severe complication rate and hospital costs was identified (R = 0.64). Hospitals with 
increasing severe complication rates (between 2010 and 2012) were associated 
with increasing costs; hospitals with declining severe complication rates were as-
sociated with cost reduction.
Conclusions
This report presents evidence for simultaneous quality improvement and cost 
reduction. Participation in a nationwide quality improvement initiative with con-
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tinuous quality measurement and benchmarked feedback reveals opportunities 
for targeted improvements, bringing the medical field forward in improving value 
of health care delivery. The focus of health care should shift to improving quality, 




Although consistently ranked number one in the European Health Consumer Index 
since 2008 1, the Dutch Health Care System is struggling with rising costs. As one of 
the most expensive healthcare systems in Europe, the expenditure rose to 13.2% 
of the gross domestic product in 2012 2. In the last decades, health care providers 
have sought for solutions to stop this ongoing rise of health care costs. In spite of 
the well-intended effort, such as enforcing clinical guidelines or focus on volume 
and profitability of services, results have been meager.
The cornerstone of potential cost reduction could be availability of key clinical data 
on processes and outcomes of care 3. Despite the important societal and economic 
role the health care system fulfills, it still lags behind when it comes to standardized 
reporting processes. In the past, data to compare the performance of different 
health care providers were scarce. With Sweden as a pioneer, worldwide clinical 
registries (audits) have been initiated on a regional or national level, leading to 
demonstrable improvement in clinical outcomes and smaller variation between 
providers 4-7. With the introduction of the Dutch Surgical Colorectal Audit (DSCA) in 
2009 8, robust quality information became available, enabling monitoring, evalu-
ation, and improvement of surgical colorectal cancer care in the Netherlands. The 
DSCA dataset covers 3 aspects: case-mix variables (e.g., age, sex, and comorbidity) 
necessary for hospital comparison; process variables (e.g., wait times, multidis-
ciplinary team meetings, complete colonoscopy); and outcomes of care (e.g., 
mortality, length of hospital stay, number of lymph nodes, and complications like 
anastomotic leakage, pneumonia, or reinterventions). Key performance indicators, 
accompanied by a national benchmark, are fed back to clinicians on a weekly basis. 
Since the introduction of the DSCA, postoperative morbidity and mortality have de-
clined. Despite the substantial registration effort, this might have led to significant 
savings in costs 7.  
To explore the effect of this nationwide quality improvement initiative on health 
care costs, we conducted a comprehensive multi-center study involving 29 Dutch 
hospitals, using detailed clinical data from the DSCA and financial data based on 
time-driven, activity-based costing 9. The aim of this study was to analyze whether 
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nationwide collection of key clinical data and benchmarked feedback on perfor-
mance indicators for colorectal cancer care lead to a reduction of hospital costs. 
Moreover, by combining and examining both clinical and financial outcomes, we 
examined whether identification of best practice hospitals, providing high quality 
colorectal cancer care for relatively low costs, is feasible.
METHODS
Clinical data
The dataset was retrieved from the DSCA, a population-based database in which 
detailed patient, tumor, diagnostic, procedural, and outcomes data are registered 
for all patients in the Netherlands undergoing resection of a primary colorectal 
carcinoma. The DSCA dataset is based on evidence-based guidelines, and each 
participating hospital appoints a surgeon responsible for (supervising) the data 
registration in a secured web form. Data are retrieved directly from the hospital 
information system (e.g., date of birth, sex, and unique patient identification 
number) and by manual data collection (e.g., tumor and operation characteristics). 
Data validity is achieved in various ways: by providing direct feedback on missing 
or erroneous data during data entry through quality control tools that are built in 
the program, by providing feedback information on the number of patients and 
completeness of the data per hospital, and by yearly external validation of the total 
dataset. The dataset shows nearly 100% completeness on most items and high 
accuracy level on validation (97% in 2012) against the Netherlands Cancer Registry 
7,8. A detailed description of the DSCA has been published recently 7,10. 
Financial data
The economic evaluation was conducted from a hospital perspective. As such only 
in-hospital costs were considered. Costs were taken into account from the day of 
initial surgery till discharge (primary admission) and up to 90 days after discharge 
(Q1). Information on resource use at patient level (e.g., laboratory orders, op-
eration room time, or ward days, Supplemental Table 1) was extracted from the 
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hospital information system from each participating hospital. For each hospital, 
translation of patient level resource use into costs was provided by Performation 
(formerly known as TRAG Performance Intelligence), a health care consultancy 
firm providing patient level costing and benchmarking products for more than 100 
hospitals across Europe 11,12. Costs were calculated using time-driven activity-based 
costing (TD-ABC) 9 which is an advanced method for understanding hospitals costs 
13,14. Cost price calculations were standardized by Performation, so uniformity in 
methodology existed between all participating hospitals. The most recent cost 
price model (2012) for each hospital was used for all 3 years (2010, 2011, and 
2012) to avoid differences due to inflation or the different models themselves. 
Different activities are grouped into 8 categories, as shown in Supplemental Table 
1. Specialists’ fees, medication costs, and costs for dialyses were excluded because 
registration of these parameters was not uniform in the participating hospitals, 
making equal comparison impossible.
Inclusion criteria
Hospital selection (n = 29) was based on the availability of detailed cost-price 
information for 3 consecutive years (2010, 2011, and 2012). The participating 
hospitals represent approximately one-third of the colorectal cancer procedures 
performed annually in the Netherlands (Supplemental Table 2), and 21 hospitals 
(72%) have a surgical teaching program. Patients undergoing surgical resection for 
primary colorectal cancer between January 1, 2010 and December 31, 2012 had to 
be registered in the DSCA before December 1, 2013. Minimal data requirements to 
consider a patient eligible for matching with the financial dataset were information 
on tumor location, date of surgery, and mortality status (10,101 eligible patients).
Match
The unique patient identification number combined with hospital of admission was 
used to match patients registered in the DSCA to their information in the financial 
database, resulting in a match of 98.1% (9,913 patients). A total of 188 patients 
(1.9%) without a match were excluded from analyses. 
47
ImprovIng QualIty and reduCIng hospItal Costs
3
Definitions
Primary outcomes measures for quality of health care were postoperative mortal-
ity, defined as in-hospital death or within 30-days after surgery, and severe com-
plications, defined as complications occurring during admission or within 30 days 
after surgery and leading to mortality, reintervention (operative or percutaneous), 
or a prolonged hospital stay of 14 days or more. The primary financial measure was 
total cost (primary admission up to 90 days after discharge). Other outcomes were 
length of hospital stay (starting from day of operation = day 1), costs of primary 
admission, costs of Q1 (first 90 days after discharge), and costs of primary admis-
sion and Q1 by category (as mentioned in Supplemental Table 1).
Analysis
Chi-square test and One-way Anova were used to investigate differences between 
patients’ characteristics in the 3 analyzed years (Table 1). Three separate analyses 
were performed in this study. Outcomes in the first 2 analyses were risk-adjusted 
where stated, because high-risk patients are not evenly distributed between hos-
pitals15. All significant (p < 0.10) risks factors (listed in Table 1) in univariate logistic 
regressions for severe complications were included in the multivariate model. Patient 
characteristics associated with severe complications were sex, BMI (categorical), age 
(categorical), comorbidity (Charlson score) 16, American Society of Anesthesiologists 
classification (ASA), presence of double tumor, location of tumor, stage of tumor 
(TNM), preoperative radiotherapy, resection of distant metastases, and urgency of 
resection. Patient characteristics associated with mortality were BMI, age, comorbid-
ity (Charlson score) 16, ASA classification, location of tumor, stage of tumor (TNM), 
preoperative radiotherapy, distant metastases, and urgency of resection. Because 
BMI had more than 5% missing values, they were coded as a separate category to 
include those patients in the statistical analysis. To model financial outcomes and 
severe complications, the same patient characteristics were used. 
The first method investigated differences in clinical and financial outcomes between 
the 3 consecutive years (Figure 1 and 2). Differences in outcomes between 2010 and 
2012 were shown as crude relative differences (RD). To investigate if differences be-
tween 2010 and 2012 were due to differences in patient characteristics or variability 
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Table 1. Patient, tumor and treatment characteristic of patients, stratified by year of operation
Total 2010 2011 2012  
N (%) N (%) N (%) N (%) p-value
Total  9 913 3 131 3 152 3 630  
BMI (mean)  26.1 26.0 26.2 26.1 0.22
Age (mean)  69.9 70.1 69.7 69.9 0.39
Charlson score Charlson 0 5 309 (3.6) 1 688 (53.9) 1 646 (52.2) 1 975 (54.4)
 Charlson 1 2 265 (22.8) 721 (23.0) 716 (22.7) 828 (22.8) 0.20
 Charlson 2+ 2 339 (23.6) 722 (23.1) 790 (25.1) 827 (22.8)
ASA score I-II 7 468 (75.3) 2 376 (76.3) 2 372 (75.8) 2 720 (75.0)
 III 2 239 (22.6) 681 (21.9) 712 (22.7) 846 (23.3) 0.45
 IV-V 164 (1.7) 59 (1.9) 46 (1.5) 59 (1.6)
Double tumor Yes 325 (3.3) 78 (2.5) 102 (3.2) 145 (4.0) 0.002
Tumor location Right colon 3 186 (32.1) 1 036 (33.1) 960 (30.5) 1 190 (32.8)
 Left colon 1 151 (11.6) 356 (11.4) 368 (11.7) 427 (11.8) 0.04
 Sigmoid 2 673 (27.0) 863 (27.6) 892 (28.3) 918 (25.3)
 Rectum 2 903 (29.3) 876 (28.0) 932 (29.6) 1 095 (30.2)
Tumor stage (TNM)
Stadium 
unknown 180 (1.8) 55 (1.8) 53 (1.7) 72 (2.0)
 Stadium 0 169 (1.7) 13 (0.4) 70 (2.2) 86 (2.4)
 Stadium 1 646 (6.5) 210 (6.8) 178 (5.7) 258 (7.1) <0.001
 Stadium 2 2 077 (21.0) 669 (21.6) 677 (21.8) 731 (20.2)
 Stadium 3 5 454 (55.0) 1 731 (55.8) 1 727 (55.5) 1 996 (55.1)
 Stadium 4 1 312 (13.2) 425 (13.7) 407 (13.1) 480 (13.2)
Preoperative RT None 7 439 (75.0) 2 388 (76.3) 2 311 (73.3) 2 740 (75.5)
 5 x 5 Gy 1 386 (14.0) 445 (14.2) 476 (15.1) 465 (12.8) 0.002
 60 Gy / else 1 088 (11.0) 298 (9.5) 365 (11.6) 425 (11.7)
Distant metastases Yes 1 038 (10.5) 333 (10.6) 346 (11.0) 359 (9.9) 0.32
Metastasectomy Yes 290 (2.9) 63 (2.0) 114 (3.6) 113 (3.1) 0.001
Extended resections Yes 845 (8.5) 273 (8.7) 264 (8.4) 308 (8.5) 0.88
Urgency of resection Urgent 1 334 (13.5) 432 (13.8) 440 (14.0) 462 (12.7) 0.26
Other characteristics*     
Surgical approach Laparoscopic 4 579 (46.2) 1 227 (39.8) 1 436 (45.6) 1 916 (52.8) <0.001
Anastomosis or stoma Anastomose 6 319 (63.8) 2 058 (67.6) 2 033 (65.4) 2 228 (65.5)
 
Anastomose 
& stoma 1 236 (12.5) 333 (10.9) 412 (13.2) 491 (14.4) 0.001
 Stoma 2 002 (20.1) 655 (21.5) 665 (21.4) 682 (20.1)
Abbreviations: CI, 95% confidence interval; BMI, Body Mass Index; ASA, American Society of Anaesthesi-
ologists risk score; Left colon, left colon and colon transversum; TNM, Classification of Malignant Tumors; 
RT, radiotherapy; Gy, gray. Statistical analyses performed using Chi-square test or one-way Anova. *Other 
characteristics are mainly based on surgeon-choice; therefore they were not used for composing the mul-
tivariate model for risk-adjustment.
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between hospitals, crude RDs were followed by (in parentheses) risk-adjusted RDs/
odds rati os (OR) for diff erences in pati ent characteristi cs and hospitals as random ef-
fects. Adjusted outcomes were esti mated by using univariate and multi variate mixed 
eff ects models with hospitals as random eff ects to account for the presence of vari-
ability between hospitals. Mixed eff ects models are designed to handle nested data 
(like pati ents in each hospital) and unequal group study. The likelihood rati o test, 
used to assess whether the variance of the random eff ect is signifi cant, was highly 
stati sti cally signifi cant in all esti mated models, suggesti ng that the mixed models 
are required for the outcomes under study 17,18. Because outcomes such as hospital 
length of stay and costs are right-skewed, a log-transformati on has been applied to 
the outcomes of interest before fi tti  ng the model of interest.
Figure 1. Clinical outcomes aft er colorectal surgery
 2010 2011 2012  Comparison 2010 vs 2012
Number of pati ents 3131 3152 3630  RD OR/ RD (95% CI)*   p-value*
Severe complicati on (%) 25.2% 22.0% 20.2%  -20% 0.739 (0.653 : 0.836) <0.001
Mortality (%) 4.2% 3.7% 3.0%  -29% 0.757 (0.571 : 1.003) 0.05
LOS (days) 13.5 12.4 11.7  -13% -11% (-14% : -8%) <0.001
Improved clinical outcomes between 2010 and 2012 (clinical data retrieved from the Dutch Surgical 
Colorectal Audit): Severe complicati on rate, mortality and length of hospital stay strati fi ed by year of sur-
gery. Arrow represents relati ve diff erence between 2010 and 2012. 
Abbreviati ons:  RD, relati ve diff erence; CI, confi dence interval; LOS, mean length of stay of primary admis-
sion. 
* Risk-adjusted OR’s and RD’s for diff erences in pati ent characteristi cs and hospitals as random eff ect.
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The second analysis focused on hospital performance in terms of costs and severe 
complicati on rate. An unadjusted descripti ve analysis (Figure 3A) and a risk-adjusted 
analysis (Figure 3B) were performed. To compute the risk-adjusted average costs 
or severe complicati ons rate per each center, a multi ple linear mixed regression 
model (log-transformati on has been applied) or a mixed regression model was 
used (with hospital as random eff ects to account for the presence of variability 
between hospitals).
For the third (descripti ve) analysis (Figure 4), hospitals were strati fi ed by whether 
they improved or worsened for severe complicati ons between 2010 and 2012: 
worsened hospitals (crude RD < 0%), improved hospitals (crude RD 0% to 10%), 
and strongly improved hospitals (crude RD > 10%). Unadjusted hospital averages 
for severe complicati ons and costs per pati ent (costs of primary admission up to 
90 days aft er discharge) were used because pati ent characteristi cs at hospital level 
hardly diff ered between 2010 and 2012 (data not shown). Means per group were 
calculated using hospital averages. Stati sti cal analyses were performed by using 
SPSS (version 22; IBM) and R (version 18). Confi dence intervals (CI) were stated at 
95%.
Figure 2. Financial outcomes aft er colorectal cancer surgery
Average costs of a colorectal cancer pati ent by year of surgery. Costs for primary admission signifi cant 
decreases without an increase in costs during Q1. Arrow represents relati ve diff erence 2010 vs 2012. Ab-
breviati ons: Q1, fi rst 90 days aft er discharge. * Signifi cant diff erent aft er risk-adjustment for diff erences in 
pati ent characteristi cs and hospitals as random eff ect (RD -7%, CI -10%: -5%, p<0.001).
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A total of 9,913 pati ents were eligible for analysis. All analyzed pati ent, tumor, and 
operati on characteristi cs of the studied populati on are shown in Table 1. 
Diff erences between three consecuti ve years
Between 2010 and 2012, severe complicati on rate, mortality rate, and length of 
hospital stay respecti vely declined by 20% (risk-adjusted OR 0.739, 95% CI 0.653 
to 0.836, p < 0.001), 29% (risk-adjusted OR 0.757, 95% CI 0.571 to 1.003, p = 0.05), 
and 13% (risk-adjusted RD -12%, 95% CI -15% to -9%, p < 0.001) (Figure 1). The me-
dian length of hospital stay declined from 9 days (2010) to 8 days (2012). Financial 
outcomes were grouped by resource category, as shown in Supplemental Table 1. 
Figure 4. Hospitals with strong quality improvement have higher reducti on in costs
Hospitals strati fi ed by relati ve diff erence for severe complicati on between 2010 and 2012. In black hos-
pitals that worsened (=<0% improvement in severe complicati on rate), in grey hospitals that improved 
(=0%-10% improvement in severe complicati on rate) and white hospitals that strongly improved (>10% 
improvement in severe complicati on rate). Unadjusted outcomes are shown.
 N (hospitals) Mean RD* Cost reducti on**
    Worsened hospitals (<0% improvement) 7  5.9% €390 
    Improved hospitals (0-10% improvement) 12  -4.6% -€1,353 
    Strong improved hospitals (>10% improvement) 10  -12.8% -€2,158 
*Mean relati ve diff erence in severe complicati ons. 
** Mean cost reducti on per pati ent (by using hospital averages).
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Between 2010 and 2012, total costs declined by 8% (risk-adjusted RD -7%, 95% 
CI -9 to -4%, p < 0.001). In detail, a reduction was seen for costs related to opera-
tion, ward, intensive care, radiology, laboratory, and material. Only in the category 
“other costs” was an increase seen between 2010 and 2012 (Table 2). Between 
2010 and 2012, costs during primary admission significantly decreased by 9% (risk-
adjusted RD -7%, 95% CI -10% to -5%, p < 0.001). Costs during Q1 decreased by 3%, 
although this was not statistically significant (risk-adjusted RD -2%, 95% CI -10% to 
6%, p = 0.65) (Figure 2). Odds ratios and RDs between 2010 and 2012 without risk 
adjustment for differences in patient characteristics are shown in Supplemental 
Table 3.
Differences between hospitals
The average severe complication rate per hospital varied from 9.1% to 46% (Figure 
3A). The average costs (primary admission and Q1) per hospital of a colorectal 
cancer patient ranged from €9,777 to €19,417 (Figure 3A). At the hospital level, 
a correlation was identified between severe complication rate and average costs 
per patient (correlation coefficient [R] = 0.64, Figure 3A). Variation in average 
costs per patient between hospitals with comparable severe complication rates 
was identified, for example, for the 2 hospitals indicated with grey diamonds in 
Table 2. Average costs of one colorectal cancer patient stratified by year of operation
 2010 2011 2012  RD
Operation € 3 799 € 3 856 € 3 774 -1%
Ward € 5 391 € 5 003 € 4 716 -13%
Intensive care € 2 866 € 2 483 € 2 514 -12%
Radiology €  265 €  251 €  240 -9%
Laboratory €  786 €  775 €  751 -4%
Consulting €  410 €  423 €  404 -1%
Materials €  260 €  208 €  211 -19%
Other €  461 €  513 €  535 +16%
Total € 14 237 € 13 512 € 13 145 -8%*
Average costs per patient (total costs of primary admission up to 90 days after discharge) by resource cat-
egory stratified by year of surgery. Abbreviations: RD, relative difference. *Risk-adjusted RD -7%, CI -9%: 
-4%, p<0.001 (risk-adjustment for differences in patient characteristics and for hospitals as random effect).
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Figure 3A (the lighter grey hospital had 49% lower costs compared with the other 
hospital). A weak correlation was identified between mortality rate and hospital 
costs (R = 0.25). Analyses were repeated with adjustment for differences in patient 
characteristics in order to compare hospital performances (Figure 3B). Hospitals 
with lower adjusted severe complication rates than the adjusted average (< 20.1%) 
and with lower adjusted costs than the adjusted average (< €10,645) were defined 
as “best performing” hospitals (lower left quadrant in Figure 3B [n = 10; 3,524 
patients], average is calculated at hospital level). Hospitals with higher adjusted 
severe complication rates than the adjusted average (> 20.1%) and with higher 
adjusted costs than the adjusted average (> €10,645) were defined as “improve 
potential” hospitals (upper right quadrant in Figure 3B, n = 8; 3,320 patients). “Best 
performing” hospitals were associated with a lower crude severe complication 
rate (-40%), lower crude mortality rate (-23%), and lower crude average costs per 
patient (-28%), as compared with “improve potential” hospitals (Figure 3C). Hos-
pitals that were not able to improve their severe complication rate between 2010 
and 2012 (crude RD < 0%, n = 7) were not able to reduce costs (€-390). Hospitals 
that improved between 2010 and 2012 (crude RD 0% to 10%, n = 12) or strongly 
improved (crude RD > 10%, n = 10) made remarkable savings (€1,353 and €2,158 
per patient, respectively) (Figure 4).
DISCUSSION
This article presents evidence for the inverse relationship between quality 
improvement and health care costs. By participating in a nationwide quality im-
provement initiative, and therefore enabling continuous quality measurement and 
benchmarked feedback, clinical outcomes of patients undergoing colorectal cancer 
surgery improved in 3 consecutive years (Figure 1), with a simultaneous substantial 
reduction in hospital costs (Figures 2 and 4). In addition, this report highlights 
variation between hospitals in quality of care as well as costs per patient. This 
enables identification of “best practice” hospitals, providing high quality care for 
relatively low costs (Figure 3). Revealing the high leverage processes of care behind 
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these “best practices” gives the opportunity to bring the medical field forward in 
improving the value of health care delivery 3,13.
As shown in a recent review of the literature, studies describing the inverse rela-
tionship between quality improvement and hospital costs by quality improvement 
programs are scarce 19. This is the first study outside the United States to describe 
such an inverse relationship based on original financial and clinical data. Therefore, 
our conclusions provide additional evidence for cost reduction by quality improve-
ment programs, as seen in the American College of Surgeons National Surgical 
Quality Improvement Program 20-22. Existing studies were, however, hampered by 
their reliance on single-center data 20 or by a lack of uniformity and/or transpar-
ency in cost registration between different institutions, and therefore using proxies 
of real costs, like fixed costs of complications 21,22 or claim payments 23. In addition 
to those earlier studies, this multicenter study analyzed detailed clinical data (Table 
1) combined with actual costs for every individual patient, based on time-driven 
activity-based costing 9 which is an advanced method for understanding hospitals 
costs 13,14. Moreover, extensive registration of clinical information in the DSCA 
resulted in availability of detailed patient characteristics (Table 1). This enabled 
appropriate risk-adjustment in the comparison of hospital performances (Figure 
3B), as high-risk patients are not evenly distributed between hospitals 15. 
A recent study of Eappen and colleagues 24 noted that some hospitals (depending 
on payer mix) have the potential for adverse near-time financial consequences 
when decreasing post-surgical complications. Under some payers, the occurrence 
of surgical complications was associated with higher hospital contribution margins 
(revenue minus variable costs), therefore providing a perverse stimulus for health 
care providers. The Dutch health care system does not have different reimburse-
ments for patients with or without complications, so reducing (severe) complica-
tions in Dutch hospitals (Figure 1) will directly benefit hospital finances (Table 2).
Conclusions based on this study support the value based health care theory of 
Michael Porter 3,13,25. Porter advises health care providers to focus on optimizing 
value for patients, describing value as “the health outcomes achieved that matter 
to patients, relative to the costs of achieving those outcomes.” As seen in this study, 
the reduction of complications after colorectal surgery is undoubtedly beneficial to 
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patients and reduces costs for providers as well 26. A recent article from our group 
described several key elements crucial for the success of the DSCA 7, including the 
leading role of the Association of Surgeons of the Netherlands, performance indica-
tors based on evidence-based guidelines, web-based registration by (or under the 
supervision of) medical specialists themselves, weekly updated feedback of indica-
tor results to participants, and annual external data verification with other data 
sources. By providing continuous feedback of benchmarked performance informa-
tion to colorectal surgeons, existing problems in their care process are identified 
and improved. Guideline adherence has improved significantly since the beginning 
of the DSCA, as evidenced by the number of complete preoperative colonoscopies, 
the percentage of cases preoperatively discussed in a multidisciplinary team, and 
the percentage of circumferential resection margins reported in the pathology 
report after rectal cancer resection. 7.  
Because the extensive registration of patient characteristics in a clinical audit is 
a cost- and time-consuming exercise 27, one might argue that registration costs 
should be taken into account in our analyses. Therefore, we also looked at the 
costs of retrieving, entering, and verifying the data; if costs for participation in the 
DSCA were incorporated in the analysis, participation would still be cost effective: 
average costs for clinical auditing in the 29 hospitals was roughly €77 per patient 
for participation in the audit and additional costs of €43 for entering the data 
(Supplemental Table 4, online only). This resulted in almost €1.2 million auditing 
costs for all 3 years. Total cost reduction for 2011 and 2012 was more than €6.2 
million (yearly cost reduction per patient multiplied by yearly volume in 2011 and 
2012, retrieved from Table 2) resulting in a 3-year overall net saving of more than 
€5 million.
We also developed a method to identify “best practice” hospitals, by combining 
clinical outcomes with financial outcomes. As shown in Figure 3A, hospitals shown 
in light grey belong to the quartile of hospitals with lowest severe complication 
rates. Although both these hospitals had low severe complication rates, 1 hospi-
tal spent 49% less money than the other hospital because of higher costs of the 
resources used (data not shown). This means that the expensive hospital has a 
lot of potential to reduce its total costs when it is able to reduce its resource cost. 
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Therefore, besides looking at quality only, identifying “best practice” hospitals on 
both dimensions (Figure 3B) might lead to better insights into how to improve 
quality, reduce needed resources, and save costs. Moreover, finding the group of 
best practices hospitals will provide a realistic goal for all other hospitals, enabling 
further development of a sustainable health care system. If, between 2010 and 
2012, all hospitals performed on the level of best practice hospitals, the additional 
savings in this study would have been more than €20 million (Figure 3B, the sub-
group of best practice hospitals have €2,340 lower costs per patient [€11,266] than 
the study average [€13,606]). 
According to our hypothesis, the darker grey hospital in Figure 3A could be consid-
ered an outlier (low complication rate but expensive). Therefore, we repeated the 
analyses at hospital level after excluding this outlier, and this resulted in a higher 
correlation coefficient (R = 0.80) compared with that in the previous analysis, pro-
viding even stronger evidence for our study hypothesis.
Limitations
First, there might be other reasons for the established quality improvement during 
this time period, such as the Enhanced Recovery After Surgery (ERAS) protocol or 
secular trends not registered in the DSCA. However, the ERAS protocol was already 
implemented in the Netherlands before 2010. Moreover, without availability of 
key data on outcomes, health care organizations are flying blind in deciding what 
should be targets for quality improvement initiatives. Also a reduction in costs 
might be established by other reasons than quality improvement programs alone 
(like pressures on length of stay due to hospital capacity). Second, the increased 
use of laparoscopic techniques in colorectal surgery (Table 1) might have had a 
positive effect on its own in improving clinical outcomes28 and therefore leading to 
a reduction in costs29. On the other hand laparoscopic surgery can generate costs 
as well. Since laparoscopic approach for (elective) surgery is a choice a surgeon can 
make we chose not to include this in the risk-adjustment model (see footnote Table 
1). Third, some costs, like specialist fees and costs of medication and dialyses, were 
excluded in our analyses since registration of these resources were not uniform in 
the participating hospitals. This might lead to an underestimation of the real costs 
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although we do not expect that this would affect our main findings since it affects 
all three years. Moreover, one could argue that hospitals with low complication 
rates have better surgeons, though these surgeons might be more expensive. Al-
though specialist fees where not registered uniformly in the participating hospitals, 
specialist fees in the Netherlands are quite comparable between public hospitals, 
making this argument less likely. Fourth, long-term survival of patients is not reg-
istered in the DSCA yet. However a number of intermediate parameters, which 
could be associated to long-term outcome of cancer resections, are available. 
For example between 2009 and 2011, the percentage of positive Circumferential 
Resection Margins, a quality indicator for rectal cancer surgery associated with the 
risk for local recurrence, declined significantly.7 This was also observed during our 
study period (data not shown). Although improved outcome on this quality indica-
tor is associated with better long-term survival30, future follow up studies should 
be performed to confirm survival benefits in our population. Finally, one might 
argue that outcomes improved due to regionalization of difficult cases to tertiary 
centers not participating in this study.  However, patient characteristics between 
the three consecutive years did not change tremendously and the annual volume 
of procedures increased (Table 1), making referral of patient to other institutions 
less likely. 
Further perspectives
Nationwide outcome registries might serve as an ideal framework to address 
effectiveness of healthcare since measuring, reporting and comparing outcomes 
could also guide cost reductions. Analyzing costs should be a standard procedure 
in the continuous evaluation of care processes in hospitals. In addition, combining 
clinical and financial outcomes with Patient Reported Outcome Measures (PROMs) 
provides an even superior ‘best practice’. Risk-adjusted benchmarking on quality, 
costs and PROMs will enable healthcare providers to learn from best practices and 
lead to higher quality of care with the use of fewer resources.
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CONCLUSIONS
This article supports the Value Based Healthcare agenda 3,13,25 by presenting 
evidence for the inverse relationship between quality improvement and health 
care costs. By participation in a nationwide quality improvement initiative with 
continuous quality measurement and benchmarked feedback, opportunities for 
targeted improvements are revealed which can bring the medical field forward in 
continuous improvement of value of healthcare delivery. As research presented in 
this manuscript suggests, focus in healthcare should shift to initiatives that aim to 
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Supplemental Table 1. Different categories of resources extracted from the Hospital Information System
Category Examples within category
Operation Surgery time, operation room session 
Ward Inpatient ward days
Intensive care Intensive Care Unit days, Medium Care Unit days, Cardiac Care Unit days
Radiology Ultra sound, X-ray, CT scan, MRI scan
Laboratory Activities related to pathology, haematology, clinical chemistry, microbiology
Consulting Consults other medical specialist, outpatient department visits
Materials Blood products, prostheses and implants
Other Electrocardiography, spirometry, physiotherapy, medical rehabilitation
Supplemental Table 2. Outcomes after colorectal cancer surgery for the participating hospitals in this 
study (29 hospitals) as compared to national outcomes (all 92 hospitals)
This study  National outcomes*
2010 2011 2012 2010 2011 2012
Number patients 3131 3152 3630 7888 8757 9556
Mortality 4% 4% 3% 4% 3% 3%
Major morbidity 25% 22% 20% 24% 21% 20%
* Data retrieved form the Dutch Surgical Colorectal Audit annual reports 2010 – 2012 (www.clinicalaudit.
nl).
Supplemental table 3. Relative difference 2010 - 2012 without risk-adjustment for differences in patient 
characteristics
    Univariate analyses
  Crude RD  OR/ RD 95% CI P-value
Severe complications  -20%  0.758 (0.675: 0.850) <0.001
Mortality  -29%  0.698 (0.539: 0.903) 0.006
Costs primary admission  -9%  -7% (-10%: -4%) <0.001
Costs Q1  -3%  +1% (-7%: 10%) 0.76
Total costs  -8%  -6% (-9%: -3%) <0.001
All outcomes were only adjusted for hospitals as random effect. Abbreviations: RD, relative difference; OR, 
odds ratio; CI, confidence interval.
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Supplemental Table 4. Yearly costs of clinical auditing in 2012
  Price N Total price
Fixed costs  Yearly hospital fee € 3 000 29 € 87 000 
  Monthly hospital fee €  300 29 x 12 € 104 400 
Variable costs  Fee per patient €  25 3627 € 90 675 
  Costs of registration* €  17 3627 € 61 659 
  Costs of verification** €  26 3627 € 92 489 
Total costs  All patients in 29 hospitals €  120 3627 € 436 223 
Costs based on Dutch Surgical Colorectal Audit 2013 fee.  *Based on 30 minutes of registration by a Phy-
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Healthcare providers worldwide are struggling with rising costs while hospitals 
budgets are under stress. Colorectal cancer surgery is commonly performed, how-
ever it is associated with a disproportionate share of adverse events in general 
surgery. Since adverse events are associated with extra hospital costs it seems 
important to explicitly discuss the costs of complications and the risk factors for 
high-costs after colorectal surgery.
Methods 
Retrospective analysis of clinical and financial outcomes after colorectal cancer 
surgery in 29 Dutch hospitals (6768 patients). Detailed clinical data was derived 
from the 2011-2012 population-based Dutch Surgical Colorectal Audit database. 
Costs were measured uniform in all participating hospitals and based on Time-
Driven Activity-Based Costing.
Findings
Of total hospital costs in this study, 31% was spent on complications and the top 5% 
most expensive patients were accountable for 23% of hospitals budgets. Minor and 
severe complications were respectively associated with a 26% and 196% increase 
in costs as compared to patients without complications. Independent from other 
risk factors, ASA IV, double tumor, ASA III, short course preoperative radiotherapy 
and TNM-4 stadium disease were the top-5 attributors to high costs.
Conclusions 
This article shows that complications after colorectal cancer surgery are associated 
with a substantial increase in costs. Although not all surgical complications can 
be prevented, reducing complications will result in considerable cost savings. By 
providing a business case we show that investments made to develop targeted 
quality improvement programs will pay off eventually. Results based on this study 
should encourage healthcare providers to endorse quality improvement efforts.
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INTRODUCTION
Nowadays, healthcare providers worldwide are struggling with rising costs while 
hospitals budgets are under stress. In response to the current demand for financial 
transparency, it seems important to explicitly discuss underlying costs of services 
provided. Earlier studies showed that hospital costs are associated with quality of 
healthcare where hospitals providing high quality care have lower costs 12. Postop-
erative complications lead to increased resource utilization and as a consequence 
to higher healthcare costs 3-9. Therefore more and more pressure is being exerted 
on health care providers to simultaneously improve quality and reduce costs of 
health care provided.
Colorectal cancer surgery is a commonly performed procedure, but remains associ-
ated with high postoperative morbidity and mortality and accounts for an extraor-
dinary share of adverse events in general surgery 10. In the Netherlands, roughly 
10000 colorectal cancer procedures are performed every year 11. As of 2009, de-
tailed patient and outcome characteristics of colorectal surgery are registered in 
the nationwide Dutch Surgical Colorectal Audit (DSCA) to monitor, evaluate and 
improve colorectal cancer care11,12. In order to facilitate improvement initiatives 
aiming for a decrease in healthcare costs by reducing complications, the primary 
objective of the current study was to explore the association between complica-
tions after colorectal cancer surgery and hospital costs. To analyze the financial 
impact of complications also after hospitalization, we included hospitals costs up 
to 90 days after discharge. A secondary aim of the present study was to investigate 
the existence of common risk factors for complications and their associated costs.
PATIENTS AND METHODS
Clinical data
The data set was retrieved from the Dutch Surgical Colorectal Audit (DSCA) a na-
tionwide, population based database where detailed patient, tumor, diagnostic, 
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procedural and outcome data are registered for patients who undergo a resection 
of a primary colorectal carcinoma in the Netherlands. The dataset shows a nearly 
100% completeness on most items and high accuracy level of validation compared 
to the Netherlands Cancer Registry 11,12. A detailed description of the DSCA has 
been published recently 12,13. 
Financial data
The economic evaluation was conducted from a hospital perspective. Therefore 
only ‘in-hospital’ costs were considered in this study. Costs were taken into ac-
count from the day of initial surgery till discharge (= primary admission) up to 90 
days after discharge (= Q1). Resource utilization at patient level was extracted 
from the Hospital Information System from each participating hospital. For each 
hospital, translation of patient level resource utilization into costs was provided 
by Performation (Bilthoven, The Netherlands), which is a healthcare consultancy 
firm providing patient level costing and benchmarking products for more than 
100 hospitals across Europe 14,1516. Costs were calculated by using Time-Driven 
Activity-Based Costing (TD-ABC) methodology 17 which is an advanced method for 
understanding hospitals costs18. Cost price calculations are standardized by Perfor-
mation and therefore uniformity in methodology exists between all participating 
hospitals. The most recent cost price model of 2012 for each hospital was used 
for both years (2011 and 2012) to avoid differences due to inflation or to the dif-
ferent models themselves. Different activities are grouped into eight categories 
as shown in Supplemental Table 1. All activities consisted of direct (e.g. personnel 
staff, material and equipment) and indirect costs. For example, direct costs for an 
inpatient day (category ‘ward’) consisted of (a) personnel as salary of ward nurses 
and administrative personnel, (b) material costs as bed linen and bandages and (c) 
depreciation of equipment such as ward inventory. Examples of indirect costs are 
those related to information technology, building depreciation, cleaning, catering, 
etc. Specialists’ fees, medication and dialyses costs were excluded since registra-
tion of these parameters was not uniform in all participating hospitals making 
equal comparison impossible. 
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Inclusion criteria
Hospital selection (n = 29) was based on the availability of detailed cost-price infor-
mation for two consecutive years. In these hospitals approximately a third of the 
entire colorectal cancer surgery procedures annually performed in the Netherlands 
was carried on. From the 29 hospitals, 21 (72%) have a surgical teaching program. 
Patients undergoing surgical resection for primary colorectal cancer between Janu-
ary 1st, 2011 and December 31st, 2012 had to be registered in the DSCA before 
December 1st 2013. Minimal data requirements to consider a patient eligible for 
matching with the financial dataset was information concerning tumor location, 
date of surgery and mortality status.
Match
Unique Patient Identification Number (UPIN) combined with hospital of admis-
sion was used to match patients registered in the DSCA to their information in 
the financial database. For those without a match on UPIN four different patient 
characteristics were matched (date of birth, gender, hospital of admission and date 
of surgery). This method resulted in a data set of 6782 eligible patients (match > 
99%).
Definitions
Two different methods of analyzing complications were used. The first method 
divided complications into two groups as described earlier 19,20: (1) mild complica-
tions, defined as any complication occurring within 30 days after resection and not 
being a severe complication and (2) severe complications, defined as a complica-
tion with serious consequences: leading to mortality, a reintervention (operative or 
percutaneous), or a postoperative hospital stay of at least 14 days. Any patient not 
having a mild or severe complication was analyzed as ‘no complication’. The second 
method classifies complications in 7 categories: (1) surgical complications, (2) pul-
monary complications, defined as a complication mainly related to the lung (except 
for pulmonary embolism), e.g. bacterial pneumonia or viral pneumonia. (3) Cardiac 
complications, defined as a complication which cause is related to the heart, e.g. 
cor pulmonale or myocardial infarction. (4) Neurologic complications, defined as 
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a complication which cause is related to the nerve system or brain, e.g. cerebro-
vascular accident. (5) Infectious complications defined as any infection other than 
surgical infection or pneumonia, e.g. urinary tract infection. (6) Thromboembolic 
complications, defined as a complication which cause is related to the blocking of a 
blood vessel due to the formation of a blood clot (except for cerebral accidents), e.g. 
pulmonary embolism or deep vein thrombosis. (7) Other complications, defined as 
any complication not listed in any of the categories above. Outcome measures for 
costs of healthcare were (1) hospital costs of primary admission, (2) hospital costs 
after discharge up to 90 days (= Q1), (3) total hospital costs (= hospital costs of 
primary admission and Q1) (4) length of hospital stay, (5) length of intensive care 
(IC) stay and (6) operation time.
Statistical analyses 
Chi-square test and one-way Anova were used to investigate differences between 
patients’ characteristics (Table 1).
Three different analyses were performed in this study. In the first analysis cost 
differences between patients with none-, mild- or severe complications were 
analyzed. Costs were calculated for primary admission, first 90 days after discharge 
(Q1) and total costs (primary admission and Q1). Mixed model with hospitals 
as random effects were used to account for the presence of possible variability 
between hospitals and are designed to handle nested data (like patients in each 
hospital) and unequal group study 21,22. 
The second method analyzed differences in total costs (primary admission and Q1) 
among 7 categories of complications by using multivariate regression models with 
hospitals as random effects. First, the analysis was performed without risk-adjust-
ment; then with risk-adjustment for patient’s characteristics illustrated in Table 
1; in the last analysis risk-adjustment for patient’s characteristics and all type of 
complications were included in the mixed model. Only patients’ characteristics that 
did not depend on choices made by a surgeon were used for the risk-adjustment 
model (therefore surgical approach and construction of a stoma were not used for 
risk-adjustment) (Table 1).
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In the third analysis risk factors (patient characteristics listed in Table 1) associated 
with severe complications and total costs (primary admission and Q1) were inves-
tigated by using multivariate regression models with hospitals as random effects. 
Statistical analyses were performed by using SPSS (version 20; IBM) and R (version 
18). Outcomes are presented as the mean. Confidence intervals (CI) were stated 
at 95%.
RESULTS
A total of 6782 patients were eligible for analysis. 819 patients (12.1%) suffered 
from mild complications, 1426 patients (21.0%) suffered from severe complica-
tions. All analyzed patient, tumor and procedural characteristics of the studied 
population are shown in Table 1.
Distribution of costs and additional costs of complications 
Patients were grouped as 2.5% (n = 170) of the whole analyzed population: aver-
age total costs (primary admission and Q1) for patients ranged from €3403 (least 
expensive 2.5%) to €79953 (most expensive 2.5%). The top 5% most expensive 
patients were accountable for 23% of the total hospital costs analyzed in this study 
(Figure 1A). Highest total costs for one single patient was €205946.
Total hospital costs (primary admission and Q1) of our studied population was 
€90.308 million (100%). Average costs for one patient without complications was 
€9226. This resulted in €62.569 million (69%) in ‘baseline’ costs (€9226 X 6782 pa-
tients). Patients with mild and severe complications were respectively associated 


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 1. Illustrative picture: Distribution of costs and additional costs of patients with complications
A. Each bar represents mean costs of 2,5% (170 patients) of the analyzed patients in this study. Top 5% 
most expensive patients (two dark grey bars) are accountable for 23% of the total costs.
B. Baseline costs are accountable for 69% (€62 million) of total hospital costs. Patients with mild and se-
vere complications are respectively accountable for 2% (€2 million) and 29% (€26 million) additional costs.
Minor and severe complications
Costs related to primary admission only were higher for patients with minor (€9061) 
and severe complications (€23616) as compared to patients without complications 
(€7470). Using the mixed model with hospitals as random effects costs significant 
increased for patients with minor and severe complications with respectively €1623 
(CI €795: €2451, p < 0.001) and €16059 (CI €15401: €16716, p < 0.001).
Costs related to the first 90 days after discharge were higher for patients with 
minor (€2587) and severe complications (€3671) as compared to patients without 
complications (€1756). Using the mixed model with hospitals as random effects 
costs significantly increased for patients with minor and severe complications with 
respectively €799 (CI €415: €1183, p < 0.001) and €1869 (CI €1564: €2174, p < 
0.001) (Figure 2).
For total hospital costs (primary admission and Q1) minor complications were 
associated with a significant 26% increase in costs. Using the mixed model with 
hospitals as random effects costs significantly increased with €2403 (CI €1497: 
€3309, p < 0.001). This increase mainly depended on higher costs in the categories 
ward, intensive care and operation (Table 2A). 
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Major complications were associated with an even higher increase (= 196%) in costs. 
Using the mixed model with hospitals as random effects costs significantly increased 
with €17906 (CI €17189: €18623, p < 0.001). This increase mainly depended on 
higher costs in the categories intensive care, ward and operation (Table 2A). 
Patients suffering minor complications and major complications had longer total 
operation time, hospital stay and Intensive Care stay (Table 2B).
Figure 2. Increase in costs for 
colorectal cancer patients with a 
complicated course 
Average costs per patient of prima-
ry admission and Q1 (=first 90 days 
after discharge). Arrow represents 
difference as compared to ‘no com-
plications’.
Table 2a.  Detailed overview of costs of complications
  No complication  Minor complication  Major complication 
n 4527 819 1422
Categories    
 Operation € 3492 € 3674 € 4912
 Ward € 3653 € 4957 € 8593
 Intensive care € 670 € 1025 € 9167
 Radiology € 148 € 239 € 558
 Laboratory € 480 € 609 € 1749
 Consulting € 338 € 453 € 630
 Materials € 107 € 185 € 550
 Other € 339 € 505 € 1128




All types of complications were associated with large increase in hospital costs, 
compared with those without complications. Most common complications were 
surgical complications (n = 1347, 19.9%). The largest increase in unadjusted costs 
was seen for pulmonary complications (n = 465, €14873, CI €13603: €16144, p < 
0.001). After risk-adjustment for patient characteristics pulmonary complications 
were still associated with the largest attributable costs as well (=€14308, CI €13050: 
€15565, p < 0.001). After risk-adjustment, for patient characteristics and for other 
complications, surgical complications were associated with the largest attributable 
costs (= €12131, CI €11398: €12863, p < 0.001) (Figure 3). In detail, patients suf-
fering from an anastomotic leakage (n= 468, €33486) were almost 3 times more 
expensive than patients without an anastomotic leakage (n = 6314, €11821).
Patients’ characteristics associated with clinical and financial outcomes
Independent from other risk factors, the strongest association with severe com-
plications was seen for ASA IV-V (OR 3.998, CI 2.582:6.188, p < 0.001), urgent 
resections (OR 1.886, CI 1.554:2.289, p < 0.001) and 5 x 5 Gray preoperative radio-
therapy (OR 1.809, CI 1.318:2.482, p < 0.001). Independent from other risk factors, 
the strongest association with increased costs was seen for ASA IVV patients (RC 
€7264, CI €4355: €10172, p < 0.001), patients with synchronous tumors (RC €3302, 
CI €1388: €5215, p = 0.001) and ASA III patients (RC €3295, CI €2327: €4266, p < 
0.001) (Figure 4).
Table 2b.  Attributers of costs
  No complication  Minor complication  Major complication 
n 4527 819 1422
Attributers    
 Operation time (hour) 3.01 3.22 3.32
 Hospital LOS (days)* 10.29 13.97 28.60
 IC LOS (days) 0.40 0.59 4.95
Data is shown from day of primary surgery up to 90 days after discharge (therefore costs/ hours/ days 
associated with re-hospitalizations or re-operations up to 90 days after discharge are included). Abbrevia-
tions: LOS, length of stay; IC, intensive care. * Including IC days.
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Adjusted for patient 
characteristics
Adjusted for patient 
characteristics and all  
other complications  
 n   95% CI  95% CI  95% CI
Surgical 1347 19.9% € 14638 € 13875 € 15401 € 13894 € 13142 € 14646 € 12131 € 11398 € 12863
Pulmonary 465 6.9% € 14873 € 13603 € 16144 € 14308 € 13050 € 15565 € 10024 € 8858 € 11189
Cardiological 271 4.0% € 13290 € 11621 € 14959 € 12014 € 10353 € 13675 € 7156 € 5660 € 8653
Thromboembolic 52 0.8% € 13363 € 9576 € 17151 € 11739 € 8073 € 15404 € 6598 € 3374 € 9823
Neurologic 117 1.7% € 12120 € 9578 € 14662 € 10931 € 8454 € 13408 € 6424 € 4233 € 8615
Infectious 353 5.2% € 9424 € 7940 € 10908 € 7843 € 6389 € 9297 € 4290 € 2998 € 5583
Other 502 7.4% € 8124 € 6860 € 9389 € 6977 € 5739 € 8215 € 4485 € 3389 € 5582
Figure 3. Relationship of complications after colorectal surgery to unadjusted and adjusted hospital costs
Attributable increase in costs with complication is shown. In graph std. error is shown. *P-values for all 




This is the first European multicenter study providing a detailed estimate of hos-
pital costs associated with adverse events in colorectal cancer surgery. In addition 
this report shows that almost a quarter of hospitals budget for colorectal cancer 
surgery is spend on a relatively small percentage of patients and almost a third of 
hospitals budget is spend on treating complications. Our report highlights that risk 
factors for severe complications are associated with high costs as well. Since more 
Figure 4. Risk factors associated with severe complications and costs of those severe complications
Risk factors (patient characteristics listed in Table 1) associated with severe complications and total costs 
(primary admission and Q1) were investigated by using multivariate regression models with hospitals as 
random effects. Abbreviations: BMI, Body Mass Index; ASA, American Society of Anesthesiologists risk 
score; Left colon, including transverse colon; TNM, Classification of Malignant Tumors; Gy, gray.
79
the busIness Case for hospItals
4
and more pressure is being exerted on health care providers to simultaneously 
improve quality and reduce the costs of the provided care, the conclusions based 
on this article should catalyze the development of targeted quality improvement 
programs.
Complications after colorectal cancer surgery in this report were common and 
occurring after 33% of the procedures performed. In the studied population, 12% 
had mild complications and 21% had severe complications which is comparable 
with an earlier study using data from the American College of Surgeons National 
Surgical Quality Improvement Program (29% of adverse events) 10. The average 
costs of colorectal patients (and their complications) in our study are consistent 
with earlier studies as well3, however we provide this evidence based on detailed 
clinical and financial data. In addition to the existing literature, this study has some 
major advantages. Our results are based on multi-center data, which gives a more 
comprehensive perspective as publication bias of individual ‘well performing’ 
hospitals 3-5 is avoided. Instead of using insurance claim data to calculate costs 7,9 
this study was performed from a hospitals perspective using TD-ABC methodology, 
which is a superior method for measuring and understanding costs 17,18. Clinical 
data was retrieved from the detailed DSCA dataset, therefore enabling accurate 
risk-adjustment 13. Moreover, since the DSCA is a population-based registry, the 
data was not hampered by overrepresentation of a specific group of patients (Table 
1). In contrast, two recent multi-center studies from the United States analyzing 
costs of complications retrieved their data from Veterans Affairs hospitals 6,8. 
Almost 95% of their analyzed patients were male which is a major risk factor for 
complications itself 23 and consequently a risk factor for increased costs (Figure 4).
Surgical complications were most common after colorectal cancer surgery and were, 
independent from differences in patient characteristics and other complications, 
associated with the highest increase in hospital costs (Figure 3). After adjustment 
for other complications, strongest decrease in additional costs was seen for throm-
boembolic complications (reduction of €5141). This suggests that thromboembolic 
complications often occur at the same time with other complications. 
To create more insight in the relation between severe complications and the costs 
of severe complications we analyzed risk factors for severe complications and 
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hospital costs. For almost every risk factor associated with the development of 
severe complications, a similar trend was seen for developing high hospital costs. 
This means that patients with a high risk for complications are a risk for generating 
high hospital costs as well. ASA IV-V, short course radiotherapy, ASA III and TNM-
stage 4 were top-5 risk factors for both developing severe complications as well 
as high hospital costs (Figure 4). Remarkable is the inverse relationship between 
severe complications and costs for patients older than 80 years. As compared to 
patients under 60 years and independently from other risk factors, octogenarians 
were associated with a significant increased risk for developing severe complica-
tions (OR 1.449, CI 1.158:1.812, p = 0.001) though associated with a decrease in 
hospital costs (RC €-691, CI €-1984: €601, p = 0.29). Nevertheless, when looking at 
unadjusted averages, octogenarians were still associated with slightly higher costs 
as compared to patients under 60 years (data not shown). This means that high age 
itself (> 80 years) is not associated with higher hospital costs though comorbidities 
(or other patient characteristics) of octogenarians are.
Limitations
This study has some limitations. First of all one might argue that in their attempts 
to achieve lower complication rates, participants might not register patients with 
complications. Also under-registration of complications themselves might happen, 
in order to achieve lower complication rates. However, registration of surgical 
colorectal cancer patients in the DSCA is a National Performance Indicator 12, result-
ing in high completeness of the DSCA as compared to the National Cancer Registry 
11. We also looked in detail to hospital costs of patients without complications; 
outliers in costs were hardly seen, making this under-registration less plausible. 
Second, some costs are not likely to be affected by a reduction of complications in 
the short term, like overhead costs and staffing. Therefore, assuming a direct rela-
tionship between a single complication and costs may not be appropriate. Third, 
a direct relationship between the introduction of clinical auditing for colorectal 
cancer surgery in the Netherlands and the marked reduction of complications can 
hardly be proven. The introduction of laparoscopic surgery in many hospitals, or 
other secular trends registered in the audit or not, may have lead to an improve-
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ment in quality of care itself. Nevertheless, without availability of key data on out-
comes, health care organizations are flying blind in deciding what should be targets 
for quality improvement initiatives. Moreover, combining key outcome data with 
accurate financial outcomes should be the cornerstone of developing an affordable 
health care system 18.
The business case
An addition to studies from the United States describing costs of complications 
after surgery 5,6,8 is the specific selection of colorectal cancer patients analyzed 
in this study. Those earlier studies analyzed a broad variation of general (and/or 
vascular) surgical procedures, which makes their conclusions harder to implement 
for targeted improvement programs. As described by Schilling et al. colon surgery 
is associated with a disproportional share of complications in general surgery. 
Representing only 10% of the analyzed procedures in their study, colon surgery 
was responsible for almost 25% of the complications 10. Obviously, a decline in 
complication rates after colorectal surgery will be of most benefit to the patients, 
however one might argue that a business case for quality improvement can be 
made for hospitals as well 24. Described by an earlier study of our group, severe 
complication rates after implementation of a nationwide colorectal surgical audit 
dropped from 25% in 2010 to 20% in 2012 2. If a hospital performed an average of 
100 colorectal cancer procedures per year and had an average severe complica-
tion rate in 2010 of 25%, an annual reduction in severe complications of 10% may 
lead to a saving of €120000 in 2012 as compared to 2010 (1 major complication is 
associated with €16059 of additional costs, Supplemental Table 2). A reduction of 
complications can only be achieved when key data regarding clinical outcomes is 
available, identifying areas for targeted quality improvement programs. Since this 
is a cost and time consuming exercise 25 we also calculated  the costs for participa-
tion in the DSCA for this exampled hospital (Supplemental Table 3). If yearly costs 
for participation (€13350) were incorporated in the analysis as well, overall profit 
after three years for this single hospital would be more then €80000 (Supplemen-
tal Table 2). This should be a strong incentive for healthcare providers to support 
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and develop targeted quality improvement programs in order to simultaneously 
improve quality of healthcare and reduce costs.
Future perspectives
A recent study from the United States 26 described that under some payers the 
occurrence of surgical complications was associated with higher hospital contribu-
tion margins, therefore providing a perverse stimulus for healthcare providers. The 
Dutch healthcare system does not have different reimbursements for patients with 
or without complications, and therefore reducing complications in Dutch hospitals 
will directly benefit hospitals finances. A solution to overcome contra-productive 
reimbursement systems 26, might be the introduction of bundled payments that 
are tied to overall care for a medical condition 18. Well-designed bundled payments 
encourage teamwork and should include severity adjustments for more complex 
patients (in order to compensate for potential higher costs as seen in Figure 4). 
Ideally, these bundled payments should hold the provider financial responsible for 
avoidable complications, preferable for a long period (e.g. 1 or 2 year after sur-
gery), resulting in a strong incent to improve (long-term) outcomes for patients 18. 
Providers might benefit from improving efficiency while maintaining or improving 
the value for patients, as seen in certain regions in Sweden 27.
CONCLUSIONS
This study shows that besides patients health care providers suffer from complica-
tions as well: tremendous increase in costs is seen for colorectal cancer patients 
with a complicated postoperative recovery. Key data on clinical outcomes is neces-
sary to measure value and to identify patients at risk. Admitting that surgical audits 
are time and costs consuming exercises, our business case shows that investments 
made to develop targeted quality improvement programs will pay of eventually. 
Therefore conclusions based on this study should be an impetus for healthcare 
providers to develop and maintain targeted quality improvement programs.
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SUPPLEMENTAL MATERIAL
Supplemental Table 1. Different categories of resources extracted from the Hospital Information System
Category Examples within category
Operation Surgery time, operation room session 
Ward Inpatient ward days
Intensive care Intensive Care Unit days, Medium Care Unit days, Cardiac Care Unit days
Radiology Ultra sound, X-ray, CT scan, MRI scan
Laboratory Activities related to pathology, haematology, clinical chemistry, microbiology
Consulting Consults other medical specialist, outpatient department visits
Materials Blood products, prostheses and implants
Other Electrocardiography, spirometry, physiotherapy, medical rehabilitation
Supplemental Table 2. The business case
 2010 2011 2012 Total
Yearly cost of registration* € 13350 € 13350 € 13350 € 40050
Severe complication rate (%) 25,0% 22,5% 20,0% n/a
Potential cost saving (€)** n/a € 40148 € 80295 € 120443 
Net saving -€ 13350 € 26798 € 66945 € 80393
Potential cost saving for one hospital performing 100 colorectal cancer procedures a year. * See supple-
mental table 3. ** As compared to 2010 and based on €16059 of additional costs of 1 severe complication.
Supplemental Table 3. Yearly costs of clinical auditing in 2012
  Cost price n total
Fixed costs  Yearly hospital fee*  € 3000 1  € 3000 
  Monthly hospital fee*  € 300 12  € 3600 
Variable costs  Fee per patient*  € 25 100  € 2500 
  Costs of registration**  € 17 100  € 1700 
  Costs of verification***  € 26 100  € 2550 
Total costs  Total per patient  € 134 100  € 13350 
* Costs based on Dutch Surgical Colorectal Audit 2012 fee. ** Based on 30 minutes of registration by a 
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To compare actual 90-day hospital costs between elective open and laparoscopic 
colon and rectal cancer resection in a daily practice multicenter setting, stratified 
for operative risk.
Summary background data
Laparoscopic resection has developed as a commonly accepted surgical procedure 
for colorectal cancer. There are conflicting data on the influence of laparoscopy on 
hospital costs, without separate analyses based on operative risk.
Methods
Retrospective analyses using a population-based database (Dutch Surgical Colorec-
tal Audit). All elective resections for a T1-3N0-2M0 stage colorectal cancer were 
included between 2010 and 2012 in 29 Dutch hospitals. Operative risk-was strati-
fied for age (75 < years/ ≥ 75 years) and ASA status (I-II/III-IV). Ninety-day hospital 
costs were measured uniformly in all hospitals based on time-driven activity-based 
costing.
Results
Total 90-day hospital costs ranged from €10474 to €20865 in the predefined 
subgroups. For colon cancer surgery (N = 4202), laparoscopic resection was less 
expensive than open resection in all subgroups, savings because of to laparoscopy 
ranged from €409 (<75 years ASA I-II) to €1932 (≥ 75years ASA I-II). In patients ≥75 
years and ASA I-II, laparoscopic resection was associated with 46% less mortality 
(p = 0.05), 41% less severe complications (p < 0.001), 25% less hospital stay (p = 
0.013), and 65% less ICU stay (p < 0.001). For rectal cancer surgery (N = 2328), all 
laparoscopic subgroups had significantly higher total hospital costs, ranging from 
€501 (<75 years ASA I-II) to €2515 (≥75 years ASA III-IV). 
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Conclusions
Laparoscopic resection resulted in the largest cost reduction in patients over 75 
years with ASA I-II undergoing colonic resection, and the largest cost increase in 





During the past two decades, laparoscopic resection has developed as a commonly 
accepted surgical procedure for colorectal cancer, although two recent randomized 
controlled trials (RCTs) question its routine use for rectal cancer. 1,2. Laparoscopy 
for colorectal cancer is associated with faster postoperative recovery, similar long-
term oncological outcome and similar or better long-term surgical outcome (risk 
of adhesion related small bowel obstruction and incisional hernia) as compared 
with open resection 3-6. However, there have been questions regarding the cost 
efficacy, mostly because of prolonged operative time and higher costs of operative 
materials (e.g. disposables) 7,8.
Most studies analyzing financial outcomes after open and laparoscopic resection 
were based on RCTs 9-11. Although RCTs are the cornerstone of clinical research, their 
limitations should be acknowledged, especially regarding external validity 12. This is 
related to selection of centers, specialists and patients that participate in these trials. 
Therefore there is an increasing demand for population-based studies as they may 
provide important clinical data from patients often not eligible for RCTs 13. 
Population-based studies analyzing actual hospital costs after laparoscopic and open 
colorectal cancer resections are scarce. One of the problems is a lack of uniformity 
and transparency in registration between different institutions. Another challenge 
when using population-based data is dealing with nonrandomized comparisons. Dif-
ferences in patient characteristics can be taken into account by performing multivari-
ate analysis, though this will not correct for unknown factors, which may influence 
the decision to perform open or laparoscopic surgery. As recently published, the 
use of risk-stratified comparison between homogenous subgroups based on known 
operative risk factors is an inventive way to minimize the inherent risk of selection 
bias in population studies 14. This also provides better insight in clinically relevant 
subgroups. Regarding costs, this may be of interest for healthcare providers and/or 
payers by identifying subgroups of colorectal cancer patients’ that financially benefit 
most from either an open or a laparoscopic approach.
Therefore, the purpose of this population-based analysis was to compare actual 
90-day hospital costs between elective laparoscopic and open resection of localized 
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nonmetastatic colorectal cancer in clinically relevant subgroups based on tumor 
location and operative risk.
METHODS
Data collection
Data used for this multi-center study (n = 29) was retrieved from a combined clinical 
and financial dataset of the Dutch Value Based Healthcare Study. A detailed descrip-
tion of this combined dataset has been published recently 15. Briefly, the clinical data 
set was retrieved from the Dutch Surgical Colorectal Audit (DSCA), a population-based 
database in which detailed patient, tumor, diagnostic, procedural and outcome data 
are registered of all patients undergoing a resection of a primary colorectal carcinoma 
in the Netherlands 16,17. The economic evaluation was conducted from a hospital 
perspective. As such, only in-hospital costs were considered. Costs were taken into 
account from the day of initial surgery till discharge (primary admission) and first 90 
days after discharge (Q1). For each hospital, translation of patient level resource uti-
lization (extracted from the Hospital Information System) into costs was provided by 
Performation (Bilthoven, the Netherlands), a healthcare consultancy firm providing 
patient level costing and benchmarking services for more than 100 hospitals across 
Europe 18. Costs were calculated using time driven activity-based costing (TD-ABC) 
methodology 19 which is a bottom-up microcosting method that consists of calculat-
ing two parameters per activity: the costs per time unit to perform each activity 
and the overall time units spent performing the activity. Compared with top-down 
costing methods, the TD-ABC is superior in terms of revealing patient-level resource-
use variations and the prevention of cross-subsidizations 20,21. Cost price calculations 
were standardized by Performation and therefore uniformity in methodology exists 
between all participating hospitals. The most recent cost price model of 2012 for 
each hospital was used for all years (2010, 2011, and 2012) to avoid differences due 
to inflation or to the different models themselves. Different activities are grouped 
into four categories as shown in Supplemental Figure 1. Specialists’ fees, medication 
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costs, and costs for dialyses were excluded since registration of these parameters 
was not uniform in the participating hospitals making equal comparison impossible.
Inclusion criteria
A detailed description about the inclusion of hospitals and patients in this dataset has 
been described recently 15. Because the surgical approach is significantly influenced 
by the acute setting, locally advanced disease and metastatic disease 6, patients op-
erated in an emergency / urgent setting, with a T4 or unknown T stage, and with M1 
stage were excluded. Furthermore, transanal resection and multiple synchronous 
tumors were excluded.  This resulted in a total of 3383 patients who were excluded 
from the present analysis. Homogenous subgroups within the included patients were 
defined for further analysis based on tumor location (colon vs rectum), ASA score (I-II 
vs III-IV) and age (<75 vs ≥ 75 years). For age, a cut-off of 75 year was chosen since 
literature suggests it might be of clinical importance and many nationwide colorectal 
cancer screening programs use 75 years as a cut-off as well 22,23. 
Definitions
Laparoscopic resection was defined as any procedure started with the intention to 
resect the tumor using laparoscopic techniques (including converted resections). 
Converted laparoscopic resection was defined as a procedure that was started 
with the intention to perform a laparoscopic resection but was completed as an 
open resection. Between 2010 and 2012, no robotic surgery was performed for 
colorectal cancer in the participating hospitals.
Primary financial measure was total hospital costs (all hospital costs of primary ad-
mission up to 90 days after discharge and therefore including costs of readmission 
and reoperations). Secondary financial outcomes were costs of primary operation, 
costs of ICU stay, costs of ward stay and other costs (radiology, materials, consult-
ing, laboratory, and costs of reoperations).
Primary clinical outcome measures were postoperative mortality, defined as inhos-
pital or 30-day mortality and major morbidity, defined as an inhospital or 30-day 
adverse outcome with
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serious consequences leading to mortality, a reintervention (percutaneous or 
operative), or a postoperative primary hospital stay of at least 14 days. Secondary 
outcome measures were operation time, length of hospital stay (LOS), and length 
of ICU stay (ICU LOS).
Analysis
Chi-square test and t-test were used to investigate differences between patients’ 
characteristics in the two different groups (Table 1). Clinical and financial outcomes 
were presented unadjusted. Odds ratio (OR) with 95% confidence interval (CI) was 
calculated for each clinical binary outcome. For the financial outcomes, hospital 
stay and operation time, the normality assumption was violated and therefore a 
nonparametric test has been used to evaluate the difference between groups 24. 
Statistical analyses were performed by using SPSS (version 20.0, IBM SPSS Statistics 
for Windows, IBM Corp., Armonk, NY) and R (version 18, R: A Language and Envi-
ronment for Statistical Computing, R Foundation for Statistical Computing, Vienna, 
Austria. http://www.R-project.org) 25.
RESULTS
A total of 6530 T1-3N0-2M0 patients were included for analysis. In 4202 patients 
(64%) the tumor was located in the colon and in 2328 patients (36%) the tumor was 
located in the rectum. A total of 4126 patients (63%) were aged <75 year versus 
2404 patients (37%) aged ≥75 year, 5053 patients (77%) were ASA I-II versus 1477 
patients (23%) ASA III-IV. All analyzed patient, tumor and procedure characteristics 
of the studied population are shown in Table 1.
Colon cancer
For colon cancer, 1827 (43.5%) patients underwent an open resection and 2375 
(56.5%) patients underwent a laparoscopic resection (Table 1). The largest sub-
group was <75 years ASA I-II (786 open vs 1286 laparoscopic procedures) and the 
smallest subgroup was <75 years ASA III-IV (153 open vs 205 laparoscopic proce-










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Subgroup <75 years ASA I-II open was used as a reference group (Figure 1A). Sub-
groups <75 years ASA I-II laparoscopic and ≥75 years ASA I-II laparoscopic were 
signifi cant less expensive as compared with the reference group (95% CI €-4212, 
-€397 and €-713, €-769, respecti vely). Care provided to pati ents in each of the 
remaining subgroups was more expensive than that of the reference group: <75 
years ASA III-IV open (95%CI €3804, €4165), <75 years ASA III-IV laparoscopic 
(95%CI €2954, €3226), ≥75 years ASA I-II open (95%CI €1146, €1238), ≥75 years 
ASA III-IV open (95%CI €3678, €3987) and ≥75 years ASA III-IV laparoscopic (95%CI 
€3089, €3357). 
All four laparoscopic subgroups had signifi cant lower total hospital costs as com-
pared with the open resecti on groups with the same age and ASA score, ranging 
from -€409 for <75 years ASA I-II to -€1932 for ≥75 years ASA I-II pati ents (Figure 2). 
The largest diff erences in clinical as well as fi nancial outcomes between the two 
surgical approaches were seen in the subgroup ≥75 years ASA I-II; laparoscopic 
resecti on was associated with 46.0% less mortality (p=0.05), 41.1% less severe 
complicati ons (p<0.001), 25.2 % less LOS (p=0,013), 64.5% less ICU LOS (p<0,001) 
and 15.6% lower hospital costs (p<0,001) as compared to open resecti on (Table 2). 
Figure 1. Total costs of colon and rectum cancer resecti ons strati fi ed by sub-group
1A. Colon cancer
1B. Rectal cancer
Abbreviati ons: ASA, American Society of Anesthesiologists classifi cati on. Error bar shows standard error of 
the mean. * Signifi cant more expensive (p<0.05.) as compared to reference subgroup (ref = <75year ASA 
I-II). ** Signifi cant less expensive (p<0.05.) as compared to reference subgroup (ref = <75year ASA I-II).
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See for all details regarding mortality, severe complicati ons, hospital costs, LOS and 
operati on ti me between open and laparoscopic colon cancer resecti ons Table 2.
Of all laparoscopic colon resecti ons, 283 resecti ons (11.9%) were converted to an 
open resecti on. Mean hospital costs of all converted colon resecti ons (€13903) 
were 10% (€1209) higher than costs of open colon resecti ons (€12694) (95%CI 
€1173, €1246, p<0.001).
Rectal Cancer
For rectal cancer, 1113 (47.8%) pati ents underwent an open resecti on and 1215 
(52.2%) pati ents underwent a laparoscopic resecti on (Table 1). The largest subgroup 
was <75 years ASA I-II (691 open vs 820 laparoscopic procedures) and the smallest 
subgroup was <75 years ASA III-IV (103 open vs 82 laparoscopic procedures). 
Subgroup <75 years ASA I-II open was used as a reference group (Figure 1B). Care 
provided to pati ents in each of the remaining subgroups was more expensive than 
that of the reference group: <75 years ASA I-II laparoscopic (95%CI €483, €519), 
<75 years ASA III-IV open (95%CI €6066, €6695), <75 years ASA III-IV laparoscopic 
Figure 2.  Cost diff erence between laparoscopic and open resecti ons strati fi ed by sub-group
Abbreviati ons: ASA, American Society of Anesthesiologists classifi cati on. Error bar shows 95% upper confi -
dence interval. * Signifi cant diff erence between open and laparoscopic resecti ons (p<0.001).
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(95%CI €7125, €7874), ≥75 years ASA I-II open (95%CI €1623, €1781), ≥75 years 
ASA I-II laparoscopic (95%CI €2838, €3112), ≥75 years ASA III-IV open (95%CI 
€4389, €4839) and ≥75 years ASA III-IV laparoscopic (95%CI €6776, €7483).
All four laparoscopic subgroups had significant higher total hospital costs for resec-
tion as compared with the open subgroups with similar age and ASA, ranging from 
+€501 for <75year ASA I-II to +€2515 for ≥75 year ASA III-IV patients (Figure 2). 
The largest difference in total costs between the two procedures were seen in the 
subgroup of ≥75 years ASA III-IV; laparoscopic resection was associated with 14% 
higher hospital costs (p<0.001) as compared with open resection (Table 3). See 
for all details regarding mortality, severe complications, hospital costs, LOS and 
operation time between open and laparoscopic colon cancer resections Table 3. 
Of the laparoscopic rectal resections, 141 resections (11.6%) were converted to 
an open resection. Mean hospital costs of all converted rectal resections (€16880) 
were 14% (€2130) higher than costs of open rectal resections (€14750) (95%CI 
€2046, €2213, p<0.001).
DISCUSSION
This population-based study shows that laparoscopic colon cancer surgery can be 
performed with lower hospital costs up to 90 days after discharge as compared 
with open surgery. In contrast, for rectal cancer surgery, laparoscopy was associ-
ated with higher costs. Furthermore, operative risk appeared to be a main determi-
nant of hospital costs. The largest cost differences between laparoscopic and open 
resection could be identified for specific patient groups based on age and ASA. This 
is valuable data for health care providers and/ or payers, because it shows that the 
case mix of a colorectal cancer population and the applied surgical approach have 
their financial impact.
Colon cancer
For the colon cancer subgroups, cost differences between the two approaches 
ranged from €400 to €1900, favoring laparoscopic resection (Figure 2). The largest 
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cost savings from a laparoscopic approach were seen for elderly fit patients, which 
reflects the more favorable clinical outcome with a 46% reduction in mortality, and 
41% lower severe complication rate (Table 2). In all subgroups, higher operation 
costs were amply compensated by lower costs in each of the other categories. This 
was most likely explained by the lower severe complication rate after laparoscopy, 
resulting in less resource utilization. 
Earlier studies analyzing hospital costs after colon surgery were mostly from ter-
tiary referral centers or RCT’s with potential selection bias and restricted external 
validity 10,12. So far, population-based studies on this topic were from the US 26,27. 
These studies were based on claim data from payers, and therefore proxies of costs 
were analyzed rather than actual costs 26,27. Cost analyses in the present study were 
based on uniform cost calculations for every individual patient based on TD-ABC, 
which is a superior method for measuring and understanding actual costs 19,20. 
Rectum cancer
For rectal cancer, earlier studies analyzing hospital costs were retrieved from single 
center data 11,28,29, mostly reflecting the performance of dedicated surgical teams 
in referral centers. By the best of our knowledge, this is the first multicenter study 
analyzing hospital costs after rectal cancer surgery using a population-based data-
base, reflecting routine daily practice.
Overall, the high primary operation costs for laparoscopic rectal resections did not 
outweigh the other type of costs (Table 3), as seen for laparoscopic colon surgery 
(Table 2). A possible explanation might be that laparoscopy for rectal cancer was 
a relatively new technique between 2010 and 2012 in the Netherlands, whereas 
laparoscopy for colon cancer was already routine practice. Some hospitals might 
still have been in their learning curve. However, only four out of nine hospitals 
with an average volume of more than 20 laparoscopic rectal cancer resections per 
year showed less costs compared to open resections (data not shown). Another 
explanation for the observed discrepancy in costs between colon and rectal cancer 
resections might be related to the anastomosis. The more high-risk anastomoses 
in rectal resections might reduce the impact of laparoscopy on costs in the post-























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































anastomoses are diverted in the Netherlands, while this is seldom performed for a 
colonic anastomosis. A stoma may interfere with quick recovery (and discharge) af-
ter minimally invasive surgery and can have a significant influence on costs related 
to stoma specific complications, reinterventions, and use of materials.
Total hospital costs after rectal cancer resection were lowest for patients under 
the age of 75 years and ASA score I-II undergoing an open resection (€13,366) and 
highest for patients under the age of 75 years and ASA score I-II undergoing an 
open resection (€13,366) and highest for patients under the age of 75 years with 
ASA score III-IV undergoing a laparoscopic resection (€20,865) (Figure 1B). The high 
total costs for the young but comorbid patients (both laparoscopic and open) may 
represent an aggressive treatment of complications which might have prevented 
postoperative mortality. This is supported by a low failure to rescue patients who 
suffer from severe complications in this patient category  (6 out of 64 = 9.4%) as 
compared with those of 75years or older with ASA score III-IV (18 out of 77= 23.4%) 
(Table 3). 
Earlier studies analyzing hospital costs after colorectal cancer surgery did not 
stratify for different groups of patients 8-11,26-33. In fact, many studies did not even 
stratify for colon or rectal cancer 8,30-33. This makes interpretation difficult, because 
colon and rectal cancer are different disease entities in several aspects, and overall 
analysis does not give any insight into clinically relevant risk groups. For both colon 
and rectal cancer procedures, ASA classification had a strong effect on hospital 
costs, relatively independent of age and surgical approach (Tables 2 and 3). This 
correlates with an earlier study of our group showing that ASA score III and IV are 
strong independent contributors to high hospital costs when performing colorectal 
cancer resection s34. The inclusion of these fragile patients in our study reflects 
daily practice and therefore supports the use of population-based registries as a 
source of research data 13.  
The conversion rate for laparoscopic colon procedures (11.9%) was comparable 
with rectum procedures (11.6%). When comparing converted laparoscopic pro-
cedures to initial open procedures, converted resections were more expensive 
(for colon and rectum procedures respectively a 10% and 14% increase in costs). 
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This is mainly because converted procedures receive the disadvantages of both 
approaches: higher operation costs as seen in laparoscopic surgery combined with 
longer length of hospital stay as seen in open surgery (data not shown). Clinical 
outcomes of converted procedures in this study (data not shown) were compa-
rable with the clinical outcomes of open procedures. This is similar to the findings 
of an earlier study from our group analyzing all Dutch colorectal cancer procedures 
in 2010 6 and showing no significant differences between converted laparoscopic 
procedures and open procedures. This means that if more adequate pre-operative 
patient selection could lead to lower conversion rates, it might reduce hospital 
costs as well.
By measuring hospital costs at patient level, this study highlights the variation in 
total hospital costs between the clinical subgroups, ranging from €10,474 (≥75years 
ASA I-II colon cancer patients) to €20,865 (<75 years ASA III-IV rectal cancer pa-
tients), which is a 99% difference. In the Netherlands, no different reimbursement 
exists between colon and rectal cancer patients; neither differentiation is made 
based on age or ASA classification. Referral of rectal cancer patients to specialized 
centers for surgery has its impact on hospital’s budgeting, as five out of eight rectal 
cancer subgroups (both open and laparoscopic) were more expensive as compared 
with the most expensive colon cancer subgroup (Figure 1). Moreover, irrespective 
of location of tumor, hospitals with a catchment area in which many frail and/or 
older patients live, might suffer from this rigid reimbursement system.
Limitations
A known limitation of retrospective studies is the occurrence of coding- or docu-
mentation errors in large databases, which might affect data integrity. However, 
as these errors should effect both treatments (open and laparoscopic) we do not 
believe that this affected our main conclusions. Second, information about experi-
ence of the operating surgeon is not listed in the DSCA. One might argue that spe-
cialization of the operating surgeon rather than the operative technique itself ex-
plains outcome differences. However, in most Dutch hospitals and especially in the 
elective setting, both open and laparoscopic colorectal resections are performed 
by specialized colorectal surgeons. Third, costs of specialists’ fees, medication, and 
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dialyses were excluded in our analyses. This might underestimate total costs in both 
groups. Finally, previous abdominal surgery is not specified in the DSCA. Including 
or excluding patients with previous abdominal surgery did not influence outcome 
comparisons between laparoscopic and open resection in a previous study from 
our group 14. Therefore we included those patients in our analyses. 
We did not consider costs outside the hospital and beyond 90 days postoperatively, 
although recent literature suggests that laparoscopic approach for colon resec-
tions might result in additional out of hospital and/or long-term savings as well. 
For example, patients undergoing laparoscopic colon resection were more likely to 
be discharged home without nursing care 27. Moreover, quick recovery will result 
in earlier participation in the labor process and will reduce indirect healthcare 
costs as well. Considering recent long-term data from the LAFA study, further cost 
reduction after laparoscopic colon resection can be expected because of a reduced 
readmission and reoperation rate for adhesion related small bowel obstruction and 
incisional hernia 5. 
CONCLUSIONS
This population-based study revealed that laparoscopic resections for colon can-
cer can be performed with lower hospital costs up to 90 days after discharge as 
compared with open resections. For rectal cancer, healthcare providers should 
be aware of the higher costs after laparoscopic resection, which might be of use 
when negotiating annual contracts with payers. Finally, hospitals (and their payers) 
serving relatively high number of frail, and in less extent older, colorectal cancer 
patients should also be aware of the accompanying increased hospital costs.
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SUPPLEMENTAL MATERIAL – FIGURE LEGEND
Supplemental figure 1. Clinical and financial course of a colon cancer patient
A. Illustrative picture of a 79 year, ASA III, female patient with a caecum cancer undergoing a laparoscopic 
ileocaecal resection (day 1). Cost of primary admission (day 1 till day 41) were €42 274. Cost during Q1 
(first 90 days after discharge) were €216.
B. Different categories of resources extracted from the Hospital Information System.
Category Examples within category
Operation Surgery time, operation room session 
Ward Inpatient ward days
Intensive care Intensive Care Unit days, Medium Care Unit days, Cardiac Care Unit days
Other
 - Radiology Ultra sound, X-ray, CT scan, MRI scan
 - Laboratory Activities related to pathology, haematology, clinical chemistry, microbiology
 - Consulting Consults other medical specialist, outpatient department visits
 - Materials Blood products, prostheses and implants
 - Other Electrocardiography, spirometry, physiotherapy, medical rehabilitation
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Background and purpose 
Single-port laparoscopy (SPL) is a relatively new technique, used in various proce-
dures. There is limited knowledge about the cost effectiveness and the learning 
curve of this technique. The primary aim of this study was to compare hospital 
costs between SPL and conventional laparoscopic resections (CLR) for colorectal 
cancer; the secondary aim was to identify a learning curve of SPL. 
Methods 
All elective colorectal cancer SPL and CLR performed in a major teaching hospital 
between 2011 and 2012 that were registered in the Dutch Surgical Colorectal 
Audit were included (n = 267). The economic evaluation was conducted from a 
hospital perspective, and costs were calculated using time-driven activity-based 
costing methodology up to 90 days after discharge. When looking at SPL only, the 
introduction year (2011) was compared to the next year (2012). 
Results 
SPL (n = 78) was associated with lower mortality, lower reintervention rates, and 
more complications as compared to CLR (n = 189); however, none of these differ-
ences were statistically significant. A significant shorter operating time was seen 
in the SPL. Total costs were higher for SPL group as compared to CLR; however, 
this difference was not statistically significant. For the SPL group, most clinical 
outcomes improved between 2011 and 2012; moreover, total hospital costs for 
SPL in 2012 became comparable to CLR. 
Conclusion 
No significant differences in financial outcomes between SPL and CLR were identi-
fied. After the introduction period, SPL showed similar results as compared to CLR. 
Conclusions are based on a small single-port group and the conclusions of this 
manuscript should be an impetus for further research.
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INTRODUCTION
Laparoscopic surgery for colorectal cancer results in faster recovery, reduced 
morbidity, shorter length of hospital stay, and less postoperative pain, with similar 
oncological and longterm outcomes as compared to open surgery 1-6. There are 
several studies analyzing costs between open and laparoscopic colorectal surgery; 
however, no consensus is reached about this topic; some studies show cost neutral-
ity, while others favor open or laparoscopic surgery 7-10. Advanced minimal invasive 
techniques like single-port laparoscopy (SPL) are developed in order to reduce 
surgical trauma and/or to provide better cosmetic results and are used in both 
benign diseases and malignant diseases 11-13. In literature, there are many studies 
addressing safety and feasibility of SPL as compared to conventional laparoscopic 
resection (CLR) for colorectal cancer. However, studies on cost-effectiveness of SPL 
are scarce 14. 
In 2010, the gastrointestinal surgeons of the Jeroen Bosch Hospital started with the 
introduction of the single-port technique for less complex abdominal procedures 
15,16. This resulted in the first single-port laparoscopic colorectal resection for can-
cer in 2011. Nowadays, SPL is becoming a standard of care for multiple procedures 
in our institution. 
The objective of this study was to compare the hospital costs of SPL with CLR for 
elective colorectal cancer procedures. The secondary aim was to analyze a possible 
learning curve in SPL technique by analyzing operating times, complication rates, 
and hospital costs between the first (2011) and the second (2012) years.
MATERIALS AND METHODS
Clinical data
The clinical data set was retrieved from the Dutch Surgical Colorectal Audit (DSCA), 
a population-based database in which detailed patient, tumor, diagnostic, proce-
dural, and outcome data are registered of all patients undergoing a resection of a 
primary colorectal carcinoma in the Netherlands. Patients undergoing an elective 
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laparoscopic resection in the studied hospital were selected if the operation was 
performed between January 1, 2011, and December 31, 2012, and registered in 
the DSCA before December 1, 2013. A detailed description of the DSCA has been 
published recently 17,18.
Minimal data requirements to consider a patient eligible for matching with the 
financial dataset was information on tumor location, date of surgery, and mortality 
status.
Financial data
The economic evaluation was conducted from a hospital perspective. As such, only 
Bin-hospital^ costs were considered. Costs were taken into account from the day 
of initial surgery till discharge (=primary admission) and the first 90 days after dis-
charge (=Q1). Resource utilization at patient level was extracted from the Hospital 
Information System. Translation of patient level resource utilization into costs was 
provided by Performation (Bilthoven, The Netherlands), a healthcare consultancy 
firm providing patient-level costing and benchmarking products for more than 100 
hospitals across Europe 19,20. Costs were calculated using time-driven activity-based 
costing (TD-ABC) methodology 21 which is an advanced method for understanding 
hospitals costs. 22 Cost price calculations are standardized by Performation, and 
therefore, uniformity in methodology exists over the years. The most recent cost 
price model (2012) was used for both years (2011 and 2012) to avoid differences 
due to inflation or due to the different models themselves. Different activities are 
grouped into eight categories as shown in Supplemental Table 1. All activities con-
sisted of direct costs (e.g., personnel, material. and equipment) and indirect costs. 
For example, direct costs for an inpatient day (category “ward”) consisted of (a) 
personnel as salary of ward nurses and administrative personnel, (b) material costs 
as bed linen and bandages, and (c) depreciation of equipment such as beds and 
ward inventory. Examples of indirect costs are costs related to information tech-
nology, building depreciation, cleaning, catering, etc. Specialists’ fees, medication 
costs, and costs for dialyses were excluded since registration of these parameters 
was not uniform in both years making equal comparison impossible.
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Match
Unique patient identification number was used to match patients registered in the 
DSCA to the financial database (279 patients). Laparoscopic resections in an urgent 
setting (n = 12) were excluded, resulting in 267 eligible patients for analysis.
Definitions
CLR was defined as any procedure that started with the intention to resect the 
tumor using conventional laparoscopic techniques. SPL was defined as any proce-
dure that started with the intention to resect the tumor laparoscopic using a single 
port. The choice between the two different techniques (CLR or SPL) was made by 
the preference of the surgeon and the patient. In the studied hospital, there were 
two trained single-port laparoscopic surgeons; all SPL procedures were performed 
by at least one of these two surgeons. Laparoscopic trained surgeons, a total of 
four including in some cases the two trained SPL surgeons, performed the CLR 
procedures. In both groups, residents participated. However, the first surgeon was 
always a trained surgeon. 
Primary outcome measures for quality of health care were (1) postoperative mor-
tality, defined as in-hospital or 30-day mortality, and (2) major morbidity, defined 
as an in-hospital or 30-day adverse outcome with serious consequences leading to 
mortality, a reintervention (percutaneous or operative), or a postoperative hospital 
stay of at least 14 days. Secondary outcome measures occurring in-hospital or 
within 30 days after resection were (3) any complication, (4) prolonged length of 
stay, defined as a primary admission stay of more than 14 days, (5) reintervention 
(percutaneous or operative), (6) anastomotic leakage, (7) R1/R2 resection, (8) re-
sections in whom less than 10 lymph nodes (conform Dutch guidelines)/12 lymph 
nodes (conform international TNM guidelines) were retrieved, and (9) conversion 
to open surgery. Primary financial measure was (10) total costs per patient (=pri-
mary admission up to 90 days after discharge). Secondary financial outcomes were 
(11) duration of primary operation, (12) costs of primary operation, and (13) total 
costs by category (=primary admission up to 90 days after discharge by category as 




Chi-squared test was used to investigate differences between patients’ characteris-
tics in the two groups under study (Table 1). Absolute clinical and financial outcomes 
were presented unadjusted. To investigate the effect of CLR and SPL on the outcome 
of interest, multivariate logistic regression and linear regression were performed 23,24. 
To investigate the effect of year of surgery for the SPL group, multivariate logistic 
regression and linear regression models were employed. For multivariate logistic 
regression models, an interaction term between year and type of surgery was fitted. 
Since this is a single-center study, we could not use extended risk adjustment for all 
clinical outcomes due to the small number of events for some outcomes. For those 
outcomes (mortality, reintervention, anastomotic leakage, R1/R2 resection, and 
conversion to open surgery), odds ratios without risk adjustment were computed. 
Patient characteristics used for the regression models were sex, body mass index 
(BMI ≥30), age (≥70 years), comorbidity (Charlson score ≥2) 25, American Society of 
Anesthesiologists classification (ASA ≥3), location of tumor (colon or rectum), stage 
of tumor (TNM stage ≥3), and preoperative radiotherapy (1).
Statistical analyses were performed using SPSS (version 20; IBM) and R (version 
18). Confidence intervals (CI) were stated at 95 %.
RESULTS
No significant differences in patient characteristics were identified between the 
CLR group (n=189) and SPL group (n=78), see Table 1 for patients characteristics. 
Clinical outcomes
Percentage of patients in whom less than 12 lymph nodes were retrieved was 
significantly lower for SPL. Moreover, SPL was associated with lower mortality rate, 
lower reintervention rate, lower anastomotic leakage rate, lower R1/R2 resec-
tion rate, lower percentage of patients in whom less than 10 lymph nodes were 
retrieved, and lower conversion rate, although these differences did not reach 
statistical significance. SPL was associated with higher major morbidity, complica-
tions, and prolonged length of stay (no significant differences) (Table 2).
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Table 1. Patient, tumor and treatment characteristic for conventional laparoscopic resection (CLR) and 
single-port laparoscopy (SPL)
  CLR   SPL  p-value
  n %  n %   
Total  189 -  78 -   
Sex Male 108 57%  43 55%  0.763
BMI ≥30 kg/m2 33 18%  10 13%  0.363
Age ≥70 years 96 51%  41 53%  0.792
Charlson score Charlson ≥2 33 18%  12 15%  0.680
ASA score ASA ≥III 23 12%  7 9%  0.452
Tumor location Colon 139 74%  52 67%  0.257
 Rectum 50 27%  26 33%  
Tumor stage (TNM) Stadium ≥III 113 65%  43 61%  0.567
Double tumor Yes 2 2.6% 5 2.6% 0.970
Preoperative radiotherapy Yes 45 24%  26 33%  0.109
Abbreviations: BMI, Body Mass Index; ASA, American Society of Anaesthesiologists risk score; TNM, 
Classification of Malignant Tumours; Statistical analyses performed using Chi-square test.
Table 2. Clinical outcomes after conventional laparoscopic resection (CLR) and and single-port laparoscopy 
(SPL)
CLR SPL Odds ratio (95% CI) p-value
No. patients 189 78
Mortality 4.2% 1.3% 0.294 (0.036: 2.390) 0.25
Major morbidity 24.3% 25.6% 0.924 (0.454: 1.879) 0.83
Complication 40.7% 44.9% 1.171 (0.643: 2.132) 0.61
Prolonged length of stay 16.4% 25.6% 1.688 (0.791: 3.602) 0.17
Reintervention 16.4% 10.3% 0.582 (0.255: 1.331) 0.20
Anastomotic leakage 7.9% 6.4% 0.795 (0.278: 2.267) 0.67
R1/R2 resection 7.9% 3.8% 0.464 (0.130: 1.650) 0.24
<10 lymph nodes 28.2% 21.8% 0.469 (0.213: 1.033) 0.06
<12 lymph nodes 48.9% 39.7% 0.477 (0.245: 0.926) 0.03
Conversion to open 8.4% 5.1% 1.702 (0.546: 5.305) 0.36
Odds ratios and p-values were adjusted for differences in patient characteristics (listed in Table 1) in 
a logistic regression model. Odds ratios and p-values written in Italic were not adjusted for patient 




SPL was associated with significant shorter operation time. Costs of primary op-
eration were higher as compared to CLR (no significant differences) (Table 3). In 
all categories, costs of SPL patients were higher as compared to CLR resulting in 
significantly higher total costs for SPL (Table 4).
Time trends
Patient characteristics for SPL surgery were not significantly different between 
2011 and 2012 (data not shown). Between 2011 and 2012, the percentage of SPL 
for colorectal cancer increased from 23.7% to 31.1%. Simultaneously, almost all 
clinical outcomes improved between 2011 and 2012 (except for mortality and R1/
Table 3.  Primary operation and length of hospital stay after conventional laparoscopic resection (CLR) 
and single-port laparoscopy (SPL)
 CLR SPL Delta (95% CI) p-value
Primary operation costs  € 1.663  € 1.781 €-100 (-254: 42) 0.18
Primary operation time 3,48 3,17 0.327 (0.094: 0.544) 0.007
Length of hospital stay 12,06 13,86 -1.48 (-3.73: 0.44) 0.14
Deltas and p-values were adjusted for differences in patient characteristics (listed in Table 1) in a general 
linear mixed model. 
Table 4. Financial outcomes after conventional laparoscopic resection (CLR) and single-port laparoscopy 
(SPL)
 CLR SPL
Operation  € 1.881  € 2.063 
Ward  € 6.692  € 7.818 
ICU  € 1.823  € 2.480 
Laboratory  € 664  € 758 
Materials  € 349  € 712 
Radiology  € 343  € 368 
Consulting  € 334  € 352 
Other  € 653  € 703 
Total costs*  € 12.740  € 15.253 
Costs for each category were calculated from primary admission up to 90 days after discharge. *Delta for 
total costs was adjusted for differences in patient characteristics (listed in Table 1) in a general linear mixed 
model: Delta €-2125, 95% CI -€4973: €266, p= 0.086.
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R2 resection). Since the events in this subgroup of SPL surgery are low, differences 
in clinical outcomes did not reach statistical significance (except for percentage 
of patients in whom less than 10 and/or 12 lymph nodes were retrieved, Table 
5). Total costs (of primary admission up to 90 days after discharge) and length of 
hospital stay declined between 2011 and 2012. Moreover, primary operation time 
for SPL improved significantly (Table 5).
DISCUSSION
This is the first European study describing costs of SPL surgery for colorectal 
cancer. Our study showed no significant differences between clinical and financial 
outcomes for SPL procedures when compared to conventional laparoscopic pro-
cedures. Results of SPL in the second year (2012) improved as compared to the 
introduction year (2011).
Table 5. Clinical and financial outcomes after SPL between 2011 and 2012: a learning curve?
 2011 2012 Odds ratio (95% CI) p-value 2011 vs 2012
No. Patients (% of yearly total) 28 (23.7%) 50 (31.1%)   +31%
Mortality 0% 2.0% n/a n/a
Major morbidity 35.7% 20.0% 0.935 (0.252: 3.471) 0.83 -44%
Complication 57.1% 38.0% 0.629 (0.201: 1.971) 0.43 -33%
Prolonged length of stay 35.7% 20.0% 0.938 (0.243: 3.624) 0.93 -44%
Reintervention 10.7% 10.0% 0.921 (0.204: 4.202) 0.92 -7%
Anastomotic leakage 7.1% 6.0% 0.843 (0.130: 5.289) 0.84 -15%
R1/R2 resection 0% 6.0% n/a n/a
<10 lymph nodes 35.7% 14.0% 0.110 (0.025: 0.481) 0.003 -61%
<12 lymph nodes 53.6% 32.0% 0.281 (0.080: 0,984) 0.047 -40%
Conversion to open 10.7% 2.0% 0.170 (0.017: 1.720) 0.13 -81%
Total costs  € 19.585  € 12.827  -803 (-14326: 7327) 0.87 -35%
Primary operation time  3.39  3.05 0.66 (0.06: 1.15) 0.034 -10%
Length of hospital stay 16.35 12.46 0.63 (-8.22: 6.29) 0.86 -24%
Odds ratios and p-values were adjusted for differences in patient characteristics (listed in Table 1) in 
a logistic regression model. Odds ratios and p-values written in Italic were not adjusted for patient 
characteristics due to the small number of events for those outcomes.
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SPL techniques in our institution were first introduced in the more simple, benign 
procedures, like cholecystectomies and appendectomies as shown in an earlier 
(feasibility) study of our group 15,16. After 1 year, SPL surgeons translated this tech-
nique to the more difficult procedures, like colorectal (cancer) surgery. So far, only 
two randomized clinical trials (RCTs) compared single-port laparoscopic surgery 
with standard laparoscopy. Poon et al. described less postoperative pain after SPL 
colectomy where Huscher et al. showed no differences in major morbidity and 
mortality 26,27. Existing literature describes longer operating times, more preop-
erative complications, and a technically more challenging procedure when SPL is 
applied 11,12. Although over the last years SPL is (internationally) becoming more 
popular for colorectal procedures, literature about costs of SPL remains scarce 14.
In this study a significant shorter operating time for the SPL procedures is seen 
when In this study, a significantly shorter operating time for the SPL procedures is 
seen when compared to the conventional procedures. This might be because of a 
bias since the SPL procedures were not randomized; however, baseline characteris-
tics between the groups were similar (Table 1). Shorter operating time could result 
in lower operating costs (personnel, etc); however, in this study, we see slightly 
higher operating costs for SPL procedures compared to conventional laparoscopic 
procedures. This is mainly because of higher costs of the port used in SPL proce-
dures since the rest of the equipment did not differ.
During the introduction period of the SPL technique (2011), operation time for 
colorectal cancer resections was longer, hospital stay was prolonged, and complica-
tion rate was higher as compared to the second year (2012). This resulted in overall 
higher hospital costs for SPL procedures looking at 2-year averages as compared to 
CLR procedures (Table 4), although this difference was not significantly different. 
A reduction in complication rate after colorectal cancer resections might result in 
a decrease in healthcare costs as seen in the literature 28. The complication rate in 
the SPL group decreased in
2012 as compared to the introduction year, and therefore, total hospital costs 
became almost similar as CLR (Table 5). If the reduction in complication after SPL 
procedures would further decrease, SPL might become even less expensive in the 
future as compared to CLR. 
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In the first year (2011), a very low number of harvested lymph nodes was seen 
in the SPL group (in 35.7% of the cases, <10 lymph nodes were harvested). In the 
following year (2012), a significant improvement was seen in lymph node harvest-
ing (in 14.0% of the cases, <10 lymph nodes were harvested), resulting in lower 
rates as compared to the CLR group. Together with a shorter operation time and 
lower postoperative complication rate in the second SPL year, the improvement in 
number of harvested lymph nodes supports the idea of a learning curve for SPL 
surgery.
Single-port techniques were introduced to minimize surgical trauma and thereby 
enhance the postoperative recovery period. However, one of the concerns might 
be an increased rate of port-side hernias following singleport access 29. In 2014, 
Milas et al. published a systematic review of single-port laparoscopic cholecystec-
tomies versus multiport cholecystectomies. Overall incidence of trocar site hernia 
was low, but slightly higher in the SPL group. They concluded SPL to be an accept-
able alternative for multiport laparoscopy with modest cosmetic benefit 30. Since 
the primary outcome in this study was hospital costs up to 90 days after discharge, 
we did not specifically analyze for (long-term) trocar site hernias. Furthermore, 
the port side in SPL is frequently being used as extraction side of the specimen. In 
these cases, the cutaneous and fascial incisions were enlarged, thereby increasing 
the risk for local incisional hernias. How the findings of Milas et al. translate to 
colorectal cancer procedures should therefore be an impetus for further studies
Limitations
First of all, costs of specialists’ fees were not uniformly registered between 2011 
and 2012 and were therefore excluded in the analyses. If these costs could be 
incorporated in our analyses, the difference in operation costs between SPL and 
conventional laparoscopic surgery might become smaller due to the lower opera-
tion time for SPL resections. Shorter operating time results in less salary paid per 
procedure. A second limitation of this study was the selection bias, due to the 
retrospective character of the study, as patients were not randomized between 
the two study groups. Although no significant differences in patient characteristics 
between the two groups were seen, the extensive database of the DSCA cannot 
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rule out any additional factors not listed in the DSCA, which influenced the choice 
of procedure and therefore introduced selection bias. Finally, conclusions of supe-
riority and inferiority between the two investigated years cannot be made based 
on this small SPL study group.
Future perspectives
Outcome registries (like the DSCA) combined with financial data might serve as an 
ideal framework to address effectiveness of health care. Combining clinical and 
financial outcomes, as seen in this study, with patient-reported outcome measures 
should provide even better insights. Items as quality of life, postoperative pain, 
or cosmetic results should therefore be addressed in future (prospective) studies.
CONCLUSION
In conclusion, this 2-year retrospective study showed no significant differences in 
financial outcomes between conventional and single-port laparoscopic colorectal 
procedures. Hospital costs of SPL decreased after the introduction year (2011) as 
compared to the second year (2012). Our conclusions are based on a small SPL 
group, and therefore, further research is needed to validate our results
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SUPPLEMENTAL MATERIAL
Supplemental table 1. Different categories of resources extracted from the Hospital Information System 
Category Examples within category
Operation Surgery time, operation room session 
Ward Inpatient ward days
Intensive care Intensive Care Unit days, Medium Care Unit days, Cardiac Care Unit days
Radiology Ultra sound, X-ray, CT scan, MRI scan
Laboratory Activities related to pathology, hematology, clinical chemistry, microbiology
Consulting Consults other medical specialist, outpatient department visits
Materials Blood products, prostheses and implants
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The objective of this study was to explore the association among adverse events, 
body mass index (BMI), and hospital costs after colorectal cancer surgery in a 
country with an intermediate BMI distribution.
Methods
All colorectal cancer procedures in 29 Dutch hospitals listed in a 2010–2012 
population-based database and with a BMI>18.5 were included (n=8687). Hospital 
costs were measured uniformly and based on time-driven activity-based costing. 
The BMI classification of the World Health Organization was used.
Results
Patients in obesity classes 1 (23.6% [after risk-adjustment OR 1.245, CI 1.064–
1.479, P.0.007]) and ≥ 2 (28.1% [after risk-adjustment OR 1.816, CI 1.382–2.388, 
P<0.001]) were associated with more severe complications and higher hospital 
costs (€14,294, +9.6%, after risk-adjustment +7.9%, P<0.001; and €15,913 +22.0%, 
after risk-adjustment +21.2%, P<0.001, respectively) than normal weight patients 
(20.8% and €13,040, respectively). Pre-obese patients had significantly lower mor-
tality rates (2.7%, after risk-adjustment, OR 0.756, CI 0.577–0.991, P.0.042) than 
normal-weight patients (3.9%).
Conclusions 
Obese surgical colorectal cancer patients in a country with an intermediate BMI 
distribution are associated with a significant increase in hospital costs because 
these patients suffer from more severe complications. This is the first study to pro-
vide evidence for the “obesity paradox” for mortality in colorectal cancer surgery
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INTRODUCTION
According to the World Health Organization more than 1.9 billion adults are 
overweight (body mass index (BMI) >25 kg/m2) and of these over 600 million are 
obese (BMI >30 kg/m2) 1. Obesity is a major risk factor for several diseases, such as 
cardiovascular diseases, diabetes and several types of cancers 2. 
One of the most well-known obesity-linked cancers is colorectal cancer 2,3, the 
second leading cause of cancer-related deaths in the United States 4 and Europe 5. 
Colorectal surgery is related to a disproportional share of adverse events 6 and its 
complications account for a dramatic increase in hospital costs 7. A specific popula-
tion that is at risk includes colorectal cancer patients suffering from obesity. These 
patients are associated with increased postoperative risks of pulmonary compli-
cations, wound infections, and cardiovascular events 8-10. Regarding mortality, 
evidence from general surgery suggest that there seems to be a so-called “obesity 
paradox” that involves pre-obese and mildly obese surgical patients having lower 
mortality rates than patients of normal weight 11. However, for colorectal cancer 
patients, this relationship has not yet been identified 8,9. 
Multi-center studies describing whether obesity has a major impact on hospital 
costs after colorectal cancer surgery are scarce. Existing studies describing this 
relationship have been conducted in the relatively obese populations of the United 
States 10 and New Zealand 9 and the relative none-obese population in Japan 8. It re-
mains unclear, however, whether these results can be generalized to countries with 
more intermediate BMI distributions such as Sweden, France and the Netherlands 
12,13. Therefore, the aim of this study was to explore the association between hos-
pital costs and BMI after colorectal cancer surgery in a population-based registry 
from a country with an intermediate BMI distribution. Because hospital costs are 
closely related to complications 7, a secondary aim was to explore the association 







The data set was retrieved from the Dutch Surgical Colorectal Audit (DSCA), a na-
tionwide, population-based database in which detailed patient, tumor, diagnostic, 
procedural, and outcome data are registered for all patients who undergo resection 
of primary colorectal carcinoma in the Netherlands. The DSCA shows almost 100% 
completeness on most items and a high accuracy level in terms of validation (97% 
in 2012) against the Netherlands Cancer Registry dataset 14,15. A detailed descrip-
tion of the DSCA has been published recently 15,16. 
 
Financial data
The economic evaluation was conducted from the hospital perspective. Therefore, 
only “in-hospital” costs were considered. The costs were accounted for from the 
day of the initial surgery until discharge (= primary admission) and within the first 
90 days after discharge (= Q1). For each hospital, the translation of patient-level 
resource utilization (extracted from the hospital information system) into costs was 
provided by Performation (Bilthoven, the Netherlands), a healthcare consultancy 
firm providing patient-level costing and benchmarking services for more than 100 
hospitals across Europe 17. Costs were calculated using Time-Driven Activity-Based 
Costing (TD-ABC) methodology 18 which is an advanced method for understanding 
(hospital) costs 19. Briefly, the TD-ABC is a bottom-up micro-costing method that 
consists of calculating two parameters per activity: the costs per time unit to per-
form each activity and the overall time units spent performing the activity. Com-
pared with top-down costing methods, the TD-ABC is superior in terms of revealing 
patient-level resource-use variations and the prevention of cross-subsidizations 20. 
The cost price calculations were standardized by Performation; therefore, unifor-
mity in the methodology existed among all participating hospitals. The most recent 
cost price model of 2012 for each hospital was used for all years (2010, 2011, and 
2012) to avoid differences due to inflation and the different models themselves. 
Different activities were grouped into eight categories, as shown in Supplemental 
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Table 1. All activities contained direct hospital costs (e.g., personnel, material, and 
equipment) and indirect hospital costs. For example, direct costs for an inpatient 
day (category “ward”) consisted of the (a) salaries of the ward nurses; (b) material 
costs, including bed linens and bandages; and (c) depreciation of equipment, such 
as beds and ward inventory. Examples of indirect costs included costs related to 
information technology, building depreciation, cleaning, and catering. Specialists’ 
fees, medication costs, and costs for dialyses were excluded because the registra-
tion of these parameters was not uniform across the participating hospitals, which 
made an equal comparison impossible. 
A detailed description of the database of the Dutch Value Based Healthcare study 
has recently been published 7,21.
Inclusion criteria
Hospital selection (n=29) was based on the availability of detailed cost-price in-
formation from Performation for three consecutive years (2010, 2011, and 2012). 
Twenty-one hospitals (72%) had surgical teaching programs. The 29 participating 
hospitals had a representative BMI distribution of colorectal cancer patients that 
was compared with hat of the nationwide BMI distribution of colorectal cancer 
patients (Supplemental Table 2). Patients who underwent surgical resection for 
primary colorectal cancer between January 1st, 2010 and December 31st, 2012 
had to be registered in the DSCA before December 1st 2013. Unique Patient 
Identification Numbers (combined with the hospital of admission) were used to 
match patients registered in the DSCA to the financial database. The minimum data 
requirements to consider a patient eligible for matching with the financial dataset 
included information about tumor location, date of surgery, mortality status, and 
BMI.
Definitions
Weight categories were selected according to the WHO standards: normal weight 
[BMI 18,5-24,99 kg/m2], pre-obese [BMI 25-29,99 kg/m2], obesity class 1 [BMI 30-
34,99 kg/m2] and obesity class ≥2 (containing both obesity class 2 [BMI 35-39,99 
kg/m2] and obesity class 3 [BMI > 40 kg/m2])1.
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Primary outcome measures for quality of healthcare were (1) postoperative mor-
tality, defined as in-hospital or 30-day mortality; (2) severe complication, defined 
as in-hospital or 30-day adverse outcomes leading to mortality, reintervention 
(percutaneous or operative), or a post-operative primary hospital stays of at least 
14 days [7,22 and 3) and (3) failure to rescue (FTR), defined as the percentage of 
patients with severe complications who died in-hospital or within 30 days after re-
section 22. Secondary clinical outcome measures that occurred in-hospital or within 
30 days after resection were (4) any complications; (5) mild complications, defined 
as complications that were not severe; (6) reintervention (surgical, radiological or 
endoscopic); (7) anastomotic leakage/abscess; (8) R1/R2 resection; (9) resections 
for which fewer than 10 lymph nodes were retrieved; (10) duration of the primary 
operation; and (11) length of hospital stay (primary admission only, and the day of 
surgery was day 1).
Financial outcome measures were (1) total costs (= all hospital costs from primary 
admission to 90 days after discharge, which, therefore, included the costs of re-
admission and -operation) and (2) costs per category, as listed in Supplemental 
Table 1.
Analysis 
Chi-square test and One-way Anova were used to investigate differences between 
patients’ characteristics in the three different groups (Table 1). 
Absolute clinical and financial outcomes were presented unadjusted (and adjusted 
were stated). To investigate differences between the BMI groups for all outcomes of 
interest, a multivariate mixed effects model with risk adjustment for patients’ char-
acteristics and hospitals as random effects was estimated. Mixed models include 
additional random-effect terms and are appropriate to handle nested data (like pa-
tients in each hospital) and unequal study 23,24. Patients’ characteristics included in 
the analyses were sex, age (categorical), presence of synchronous tumors, location 
of tumor, stage of tumor (TNM), pre-operative radiotherapy, distant metastases, 
metastasectomy, and extended resections. American Society of Anesthesiologists 
(ASA) classification and Charlson score were not used for risk-adjustment as these 
characteristics have a strong correlation with BMI status. 
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As several continuous outcomes showed skewed distributions a logarithmic trans-
formation of the original variable has been applied. Logarithmic transformations 
of variables in a regression model are a common way to handle a highly skewed 
variable into one that is more a proximately normal. Results are then reported in 
the original scale by taking the exponential transformation of the estimated re-
gression coefficients. For all adjusted outcomes representing costs, the difference 
between each BMI group and the reference group (normal weight) was reported 
as an adjusted percentage.
Statistical analyses were performed by using SPSS (version 20; IBM) and R (version 
18). Outcomes are presented as the mean. Confidence intervals (CI) were stated 
at 95%.
RESULTS
A total of 9,913 patients were listed in the database. Patients who were under-
weight (n=162; 1.6%) and patients with unknown BMIs (n=1,064; 10.7%) were 
excluded, which resulted in 8,687 patients who were eligible for the analysis. Of 
the included patients, 3,666 (42.2%) were normal weight, 3,577 (41.2%) were pre-
obese, 1,145 (13.2%) were obese class 1, and 299 (3.4%) were obese class ≥2. All 
analyzed patients, tumors and procedural characteristics of the studied population 
are shown in Table 1.
Clinical outcomes
Mortality rates were lower for the pre-obese patients (2.7%) and the obesity class 
1 patients (2.4%) and higher for the obesity class ≥2 patients (4.7%) than for the 
normal-weight patients (3.9%). After adjustment for patient characteristics and 
treatment hospitals, the mortality rates were significantly lower for the pre-obese 
patients (OR 0.756, CI 0.577–0.991, P=0.042) and significant higher for the obesity 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Severe complication rates were higher for the pre-obese patients (22.4%), the 
obesity class 1 patients (23.6%) and the obesity class ≥2 patients (28.1%) than for 
the normal-weight patients (20.8%). After adjustment for patient characteristics 
and treatment hospitals, the severe complication rates were significantly higher 
for the obese class 1 patients (OR 1.245, CI 1.064–1.479, P=0.007) and the obesity 
class ≥2 patients (OR 1.816, CI 1.382–2.388, P<0.001) than for the normal weight 
patients (Table 2).
After adjustment for patient characteristics and treatment hospitals, outcomes 
such as reintervention rates, anastomotic leakage rates, radical resections and <10 
lymph nodes did not significantly differ between the pre-obese/obese patients and 
the normal-weight patients (Table 2).
Table 2. Clinical outcomes stratified by BMI category
 
Normal 
weight Pre-obese Obesity class 1 Obesity class ≥2
Outcomes (reference)  
OR      
(95% CI)*  
OR      
(95% CI)*  



























































Unadjusted percentages are shown. Outcomes in bold were significant different (p<0.05). * Odds ratios 
and 95% confidence intervals (CI) were adjusted for patient characteristics and hospital of treatment.
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Operation time was longer for the pre-obese patients (2.94 hr), obesity class 1 pa-
tients (3.03 hr), and obesity class ≥2 patients (3.27 hr) than for the normal-weight 
patients (2.83 hr). After adjustment for patient characteristics and treatment 
hospitals, the operation times were significantly longer for all of the overweight 
categories than for the normal-weight patients. The lengths of hospital stay 
(means) were longer for the pre-obese patients (9.93 days), obesity class 1 patients 
(10.41 days), and obesity class ≥2 patients (10.85 days) than for the normal-weight 
patients (9.55 days). After adjustment for patient characteristics and treatment 
hospitals, the lengths of hospital stay were significantly longer for all of the over-
weight categories than for the normal-weight patients (Table 3).
FTR rates were lower for the pre-obese patients (12.1%), obesity class 1 patients 
(10.4%), and obesity class ≥2 patients (16.7%) than for the normal-weight patients 
(18.6%). After adjustment for patient characteristics and treatment hospitals, the 
FTR rates were significant lower for the pre-obese patients (OR 0.594, CI 0.434–
0.811, P=0.001) and obesity class 1 patients (OR 0.477, CI 0.292–0.781, P=0.003) 
than for the normal-weight patients (Figure 3A).
Financial outcomes
Total hospital costs were higher for the pre-obese (€13,818, +6.0%), obesity class 
1 (€14,294, +9.6%), and obesity class ≥2 (€15,913, +22.0%) patients than for the 
normal-weight patients (€13,040). After adjustment for patient characteristics and 





class 1 Obesity class ≥2
Outcomes (reference)  
% incr.  
(95% CI)*  
% incr.  
(95% CI)*  






 +6.9%  
(4.798: 9.132) 3.27
 +15.5%  
(11.437: 19.684)
LOS (days) 9.55 9.93
 +4.0% 
(1.191: 6.955) 10.41
 +9.0%  
(4.739: 13.416) 10.85
 +13.7%  
(5.962: 21.963)
Unadjusted outcomes are shown. Outcomes in bold were significant different (p<0.05).  Operation time 
for primary operation is shown. Length of hospital stay (LOS) for primary admission is shown (day of 
surgery = day 1).  * Percentage increase (% incr.) and 95% confidence intervals (CI) were adjusted for 
patient characteristics and hospital of treatment. 
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treatment hospitals, the total hospital costs were signifi cantly greater for the obe-
sity class 1 pati ents (+7.9%, CI 3.6–12.3%, P<0.001) and obesity class ≥2 pati ents 
(+21.2%, CI 12.9–30.0%, P<0.001) than for the normal-weight pati ents (Figure 1).
In detail, the costs related to the wards, operati ons, and intensive care units were 
the greatest contributors to total hospital costs (Figures 2A–C). Aft er adjustment 
for pati ent characteristi cs and treatment hospitals, the pre-obese pati ents had sig-
nifi cantly higher operati on costs (Figure 2B) than the normal-weight pati ents. Aft er 
adjustment for pati ent characteristi cs and treatment hospitals, the obesity class 
1 pati ents had signifi cantly higher hospital costs related to the wards (Figure 2A), 
operati on (Figure 2B), laboratory (Figure 2D), and consultati on (Figure 2E). Aft er 
Figure 1. Average costs aft er colorectal cancer surgery strati fi ed by BMI category 
Unadjusted Aft er adjustment*
BMI groups Euro Increase Increase 95% CI p-value
Normal weight  € 13040 - - - -
Pre-obese  € 13818 6.0% 2.4% (-0.4%: 5.3%) 0.094
Obesity class 1  € 14294 9.6% 7.9% (3.6%: 12.3%) <0.001
Obesity class ≥ 2  € 15913 22.0% 21.2% (12.9%: 30.0%) <0.001
Costs are calculated from primary surgery up to 90 days aft er discharge.
* Adjusted for pati ent characteristi cs and hospital of treatment.
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adjustment for pati ent characteristi cs and treatment hospital, the obesity class ≥2 
pati ents had signifi cantly greater hospital costs related to the wards (Figure 2A), 
operati on (Figure 2B), laboratory (Figure 2D), consultati on (Figure 2E), and other 
costs (Figure 2H). 
Costs for pati ents without complicati ons were lower for the pre-obese pati ents 
(€9,028, -3.1%) and higher for the obesity class 1 (€9,768, +4.9%) and obesity class 
≥2 (€10,195, +9.5%) pati ents than for the normal-weight pati ents (€9,313). Aft er 
adjustment for pati ent characteristi cs and treatment hospitals, the costs of the 
obesity class 1 (+5.6%, CI 2.1–9.2%, P=0.001) and obesity class ≥2 pati ents (+14.2%, 
CI 7.2–21.8%, P<0.001) were signifi cantly greater than those of the normal-weight 
pati ents (Figure 3B). The costs of the pati ents with severe complicati ons were 
higher for the pre-obese (€28,827, +12.0%), obesity class 1 (€27,995 +8.8%,), and 
obesity class ≥2 (€29,915, +16.3%) pati ents than for the normal-weight pati ents 
(€25,727). Aft er adjustment for pati ent characteristi cs and treatment hospital, the 
Figure 2.  Comparison of all cost categories between the diff erent BMI groups
Costs are calculated from primary surgery up to 90 days aft er discharge (therefore cost of re-operati ons 
and re-admissions are included).
Blue: Adjusted outcomes for pati ent characteristi cs and hospital of treatment. * p<0.05 as compared to 
normal weight.
Red: Unadjusted outcomes. † p<0.05 between the diff erent BMI groups using ANOVA.
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costs of the pre-obese pati ents (+8.7%, CI 1.9–16.1%, P=0.012) were signifi cantly 
greater than those of the normal-weight pati ents (Figure 3C).
DISCUSSION
This populati on-based report shows that surgical colorectal cancer pati ents with 
obesity are associated with a signifi cant increase in hospital costs. This increase in 
costs may be explained by more intensive use of resources because obese pati ents 
suff er from signifi cantly more severe complicati ons than normal-weight pati ents. 
Moreover, the present study is the fi rst multi -center study to provide evidence for 
the “obesity-paradox” that has been seen in general surgery; that is, pre-obese 
pati ents undergoing colorectal cancer surgery have a signifi cantly reduced risk of 
mortality compared with normal weight pati ents.
Figure 3.  Adverse outcomes (obesity paradox) (A) and costs of pati ents without complicati ons (B) and with 
severe complicati ons (C)
A. Obesity paradox (crude percentages)
B. Costs of pati ent without complicati ons
C. Costs of pati ents with severe complicati ons
* Outcomes are signifi cant diff erent as compared to normal weight aft er adjustment for pati ent character-
isti cs and hospital of treatment (p<0.05). † Signifi cant diff erences for unadjusted outcomes between the 
BMI groups using ANOVA (p<0.05). Abbreviati ons: BMI, Body Mass Index; FTR, failure to rescue.
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Hospital costs of obese patients undergoing colorectal cancer surgery
Both overweight and obesity place a financial burden on health services and the 
wider economy 25. However, (multi-center) evidence regarding whether obesity has 
a major impact on hospital costs after colorectal cancer surgery remains scarce. 
A recent single-center study from New Zealand showed a significant increase in 
hospital costs for obese patients (>30 kg/m2); however, likely due to a small sample 
size (n=345), no distinctions between obesity classes were noted 9. Two recent 
multi-center studies reported diverse results; a study from the USA reported no 
differences in hospital costs between non-obese and obese patients, whereas a 
Japanese study reported a significant increase in hospital costs for obese patients 
(>30 kg/m2) 8,10. However, cost analyses of both multi-center studies were ham-
pered by their reliance on administrative claim data 8,10 and, therefore, did not 
analyze real costs 19. 
In this population-based study, after adjustment for patient characteristics and 
treatment hospitals, higher hospital costs were observed for both obesity class 1 
and obesity class ≥2 patients than for normal-weight patients (Figure 1). These dif-
ferences were most likely due to the increase in the severe complication rate with 
each increase in BMI because severe complications after colorectal cancer surgery 
account for a substantial rise in hospital costs 7. This supposition is also supported 
by the increased (crude) costs related to wards (Figure 2A), (re-) operations (Figure 
2B), and intensive care units (Figure 2C) for obese patients. The lack of accurate 
and comparable cost calculations across different institutions is a known limitation 
of multi-center studies analyzing hospital costs. Therefore, a major strength of this 
study was the use of uniform cost calculations for every individual patient based 
on the TD-ABC methodology 18, which is a superior method for measuring and 
understanding actual costs 19. Because the TD-ABC methodology was standardized 
in all participating hospitals, we were able to make accurate and comparable cost 
calculations for all patients from the individual institutions.. 
The ‘obesity paradox’ and FTR in colorectal cancer surgery
A large NSQIP study analyzing more than 100,000 general surgery procedures 
(bariatric and vascular surgeries excluded) found that overweight and moderately 
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obese patients have lower crude and adjusted risks of mortality than normal-weight 
patients 11. In the literature this phenomenon is called the ‘obesity paradox’, that is, 
mild obesity is associated with improved outcomes.
In the case of colorectal cancer surgery, the recent literature shows contradictory 
results. In a Japanese setting, gastrointestinal cancer patients with normal BMIs 
(23 kg/m2) had the lowest mortality rate, although this rate was not significantly 
different from that of patients with obesity 8. Regarding rectal cancer surgery, an 
Australian study showed no differences in clinical outcomes (complications and/
or mortality) of patients with between BMIs <30 kg/m2 and >30 kg/m2 26 whereas 
a NSQIP study from the United States of America (USA) showed a higher risk of 
overall morbidity for patients with BMIs >35 kg/m2 27. A study from the USA study 
that analyzed colon cancer procedures found no significant differences in clinical 
outcomes (complications and/or mortality) between none-obese and obese pa-
tients 28 whereas other studies from New Zealand and the USA have found only 
increased risks of wound-related complications for obese patients (no significant 
differences in severe complications or mortality were found) 9,10,29. 
In contrast to the earlier findings regarding colorectal cancer procedures8,9,26-29, the 
present study provided evidence for a protective effect of pre-obesity on mortality 
(Table 2 and Figure 3A), similar to that found in studies that have analyzed general 
surgery procedures 11. The discrepancy between those earlier studies 8,9,26-29 and 
the present study may be explained by the use of a detailed population-based 
database in the present study 14 which included patients who are not eligible for 
clinical trials 30. Moreover, single-center studies 9,26,28,29 often describe the work of 
dedicated teams in specialized centers and, therefore, may raise questions regard-
ing whether those results can be extrapolated to the national level. Finally, the 
three multi-center studies were all conducted with patients living in countries with 
different BMI distributions (either very low or very high BMIs) than that of the 
Dutch setting 8,10,27. This may affect clinical outcomes because the percentages of 
body fat 31 and biological factors may differ between populations. Moreover, one 
may suggest that less-obese countries have less-experienced doctors and nursing 
staff in terms of the treatment of obese patients, which could explain the relatively 
higher peri- and post-operative mortality rates for those patients 8. 
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The pre-obese patients in this study exhibited no significant differences in severe 
complication rates compared with the normal weight patients; however, the rate 
of failure to rescue these patients was significant lower, resulting in significantly 
less mortality (Figure 3A). Even the obesity class 1 patients had significantly lower 
FTR rates, although their crude severe complication rate was significant higher 
(Figure 3A). No protective effect of severe obesity (class ≥2) was observed; instead, 
these patients had significantly higher severe complication rates and significant 
higher mortality rates than the normal-weight patients. The reason for this differ-
ence is difficult to identify based on our data. Remarkably, the pre-obese patients 
suffering from severe complications were significantly more expensive than the 
normal-weight patients with severe complications (Figure 3B), which may indicate 
more intensive (and, therefore, more expensive) treatments. However, the costs of 
obese patients with severe complications were not significantly higher (Figure 3B) 
A more likely explanation may be the interaction between metabolic regulation and 
the immune response 32. The obese state is characterized by a low-grade systemic 
inflammation in which a number of adipokines, such as tumor necrosis factor α 
and some pro-inflammatory interleukins, are up-regulated 33,34. This inflammation 
engages almost the same set of molecules and signaling pathways that are engaged 
in tissue repair 32 and, therefore, may provide a more protective state for surgery. 
This benefit likely has a certain cut-off point at which the disadvantages outweigh 
the benefits, resulting in more complications in severely obese patients (Figure 3A). 
Limitations
First, a known limitation of retrospective studies is the occurrence of coding or 
documentation errors in large databases. This resulted in the exclusion of 10.7% of 
the total number of patients because the length and/or weight data were missing; 
therefore, no BMI could be calculated. Second, costs of specialists’ fees, medica-
tion and dialyses were excluded from our analyses, which may have resulted in the 
underestimation of the total costs of all groups. However, we do not believe that 
this limitation had a major impact on our conclusions. The costs of the patients 
with higher BMIs may in fact be even higher because patients with higher BMIs 
are more likely to have more comorbidities (and, therefore, higher medication 
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expenses), and these patients are associated with longer operation times (and, 
therefore, higher specialist fees). Finally, we used a population-based registry (92 
hospitals) but included only 29 hospitals in our analyses because of the lack of 
uniform cost calculations in the other institutions. However, these 29 hospitals 
represent more than one-third of all colorectal cancer procedures performed in 
the Netherlands. Moreover, the BMI distributions of the 29 studied hospitals were 
almost identical to the nation-wide BMI distribution and were therefore indicative 
of a representative selection of the population database (Supplemental Table 2).
CONCLUSIONS
As shown in this study, healthcare providers in countries with intermediate BMI 
distributions should be aware of increased (i.e., more severe) complication rates 
and increased hospital costs when treating obese colorectal cancer patients. The 
present study revealed that pre-obese colorectal cancer patients were in a protec-
tive state in terms of mortality.
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SUPPLEMENTAL MATERIAL
Supplemental Table 1. Different categories of resources extracted from the Hospital Information System
Category Examples within category
Operation Surgery time, operation room session 
Ward Inpatient ward days
Intensive care Intensive Care Unit days, Medium Care Unit days, Cardiac Care Unit days
Radiology Ultra sound, X-ray, CT scan, MRI scan
Laboratory Activities related to pathology, haematology, clinical chemistry, microbiology
Consulting Consults other medical specialist, outpatient department visits
Materials Blood products, prostheses and implants
Other Electrocardiography, spirometry, physiotherapy, medical rehabilitation
Supplemental Table 2. Distribution of Body Mass Index (BMI) in the participating hospitals and in all Dutch 
hospitals (2010-2012)
  This study (n=29) All Dutch hospitals (n=92)*
Number patients 8687 20384
BMI class
  Normal weight 3666 (42.2%) 8473 (41.6%)
  Pre-obese 3577 (41.2%) 8461 (41.5%)
  Obesity class I 1145 (13.2%) 2715 (13.3%)
  Obesity class ≥II 299 (3.4%) 735 (3.6%)
* Retrieved from the Dutch Surgical Colorectal Audit. Only patients with information on tumor location, 
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Due to increasing healthcare costs, discussions regarding increased hospital costs 
when operating on high-risk patients is rising. Therefore, the aim of this study was 
to analyze if oldest-old colorectal cancer patients have a greater impact on hospital 
costs than their younger counterparts.
Methods
All colorectal cancer procedures performed in 29 Dutch hospitals between 2010 
and 2012 and listed in the Dutch Surgical Colorectal Audit were analyzed. Oldest-
old patients (≥85 years) were compared to patients <85 years. Ninety-day hospital 
costs were measured uniformly in all hospitals based on time-driven activity-based 
costing.
Results
Compared to <85-year-old patients (n = 9130), the oldest old (n = 783) had longer 
hospital stays (LOS) (11.3 vs 13.2, p < 0.001), more severe complications (21.8% vs 
29.0%, p < 0.001), more failure to rescue (13.9% vs 37.0%, p < 0.001) and higher 
mortality (3.0% vs 10.7%, p < 0.001). Deceased oldest-old patients had significantly 
less LOS and less LOS ICU. Total hospital costs were 3% lower for oldest-old patients 
(€13168) than for <85-year-old patients (€13644, p < 0.001). In cases of severe 
complications or death, hospital costs for the oldest old were 25% and 31% lower 
than those of < 85-year-old patients (both p < 0.001).
Conclusion 
Although frequently assumed to be more expensive, operating on oldest-old pa-
tients with colorectal cancer does not increase hospital costs compared to younger 
patients. This was most likely due to faster deterioration or less aggressive treat-
ment of oldest-old patients when (severe) complications occurred.
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INTRODUCTION
Due to increasing life expectancy and earlier detection programs, the incidence 
of colorectal cancer is increasing rapidly 1,2. Surgery for colorectal cancer is associ-
ated with a disproportional share of adverse events compared to general surgery 
3, and its complications are responsible for a tremendous increase in hospital costs 
4. Although the oldest old are at risk for developing complications after colorectal 
cancer procedures 5,6, earlier studies show that surgery remains the treatment of 
choice for this subgroup 7,8. 
As of 2009, all Dutch colorectal cancer patients undergoing a resection are listed in 
a nationwide database (The Dutch Surgical Colorectal Audit, DSCA) 9. Although the 
(daily) decision-making over whether a patient can undergo an operation is primar-
ily based on clinical arguments, there is still an ongoing discussion regarding in-
creased hospital costs when operating on high-risk and/or frail patients. Moreover, 
because the Dutch health care system is struggling with rising costs (its expenditure 
rose to more than 13% of the gross domestic product in 2012 10), one might argue 
that operating on the oldest old for colorectal cancer might result in an impermis-
sible misbalance in the use of hospital resources. To facilitate this discussion, the 
aim of this study was to analyze if the oldest old (age ≥85 years) colorectal cancer 
patients have a greater impact on hospital costs than their younger counterparts. 
METHODS
Data collection
The data used for this study was retrieved from a combined clinical and financial 
dataset in the Dutch Value Based Healthcare Study. A detailed description of inclu-
sion of hospitals (n = 29) and matching of the clinical and the financial dataset has 
been described recently 11.  
The clinical data set was retrieved from the DSCA, a population-based database 
in which detailed patient, tumor, diagnostic, procedural and outcome data are 
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registered for all patients undergoing a resection of a primary colorectal carcinoma 
in the Netherlands 9,12. 
The economic evaluation was conducted from a hospital perspective. Therefore, 
only ‘in-hospital’ costs were considered. Costs were taken into account from the day 
of initial surgery until discharge (= primary admission) up to 90 days after discharge 
(= Q1). Resource utilization at the patient level (e.g., laboratory orders, operation 
room time or ward days, see Supplemental Table 1) was extracted from the Hospital 
Information System from each participating hospital. For each hospital, the transla-
tion of patient level resource utilization into costs was provided by Performation 
(Bilthoven, The Netherlands), a healthcare consultancy firm providing patient level 
costing and benchmarking products for more than 100 hospitals across Europe 13. 
Costs were calculated using Time-Driven Activity-Based Costing (TD-ABC) 14, which 
is a bottom-up micro-costing method that consists of calculating two parameters 
per activity: the costs per time unit to perform each activity and the overall time 
units spent performing the activity. Compared with top-down costing methods, the 
TD-ABC is superior in terms of revealing patient-level resource-use variations and 
the prevention of cross-subsidizations 15,16. The cost price calculations have been 
standardized by Performation, and therefore uniformity in methodology exists 
between all participating hospitals. The most recent cost price model (2012) for 
each hospital was used for all three years (2010, 2011, and 2012) to avoid differ-
ences due to inflation or the different models themselves. Different activities are 
grouped into eight categories, as shown in Supplemental Table 1. Specialists’ fees, 
medication and dialysis costs were excluded because these parameters were not 
uniform in the participating hospitals, which made equal comparisons impossible.
Definitions
The oldest old patients were defined as any patient age 85 or older. As a reference 
group, all patients <85 years old were used. The cutoff age of 85 was determined 
based on an earlier review stating that age >85 years was related to significantly 
more mortality and morbidity, such as pulmonal and cardiovascular complications 
7. This was recently confirmed in the DSCA, which showed that the risk of 30-day 
mortality increases to 10% for patients ≥85 years compared to 1% of patients <70 
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years and 4% for patients 70-84 years old 5. For the sub-analyses, extremely old 
patients were defined as patients aged 90 or older, and patients who were 85-90 
years old were used as a reference group.
The outcome measures for quality of healthcare included postoperative mortality, 
which was defined as in-hospital death or death within 30 days after surgery; any 
complications, which were defined as complications occurring during admission 
or within 30 days after surgery; severe complications, which were defined as 
complications occurring during admission or within 30 days after surgery that led 
to mortality, reintervention (operative or percutaneous), or a prolonged hospital 
stay of 14 days or more; anastomotic leakage/abscess; reintervention (surgical, 
radiological, or endoscopic); failure to rescue (FTR), which was defined as the 
percentage of patients with severe complications who died in-hospital or within 30 
days after resection 17; R1/R2 resection; resections in which fewer than 10 lymph 
nodes were retrieved; length of hospital stay (LOS, starting from day of operation 
= day 0) and LOS ICU. Financial measures were the total costs (primary admission 
up to 90 days after discharge; costs of primary admission; costs of Q1 (= first 90 
days after discharge) and total costs (primary admission and Q1) by category (as 
mentioned in Supplemental Table 1).
Analysis
A chi-square test and One-way ANOVA were used to investigate the differences 
between patient characteristics in the two groups (Table 1). Absolute clinical and 
financial outcomes were presented as unadjusted (no risk-adjustment was used 
due to the descriptive focus of this study). The significance level of the univariable 
analysis was set at a two-tailed P-value of 0.05. The odds ratio (OR) along with the 
95% confidence interval was calculated for each clinical binary outcome. The raw 
difference between the two groups (“unstandardized” mean difference) together 
with a confidence interval was computed to compare non-normal continuous out-
comes (hospital costs and LOS) 18. The use of the “unstandardized” mean difference 
may be used when the outcome was not normally distributed. Statistical analyses 
were performed using SPSS (version 20; IBM) and R (version 18). The outcomes are 
presented as the mean.
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Table 1.  Patient, tumor and operations characteristics
  <85 year  ≥85 year  
  n %  n %  
N (% of total)  9130 92.1%  783 7.9% p-value
Patient and tumor characteristics       
Age (mean in year) 68.4 87.6 <0.001
Male  5143 56.3%  328 41.9% <0.001
BMI (mean in kg/m2)  26.2  25.0 <0.001
Charlson score Charlson 0 5018 55.0%  291 37.2% <0.001
 Charlson 1 2045 22.4%  220 28.1%  
 Charlson 2+ 2067 22.6%  272 34.7%  
ASA score I-II 7077 77.8%  391 50.3% <0.001
 III 1880 20.7%  359 46.1%  
 IV-V 136 1.5%  28 3.6%  
Tumor location Right colon 2804 30.7%  382 48.4% <0.001
 Left colon 1051 11.5%  100 12.8%  
 Sigmoid 2494 27.3%  179 22.9%  
 Rectum 2781 30.5%  122 15.6%  
Tumor stage (TNM) Stage 0 164 1.8%  5 0.6% <0.001
 Stage 1 616 6.8%  30 3.9%  
 Stage 2 1924 21.2%  153 19.7%  
 Stage 3 4984 55,0%  470 60.4%  
 Stage 4 1200 13.2%  112 14.4%  
 Unknown 172 1.9%  8 1,0%  
Preoperative None 446 16.0%  39 32.0% <0.001
  -radiotherapy* 5 x 5 Gy 1282 46.1%  76 62.3%  
 Long course**/ else 1053 37.9%  7 5.7%  
Double tumor Yes 300 3.3%  25 3.2% 0.02
Distant metastases Yes 985 10.8%  53 6.8% <0.001
Operation characteristics       
Emergency resection  1161 12.7%  173 22.1% <0.001
Laparoscopic  4302 47.4%  277 35.6% <0.001
Conversion (LR only)  585 13.6%  36 13,0% 0.08
Metastasectomy  278 3.0%  12 1.5% 0.02
Extended resection  779 8.5%  66 8.4% 0.92
Anastomosis/ stoma Stoma 1791 20.3%  211 28,0% <0.001
 Anastomosis 5804 65.9%  515 68.4%  
 Anastomosis & stoma 1209 13.7%  27 3.6%  
Operation time (mean) 
***  3.07  2.65 <0.001
* Rectum only. ** Long course = 28x1.8Gy/ 25x2.0Gy ***Operation time for primary operation in hour 
is shown.  Abbreviations: BMI, Body Mass Index; ASA, American Society of Anesthesiologists risk score; 
Left colon, including transverse colon; TNM, Classification of Malignant Tumors; Gy, gray; LR, Laparoscopic 
resection.
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RESULTS
A total of 9,913 patients were eligible for analysis. Of those patients, 9,130 patients 
were aged <85 years, and 783 patients were aged ≥85 years. All analyzed patient, 
tumor and procedure characteristics of the studied population are shown in Table 
1. In particular, patients ≥85 years and older were less frequently operated on for 
rectal cancer (16% vs 31%), received less frequent pre-operative radiotherapy (68% 
vs 84%), had fewer metastases (6.8% vs 10.8%), were more often operated on in an 
emergency setting (22% vs 13%), received an anastomosis with a stoma less often 
(4% vs 14%) and were more likely to receive a primary stoma (28% vs 20%) than 
patients <85 years.
Clinical outcomes
The overall mortality rate was significantly higher for all ≥85-year-old patients (elec-
tive and emergency) than for the <85-year-old patients (10.7% vs 3.0%, OR 3.855, 
CI 2.984-4.980, p < 0.001) as well as in elective settings (7.4% vs 2.4%, OR 3.201, 
CI 2.281-4.493, p < 0.001). In addition, any complications, severe complications, 
reintervention, FTR, R1/R2 resections, LOS and LOS ICU were significantly higher for 
≥85-year-old patients than for <85-year-old patients. LOS and LOS ICU for deceased 
patients were significantly lower for ≥85-year-old patients than for <85-year-old 
patients. Anastomotic leakage and resections in which fewer than 10 lymph nodes 
were retrieved did not differ significantly between the two groups (Table 2).
Financial outcomes
Total hospital costs for ≥85-year-old patients were 3% lower compared to <85-year-
old patients (€13,168 vs €13,644, difference €476 and corresponding 95%CI €469-
483, p < 0.001). Costs related to operations, radiology, laboratory, consulting and 
other costs were lower for ≥85 year-old patients than for <85-year-old patients. 
Costs related to the ward, intensive care and materials were higher for ≥85-year-
old patients compared to <85-year-old patients (Table 3). There was minimal 
difference in the hospital costs of patients operated in an elective setting, living 
patients and patients without severe complications, which were slightly lower for 










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The total costs of pati ents operated in an emergency setti  ng were 19% lower for 
the oldest old compared to <85-year-old pati ents (€12,938 vs €15,973, AD €3,035, 
95% CI €2,920-3,150, p < 0.001). Total costs of deceased pati ents were 31% lower 
for the oldest old compared to <85-year-old pati ents (€17,999 vs €26,093, AD 
€8,094, 95% CI €7,501-€8,687, p < 0.001). The total costs of pati ents with a severe 
complicati on were 25% lower for the oldest old compared to <85-year-old pati ents 
(€21,174 vs €28,105, AD €6,931, 95% CI €6,277-€7,135, p < 0.001) (Figure 1).
Outcomes of pati ents between 85-90 and ≥90 years old  
From the oldest old, a total of 155 pati ents were classifi ed as “extreme old.” The 
mean age of pati ents 85–90 (n = 628) was 86.6 years and for ≥90-year-old pati ents 
was 91.5 years. In this study, the clinical outcomes did not diff er signifi cantly be-
tween the extreme old and pati ents 85–90 years old (except for R1/R2 resecti on 
and LOS/ LOS ICU stay) (Table 4). All extreme old pati ents and deceased extreme 
old pati ents had signifi cantly lower costs compared to 85-90-year-old pati ents and 
deceased 85-90-year-old pati ents (respecti vely -2% and -27%) (Table 5).
Figure 1. Lower hospital costs for oldest old pati ents operated in emergency setti  ng and with a compli-
cated course
Total hospital costs of resecti ons in emergency setti  ng, resecti ons leading to death and resecti ons leading 
to severe complicati ons strati fi ed by age group. * Signifi cant diff erence, p < 0.001.
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This is the first multicenter study analyzing hospital costs for the oldest old receiv-
ing colorectal cancer surgery. The findings in this study contradict our hypothesis 
because surgery for the oldest old colorectal cancer patients did not lead to in-
creased hospital costs. Because cases registered in the DSCA reflect “real world” 
surgical selection, the conclusions based on this study emphasize that (short-term) 
financial arguments should not play a major role in clinical decisions about whether 
to operate on the oldest old. 
As described earlier, people older than 85 years old are a subgroup of frail patients 
that have a high rate of complications and mortality after colorectal cancer surgery 
compared to their younger counterparts 5-7. This trend was also observed in our 
study with a tremendous increase in mortality (+257%, p < 0.001) and severe com-
plications (+33%, p < 0.001) (Table 2). Probably, the most straightforward explana-
tion is that this group of patients experiences the comorbidities listed in Table 1. 
High age itself (or other factors not listed in the DSCA) may be responsible for this 
increase as well, as shown by an earlier study of our group analyzing independent 
risk factors for severe complications after colorectal cancer surgery 4. Poor out-
comes in the oldest old might also be related to the higher number of emergency 
resections compared to patients under 85 years old (22% vs 13%, Table 1). One rea-
son might be a more frequent ‘wait and see’ policy in the oldest old, which resulted 
in more tumor-related acute bowel obstructions and therefore more emergency 
resections. This poor prognosis after emergency resections in the elderly is also 
seen in the literature, which results in high-risk procedures with mortality rates 
up to 41% 19. As shown in Table 4, no significant differences were seen for (almost 
all) clinical outcomes of patients aged 90 years and older compared to patients 
between 85 and 90 years old. This outcome supports the idea that careful selection 
for surgery in this subgroup of extreme old patients could be justified as well. 
The total hospital costs of the oldest old and patients under 85 years old were both 
between €13,000 and €14,000, although there was an essential difference in how 
these total costs were accrued (Table 3). When looking at the three major drivers 
161
hospItal Costs of oldest old ColoreCtal CanCer patIents
8
behind total costs (costs related to ward, operation and ICU), we identified that 
patients under 85 years old had lower costs related to the ward and ICU. This result 
corresponds to a shorter length of hospital stay and less severe complications in 
this group, which resulted in less ward and ICU utilization. However, the oldest old 
patients had lower total costs, which was mainly determined by lower costs related 
to the operation. This result could be explained by the shorter duration of the 
primary operation (Table 1) and by the shorter duration of other operations during 
the first 90 days of discharge (data not shown). Another explanation for the low 
total hospital costs might be that oldest old patients deteriorated faster or were 
treated less aggressively when severe complications occurred. This possibility was 
reflected in a high mortality rate but is perhaps better illustrated by a significantly 
higher failure to rescue rate: after a severe complication, 14% of the patients under 
85 years old died, whereas in the oldest old, 37% died (+166%, p < 0.001) (Table 
2). This result was underlined by the relatively low hospital costs of the oldest old 
when only looking at patients experiencing severe complications. In this subgroup, 
the total hospital costs of the oldest old were 25% lower compared to the younger 
group, which reflected less hospital resource utilization (Figure 1). Additionally, 
hospital costs after emergency resections for the oldest old were lower than in 
the younger group (Figure1). Finally, when looking at deceased patients only, the 
length of hospital stay and length of ICU stay were significantly shorter (19% and 
42%, respectively) for the deceased oldest old than for deceased patients under 85 
years old (Table 2), which suggested that earlier cessation of treatment occurred. 
That said, it remains difficult to conclude from our study whether a high mortality 
rate in the oldest old was the result of less aggressive treatment (and therefore less 
resource utilization) or if faster deterioration resulted in high mortality rates and 
therefore caused less resource utilization (i.e., the chicken and egg debate). 
The high mortality and morbidity rates after colorectal cancer surgery for the 
oldest old patients indicated the need for constructive pre-operative counseling. 
Ideally, scheduling for surgery, especially for the oldest old, should be based on 
shared decision-making, which is something that is (at the moment) inconsistently 
performed in the Netherlands 20. Moreover, as shown in a recent survey among 
European surgeons, pre-operative screening for the frailty of old cancer patients 
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is poorly performed, and collaboration with geriatricians is uncommon 21. A recent 
review of the literature showed evidence for the correlation between frailty and 
post-operative mortality, and the review authors concluded that assessment of 
frailty should be added to the pre-operative risk assessment in older patients 22. 
Identifying the frailest old patients and developing targeted improvement programs 
in collaboration with geriatricians for this group might therefore be a strategy for 
healthcare providers to reduce complications (and therefore hospital costs).
Limitations
First, the costs of medication and specialist fees were excluded from our analyses. 
This may have resulted in an underestimation of the total costs for the oldest old 
because comorbidities in this group were higher (and therefore probably utilization 
of medication as well) (Table 1). However, this effect might be compensated for by 
lower costs related to specialists’ fees, because operation times in the oldest old 
were shorter (Table I), and perhaps by lower costs for dialysis due to less aggressive 
treatment in the oldest old. Second, the DSCA is a nationwide registry (92 hospi-
tals), although only 29 hospitals were included in this study. This decision to focus 
on specific hospitals might have introduced a bias in hospital and patient selection. 
However, this selection was solely based on whether a hospital provided detailed 
cost-price information to Performation (see method section), and the distribution 
of patients under 85 years and over 85 years in the Dutch Value Based Healthcare 
study database was comparable to that in the DSCA nationwide database (7.9% 
oldest old patients in this study (Table 1) versus 7.7% nationwide 5). Finally, we did 
not have any information about colorectal cancer patients who received a con-
servative treatment or no treatment (e.g., radiotherapy only for old/frail rectum 
cancer patients) because these patients were not registered in the DSCA. Especially 
in the case of treating oldest old patients, information about the non-operative 
patients might have provided valuable insights.  
Future perspectives
First, oldest old colorectal cancer patients undergoing a resection experience high 
30-day mortality (10%) and high two-year mortality rates (36%) 5. High excess one-
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year mortality (especially for the elderly) after a colorectal cancer procedure is 
typically due to the prolonged impact of the surgery itself 23, and if elderly patients 
survive the first post-operative year, they have the same cancer-related survival 
as younger patients 24. Incorporating long-term outcomes in cost studies might 
therefore be inevitable to obtain valuable steering information for improving value 
in healthcare 16. 
Second, it is known that severe complications after colorectal cancer surgery 
double hospital costs during the first 90 days after discharge compared to resec-
tions without (severe) complications 4. It is likely that severe complications will 
affect costs outside the hospital, and patients suffering from complications will 
need more nursing care at home or will be discharged to rehabilitation facilities. 
These complications might lead to a significant cost burden for patients, family 
and society in general and underscore an important topic regarding health care 
payers and how the health care system is organized. For example, in a multi-payer 
system, payers could have incentives to enroll those who are less costly and low-
risk and avoid those who are costly and high-risk. This system is the norm in the 
United States, and the most common form of reimbursement is fee-for-service 
25. Recent research does question the use of fee-for-service because it fosters a 
eat-what-you-kill mentality, which introduces pressure to increase volume and 
decouple payment from patient outcomes 16. Perhaps a solution might be chang-
ing the reimbursement system, for example, by moving to ‘bundled payments’ as 
suggested by Michael Porter. ‘Bundled payments’ inspire teamwork and should 
include risk-adjustment and care guarantees that hold the provider responsible 
for (avoidable) complications 16. This should encourage health care providers to 
achieve excellent long-term outcomes (also for the vulnerable oldest old) and to 
realign delivery of healthcare around value for patients.
CONCLUSION
Although oldest old patients have high rates of severe complication and mortality 
after colorectal cancer surgery, they do not generate higher hospital costs than 
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younger patients. This outcome might be due to faster deterioration or less aggres-
sive treatment of oldest old patients when (severe) complications occur.
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SUPPLEMENTAL MATERIAL
Supplemental Table 1. Different categories of resources extracted from the Hospital Information System
Category Examples within category
Operation Surgery time, operation room session 
Ward Inpatient ward days
Intensive care Intensive Care Unit days, Medium Care Unit days, Cardiac Care Unit days
Radiology Ultra sound, X-ray, CT scan, MRI scan
Laboratory Activities related to pathology, haematology, clinical chemistry, microbiology
Consulting Consults other medical specialist, outpatient department visits
Materials Blood products, prostheses and implants





value-based reImbursement: a tool 
for further QualIty Improvement In 
healthCare?




A recent Dutch publication identified that costs of surgical treatment of colorectal 
carcinoma strongly differed between different risk-groups of patients. Those cost-
differences were mainly due to an increased risk of complications when operating 
frail patients, subsequently resulting in high hospital costs. This might have its 
financial impact for healthcare providers treating high volume of frail patients. Also 
this could support ‘cherry-picking of low-risk patients’ by healthcare providers, 
which might on its own not be a bad development, however the reimbursement is 
not adjusted accordingly. 
This article discusses this shortcoming of the current Dutch reimbursement system 
and suggests how a differentiated reward -where reimbursement is aligned with 
the risk profile of the patient- could serve as a tool to further quality improve-
ment in healthcare. Current clinical registries may provide the necessary patient 
characteristics for allocating the right risk profiles and may also contribute to the 
ultimate goal: reimbursement based on outcome.
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Nederland staat in de top vijf van de duurste zorgsystemen in Europa 1. Inzicht in 
kwaliteit en kosten is cruciaal om te bepalen of onze zorg waardevol is en tegen 
een redelijke prijs wordt geleverd. Daarnaast geeft dit de mogelijkheid om de be-
loning af te gaan stemmen op geleverde kwaliteit. Aan de hand van de chirurgische 
behandeling van het colorectaal carcinoom willen wij dit toelichten.
Inzicht in kwaliteit en kosten
Sinds de oprichting van de Dutch Institute for Clinical Auditing (DICA) zijn voor 
verschillende aandoeningen klinische uitkomsten van zorg inzichtelijk geworden 2. 
Door deze uitkomsten uniform en transparant te meten zijn zorgverleners in staat 
hun uitkomsten te vergelijken, expertise te delen en uiteindelijk de uitkomsten 
verder te verbeteren 3. Dat dit bijdraagt aan een duurzame gezondheidszorg is 
onlangs aangetoond in de Dutch Value Based Healthcare (DVBHC) study voor de 
chirurgische behandeling van het colorectaal carcinoom. In deze studie werden 
op patiënt-niveau gegevens van de Dutch Surgical Colorectal Audit (DSCA) van 29 
Nederlandse ziekenhuizen gekoppeld met financiële gegevens. Hierin werd gezien 
dat in drie jaar tijd (2010-2012) de mortaliteit en gecompliceerd beloop daalde met 
respectievelijk 20% en 29%. Tegelijkertijd namen de kosten in dezelfde periode met 
9% af, van 14.237 euro naar 13.145 euro per patiënt. Ziekenhuizen die het percent-
age ernstige postoperatieve complicaties niet konden verminderen (n = 7) waren 
in deze periode 390 euro per patiënt duurder uit. Ziekenhuizen die het percentage 
ernstige complicaties zagen afnemen met 0 tot 10% (n = 12) of meer dan 10% (n = 
10) waren respectievelijk 1.353 euro en 2.158 euro per patiënt goedkoper. Wan-
neer alle deelnemende ziekenhuizen (n = 29) zouden presteren als de ‘best practice 
groep’ zou er in drie jaar tijd meer dan 20 miljoen kunnen worden bespaard 4. Deze 
ontwikkelingen geven hoop dat wij steeds meer inzicht krijgen en kunnen sturen 
op de waarde van zorg, een ontwikkeling die vorig jaar in dit tijdschrift nog ter 
discussie werd gesteld 5.
Een vervolganalyse van de DVBHC study heeft geleid tot een recente publicatie 
over kostenverschillen tussen colorectale patiënten met een variërend risico 
profiel 6. Om inzicht te krijgen in verschillen tussen risicogroepen werd in deze 
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publicatie, naast stratificatie voor operatietechniek (open versus laparoscopisch), 
ook gekeken naar tumorlocatie (colon versus rectum), leeftijd (<75 jaar versus ≥75 
jaar) en ASA classificatie (ASA I-II versus ASA III-IV). Verschil in ziekenhuiskosten 
tussen de subgroepen varieerde van €10.474 voor ‘laparoscopische, ≥75jaar, ASA 
I-II colon’ patiënten tot €20.865 voor ‘laparoscopische, <75jaar, ASA III-IV rectum’ 
patiënten (een verschil van 99%). 
Het verschil van 99% tussen de duurste en goedkoopste subgroep was grotend-
eels te verklaren door het verschil in percentage ernstige complicaties. Dit werd 
voornamelijk bepaald, naast de keuze voor operatietechniek, door patiëntkara-
kteristieken, iets waar een zorgaanbieder maar beperkt (tot geen) invloed op 
heeft. Deze grote kostenverschillen geven aanleiding om te denken dat verdere 
doelmatigheidswinst in Nederland mogelijk zou kunnen zijn door het sturen op en 
het belonen van kwaliteit. Dit beloningssysteem zou niet alleen rekening moeten 
houden met de uitkomsten van geleverde zorg maar ook met verschillen in ‘case-
mix’ tussen de ziekenhuizen 7. Helaas is dit momenteel (nog) niet het geval. 
Huidig declaratie systeem
Zorgaanbieders dienen jaarlijks per zorgproduct de verkoopprijzen in bij het DBC 
Informatie Systeem (DIS) waarna de Nederlandse Zorg Autoriteit (NZA) een landeli-
jke gemiddelde berekent. Hierbij worden een aantal regels gehanteerd, waaronder 
het uitsluiten van de goedkoopste 10% en de duurste 10% verkoopprijzen voor de 
berekening 8. De verkoopprijs voor de chirurgische behandeling van het colorectaal 
carcinoom is enkel gebaseerd op onderscheid tussen de lengte van opname (tot 28 
dagen versus 28 dagen en langer) of de toepassing van HIPEC, een intra-operatieve 
behandeling met chemotherapie na cytoreductie van peritoneale metastasen bij 
een geselecteerde groep patiënten. De landelijk gemiddelde verkoopprijs van een 
colorectale ingreep zonder HIPEC, veruit het meest voorkomende zorgproduct, 
verschilt €19.835 (bijna 200%) tussen een korte en lange opnameduur (Tabel 1). 
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Kostprijzen
Kostprijzen zijn de daadwerkelijke kosten die tijdens een behandeling worden ge-
maakt. Bij veel ziekenhuizen ontbreekt het aan representatieve kostprijzen omdat 
dit buiten kerntaak van ziekenhuizen valt. Het correct toekennen van kosten aan 
deze handelingen (een verpleegdag, CT scan of operatieve ingreep) is dan ook een 
lastige exercitie en vaak worden ziekenhuizen geassisteerd door externe consul-
tants. De zorgaanbieder probeert zijn verkoopprijs vaak hoger te houden dan de 
kostprijs zodat hij een marge kan maken. In sommige gevallen kan de zorgaanbieder 
besluiten om een zorgproduct tegen een lagere prijs te verkopen onder druk van 
de zorgverzekeraar of om zo de concurrentiepositie te versterken. Omdat inzicht in 
kosten en kwaliteit belangrijk is om te bepalen waar de juiste zorg wordt geleverd 
4.  denken wij dat er hier voor ziekenhuizen nog veel te winnen valt.
In de DVBHC study zijn de financiële gegevens geleverd door het adviesbureau Perfor-
mation (Bilthoven) 9, dat voor alle 29 ziekenhuizen kostprijzen heeft berekend. Daar-
mee werd uniformiteit in de kostprijsmethodiek gewaarborgd. Voor dit artikel (Tabel 
2) is een deel van de analyse van de publicatie naar kostenverschillen tussen open en 
laparoscopische colorectale ingrepen herhaald 6. Alleen de variabele operatietechniek 
(open of laparoscopisch) is in dit artikel (Tabel 2) weggelaten omdat deze variabele 
wordt bepaald door de keuze van de chirurg in samenspraak met de patiënt. 
Tabel 1. Gemiddelde landelijke verkoopprijs (2014) berekend door de Nederlandse Zorg Autoriteit (NZA)





29199032 Uitgebreide operatie aan het maagdarmkanaal met 
maximaal 28 verpleegdagen bij kanker van dikke darm of 
endeldarm
 <28  €10.310 
29199033 Uitgebreide operatie aan het maagdarmkanaal met 
meer dan 28 verpleegdagen bij kanker van dikke darm of 
endeldarm
 ≥28  €30.175 
Data verkregen via www.opendisdata.nl.
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Tabel 2A. Kostprijzen gestratificeerd op hoofdgroep
Hoofdgroep           




≥28 dagen  
Gemiddelde 
kostprijs
Colon - -  4202  3,1%  18,2%  5,0%  €12.040 
Rectum - -  2328  1,8%  25,3%  7,8%  €15.034 
             
Tabel 2B. Kostprijzen gestratificeerd op subgroep (oplopend gesorteerd).
Subgroep           




≥28 dagen  
Gemiddelde 
kostprijs
Colon <75 ASA I-II  2072  0,6%  14,1%  3,8%  €10.960 
Colon ≥75 ASA I-II  1048  3,8%  18,5%  5,3%  €11.388 
Rectum <75 ASA I-II  1511  0,5%  21,7%  5,8%  €13.638 
Colon <75 ASA III-IV  358  3,4%  21,8%  6,1%  €14.687 
Colon ≥75 ASA III-IV  724  9,3%  27,6%  7,2%  €14.767 
Rectum ≥75 ASA I-II  422  2,1%  27,7%  10,2%  €15.731 
Rectum ≥75 ASA III-IV  210  8,6%  36,7%  14,3%  €19.094 
Rectum <75 ASA III-IV  185  3,2%  35,7%  11,4%  €20.242 
Data verkregen uit de Dutch Value Based Healthcare Study. Ziekenhuiskosten van electieve colorectale 
ingrepen zijn gemeten vanaf operatie tot en met 90 dagen na ontslag, exclusief specialisten honorarium, 
en kosten van medicatie/ dialyse (zie referentie 4).
Verschil tussen verkoopprijs en kostprijs
Het absolute verschil tussen de verkoopprijs en de kostprijs in dit artikel is onder 
andere te verklaren doordat de kosten anders zijn berekend. De financiële uit-
komsten in de DVBHC study zijn bijvoorbeeld gemeten tot 90 dagen na ontslag 
en bevatten alle ziekenhuiskosten. Daarentegen is de gemiddelde verkoopprijs, 
berekend door de NZA, gemeten tot 42 dagen na ontslag en bevat alleen de DBC 
gerelateerde kosten. Daarom hebben wij in Tabel 3 naar de verhouding tussen de 
verschillende patiëntgroepen gekeken. Hierbij zien wij dat voor rectum chirurgie 
de kostprijs 25% (€2.994) hoger ligt dan voor colon chirurgie (Tabel 3A). De verk-
laring hiervoor is dat rectum chirurgie over het algemeen als complexer wordt 
beschouwd met een hogere kans op complicaties (en daardoor langere ligduur) 
dan colon chirurgie 3. Kijken we vervolgens voor rectum chirurgie naar de berek-
175
reImbursement and QualIty Improvement
9
ende gemiddelde verkoopprijs van de NZA dan ligt het bedrag bij rectum chirurgie 
gemiddeld slechts 5% (€556) hoger dan bij colon chirurgie (door de iets hogere 
-2.8%- verlengde opnameduur van meer dan 28 dagen, Tabel 3A). 
Bij de verdere subgroep analyse is ook rekening gehouden met leeftijd en co-
morbiditeit. Hier loopt het verschil in kostprijs tussen de goedkoopste subgroep 
(colon, <75 jaar, ASA I-II) en de duurste subgroep (rectum, <75 jaar, ASA III-IV) op 
tot 85% (€8.839). Kijken we bij dezelfde twee subgroepen naar de gemiddelde 
verkoopprijzen, dan zien we dat het verschil terugloopt naar 14% (€1.510, Tabel 
3B). 
Tabel 3A. Relatief verschil in kostprijs en verkoopprijs tussen de twee hoofdgroepen
Hoofdgroep         
Locatie  
Op basis van 
gemiddelde kostprijs  Op basis van gemiddelde verkoopprijs
Colon  €12.040  €11.303 (95,0% x €10.310) + (5,0% x €30.175) 
Rectum  €15.034  €11.859 (92,2% x €10.310) + (7,8% x €30.175)
Verschil  25%     5%
Tabel 3B. Relatief verschil in kostprijs en verkoopprijs tussen de twee meest verschillende subgroepen 
(zie tabel 2b)
Subgroep         
Locatie Leeftijd ASA  
Op basis van 
gemiddelde kostprijs  Op basis van gemiddelde verkoopprijs
Colon <75 ASA I-II  €10.960  €11.065 (96,2% x €10.310) + (3,8% x €30.175)
Rectum <75 ASA III-IV  €20.242  €12.575 (88,6% x €10.310) + (11,4% x €30.175)
Verschil    85%      14%
Uitkomsten in tabel 3a zijn berekend door de uitkomsten van tabel 1 en 2 te combineren.
De tekortkomingen
Zoals hierboven weergegeven legt de huidige manier van belonen verschillende 
knelpunten bloot:
1). In het huidige systeem wordt geen onderscheid gemaakt tussen hoog dan wel 
laag risicosubgroepen. Dit zou kunnen leiden tot ‘cherry picking’ waarbij specifieke 
zorginstellingen (bijv. een zelfstandig behandelcentrum) zouden kunnen besluiten 
alleen laag-risico patiënten te opereren zoals de ASA I-II subgroepen (weergegeven 
176
Chapter 9
in Tabel 2B). Hoog risicopatiënten zouden in dit scenario worden doorverwezen 
naar bijvoorbeeld tertiaire ziekenhuizen. Hierdoor kan de winstmarge van de 
zorginstelling niet zozeer bepaald worden door het reduceren van complicaties 
maar door selectie aan de poort. Voor ‘gewone’ ziekenhuizen is deze selectie 
minder vanzelfsprekend omdat selectie aan de poort vaak de professionele verant-
woordelijkheid raakt. Niettemin is dit door ingestelde volumenormen voor bijvoor-
beeld rectum chirurgie ook in zekere mate voor deze ziekenhuizen van toepassing. 
Op zichzelf geen slechte ontwikkeling, maar dit veroorzaakt case-mix verschillen 
tussen ziekenhuizen waarop het beloningssysteem niet is ingericht.
2). Wellicht net zo belangrijk is dat in het huidige systeem de financiële prikkel tot 
het verbeteren van kwaliteit ontbreekt. In theorie bestaan er zelfs perverse prik-
kels waarbij complicaties kunnen leiden tot een hogere beloning. Immers, op basis 
van de 28 dagen regel kunnen colorectale patiënten met een lange opnameduur 
een 200% hoger bedrag opleveren dan patiënten met een voorspoedig herstel (zie 
Tabel 1). Dit is iets wat in meer en mindere maten ook geldt voor andere diagnoses 
8. Nederland staat hier in niet op zichzelf, ook in Amerika zijn er situaties waar het 
hebben van meer complicaties kan leiden tot hogere inkomsten 10. Tevens houd 
het huidige systeem de zorgaanbieder slechts 42 dagen verantwoordelijk voor he-
ropnames, wat korte termijn denken in de hand kan werken. Het opheffen van een 
tijdelijk stoma (veelal pas enkele maanden na de ingreep) valt hier bijvoorbeeld 
niet onder 11. 
Uitkomstenbekostiging
Om aan bovenstaande tekortkomingen tegemoet te komen zou idealiter de 
bekostiging afgestemd worden op behaalde uitkomsten. Hierbij moet gecorrigeerd 
worden voor zorgzwaarte en moeten zorginstellingen (financieel) risico dragen 
voor de langere termijn uitkomsten van behandelde patiënten. Verbeteren van 
uitkomsten levert dan financieel voordeel op, wat de doelen van zorgverleners, 
zorgaanbieders, verzekeraars én patiënten op één lijn brengt. Zorgaanbieder 
en zorgverzekeraar zouden dan afspraken moeten maken over de te behalen 
(verbetering in) uitkomsten en bijbehorende financiële beloning. Investeren in 
kwaliteitsverbetering wordt dan ook financieel aantrekkelijk, in plaats van een last 
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zoals dat nu soms wordt gezien. Tot slot zijn er gedachten -onder andere binnen 
Value Based Healthcare theorie - dat verdere doelmatigheid kan worden bereikt 
door de hele keten van zorg op te nemen in de beloning, inclusief preventie 12. 
Uitkomstenbekostiging over de keten van zorg heeft onder andere in de Stock-
holm regio voor indrukwekkende resultaten gezorgd. Orthopedische chirurgen, 
fysiotherapeuten en zorgverzekeraars hebben samen afspraken gemaakt voor de 
behandeling van knie- en heup artrose. Hierbij verdwenen de wachtlijsten voor 
knie- en heup operaties, lange termijn uitkomsten verbeterden en kosten werden 
gereduceerd 13. Minister Schippers heeft eenzelfde doel voor ogen en zij gaf aan 
uitkomstenbekostiging uiterlijk in 2020 te willen introduceren. Hierdoor zouden 
zorgaanbieders gestimuleerd worden om gezamenlijk optimale zorgresultaten te 
behalen en gelijktijdig de kosten te beheersen 14. 
De overgang naar uitkomstbekostiging zal in Nederland niet zomaar geregeld zijn 
en zoals minister Schippers aangeeft zou dit stapsgewijs moeten worden doorge-
voerd 14. Een eerste stap die wij voorstellen is het gedifferentieerd belonen. Zoals 
het voorbeeld over de chirurgische behandeling van het colorectaal carcinoom laat 
zien zou de zorgverzekeraar laag complexe subgroepen minder moeten belonen, 
en hoog complexe subgroepen meer moeten belonen (hiermee inspelend op 
tekortkoming 1). Zorgaanbieders die zich richten op hoog risico subgroepen krijgen 
hierdoor meer financiële ruimte om (kostbare) complicaties op te vangen. Een 
betere verdeling van de vergoeding zou er toe moeten leiden dat goed presterende 
ziekenhuizen geld over houden, ongeacht de zorgzwaarte van de patiënt. Dit geeft 
mogelijkheden om te kunnen investeren in kwaliteitsinitiatieven dat weer moet 
leiden tot nog betere zorg voor de patiënt. Een voordeel is dat op korte termijn 
een eerste stap gemaakt kan worden omdat de benodigde gegevens al beschikbaar 
zijn. Immers, klinische registraties zoals die van de DICA houden zeer gedetailleerd 
de patiënt en/of tumor karakteristieken bij voor noodzakelijke case-mix correctie. 
Tevens bieden de op uniforme wijze gemeten uitkomsten van deze registraties een 
mogelijkheid voor het implementeren van het uiteindelijke doel: belonen op basis 




Het voor zorgverleners inzichtelijk maken van uitkomsten op patiëntniveau heeft 
aantoonbaar geleid tot betere zorg en lagere kosten. Een volgende stap naar meer 
doelmatige zorg zou het implementeren van uitkomstenbekostiging kunnen zijn. 
Aangezien dit niet met een ‘big bang’ dient te gebeuren stellen wij als eerste stap 
het gedifferentieerd belonen voor, waarbij onderscheid wordt gemaakt tussen 
verschillen in zorgzwaarte tussen zorgaanbieders. 
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Ever since the publication of Michael Porters’ book ‘redefining healthcare: creating 
value based competition on results’ 1, health care providers have been developing 
frameworks for realigning the delivery of health care around value for patients. 
Since challenges for obtaining a sustainable healthcare system in the future include 
dealing with advances in technology, availability of expensive medications, chronic 
illness and ageing, it seems unavoidable to re-evaluate the way we have been 
providing care to our patients. 
Surgical auditing and hospital costs
With the continuous rise of healthcare costs, healthcare providers, insurance 
companies, governments, and patients demand for information and transparency 
on performance of hospitals. Surgical audits are primarily initiated to monitor out-
comes in order to reduce variation between institutions and improve quality of care 
2,3. Although frequently assumed, evidence of surgical auditing as a tool to reduce 
hospital costs remains scarce. In chapter 2 4 we describe the results of a systematic 
review: of more than 3600 investigated manuscripts on effects of surgical auditing, 
only six manuscripts reported a relationship between surgical auditing and hospital 
costs. All six showed a positive effect of surgical auditing on reducing costs. The 
biggest reduction was seen for the more complex procedures, probably because 
prevention of adverse events in these procedures might be of greater clinical 5 
and therefore financial importance. Since auditing is a time consuming effort 6, the 
question remains how auditing will effect outcomes –and costs- of ‘high-volume 
low-complex’ procedures, like procedures related to inguinal hernia and hip frac-
tures. Also a general note of caution should be made regarding publication bias 
when performing a review of the literature: studies showing negative outcomes, in 
our case of surgical auditing, might be less likely submitted for publication by the 
authors. 
Conclusions of our systematic review were supported by the findings from the 
DVBHC-study. In chapter 3 7 we describe the relationship between severe com-
plications and hospital costs for 29 hospitals participating in the Dutch Surgical 
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Colorectal Audit (DSCA). Between 2010 and 2012, the participating hospitals 
reduced their severe complications by 20%, their mortality rate by 29% and simul-
taneously hospital costs by eight percent. Moreover, an inverse relation between 
severe complication rate and hospital costs was identified and hospitals with the 
strongest improvement in three years had the strongest cost reduction. The total 
estimated cost reduction in the three consecutive years was more than €5 mil-
lion for the participating hospitals. Even more, by combining clinical and financial 
outcomes we identified ‘best practice’ hospitals, and therefore providing a realistic 
goal for all other hospitals. If between 2010 and 2012 all other hospitals in our 
study performed on the level of the best practice hospitals, the additional savings 
in this three-year-study would have been more than €20 million (Figure 3 chapter 
3 7). When comparing this to the overall Dutch hospitals budget of €23 billion a 
year, the savings might seem less impressive. However, these results should be 
interpreted in the light that we analyzed only the surgical part of one clinical diag-
nosis, leaving room for more savings, for example when the full potency of other 
registries is revealed as well. One might argue that ascribing improved quality of 
care (and cost reduction) to surgical auditing might be related to other factors: 
for example possible occurrences of secular trends not registered in the audit or 
increased rate of laparoscopic surgery. However, when comparing mortality of 
other oncologic diagnosis in the Netherlands, like gastric cancer, no reduction in 
post-operative mortality was found until the introduction of the Dutch Upper Gas-
trointestinal Cancer Audit 8. Moreover, a reduction of mortality and/ or complica-
tions can only be achieved when key data regarding clinical outcomes is available: 
without this data, health care organizations are flying blind in deciding what should 
be targets for quality improvement initiatives or in deciding which ‘peer-hospitals’ 
could serve as best practice hospitals. 
Since registering and data verification is a cost and time consuming exercise 6, we 
presented a business case in chapter 4 9. Despite the additional time -and therefore 
costs- of data registration and data verification, we show that participating in the 
DSCA resulted in overall cost reduction of € 80,393 in three years (for a hospital 
yearly volume of 100 procedures, supplemental table 2, chapter 4 9). Moreover, 
we describe in this chapter the tremendous impact of severe complications after 
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colorectal cancer surgery on hospital costs: the top fi ve percent most expensive 
pati ents were responsible for 23% of the total cost and additi onal costs of pati ents 
with complicati ons was more than 30% of the total budget (fi gure 1, chapter 4 
9). However, assuming direct relati onships between single complicati ons and 
costs may not be appropriate since some costs are not likely to be aff ected by a 
reducti on in complicati ons in the short term. For example overhead costs of the 
intensive care unit will more or less sti ll exist, regardless of the number of pati ents 
admitt ed to such unit. Also costs of staffi  ng will not change on the short term by 
a decrease in complicati ons, since most of the staff  is employed by the hospital 
based on long-term contracts. 
Laparoscopic techniques and hospital costs
During the last two decades, laparoscopic resecti on has developed as a commonly 
accepted surgical procedure for colorectal cancer. Existi ng literature showed that 
laparoscopy for colorectal cancer is associated with faster postoperati ve recovery, 
similar long-term oncological outcome and similar or bett er long-term surgical 
outcome (risk of adhesion related small bowel obstructi on and incisional hernia) 
Figure 1. Laparoscopy vs open colorectal cancer resecti on (unpublished fi gure)
All electi ve T1-4N0-2M0-2 stage colorectal cancer pati ents were included. Laparoscopic resecti on (n=4237) 
was associated with longer operati on ti me (A) and higher operati on costs (B) as compared to open resec-
ti on (n=3937). Total costs were lower for laparoscopic resecti on as compared to open resecti on (C). Ar-
row represents relati ve diff erence of unadjusted outcomes. Abbreviati ons: LR, laparoscopic resecti on; OR, 
open resecti on. § Time and costs of primary operati on only.
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as compared to open resection 10-13, although two recent RCTs question its routine 
use for rectal cancer 14,15. Surprisingly, its effect on hospital costs is less thoroughly 
investigated. Most of the cost-studies were based on randomized controlled trials 
(RCTs) 16, which are known to describe outcomes of a selected group of patients 
operated in specialized (referral) centers 17 and their limitations should be acknowl-
edged, especially regarding external validity 18. Population-based studies analyzing 
actual hospital costs after laparoscopic and open colorectal cancer resections are 
scarce. One of the problems is a lack of uniformity and transparency in registration 
between different institutions and therefore proxies of actual costs are used, like 
DRG’s or insurance claim data (see cost calculations) 19. 
In order to analyze the effect of a laparoscopic approach on hospital costs, our 
first attempt was to analyze a pooled group of all elective T1-4N0-2M0-2 stage 
colorectal cancer patients. In this first study, differences in patient characteristics 
were taken into account by performing multivariate analysis (Figure 1). However, 
after discussing our data with experts in the field 20, we believed that multivariate 
analyses would not correct for all (unknown) factors, which may have influenced 
the decision to perform open or laparoscopic surgery. As recently published by 
our group, sub-group analyses might provide better insight in clinically relevant 
subgroups and be of more interest for health care providers and/or payers 21. 
Therefore, we reviewed our data using sub-group analyses based on tumor loca-
tion (colon vs rectum) and operative risk (age <75 years vs >75 years and ASA I-II 
vs ASA III-IV). Also, we selected T1-3N0-2M0 stage patients operated in an elective 
setting only. As shown in chapter 5 22, elective laparoscopic resection in all colon 
cancer subgroups resulted in lower hospital costs due to less severe complications 
and lower length of hospital stay. For all rectal cancer subgroups, laparoscopy 
resulted in higher hospital costs. This was probably due to the high rate of stoma 
construction in rectal cancer surgery (approximately 80%, Table 1 chapter 5 22) and 
therefore eliminating advantages seen after laparoscopic colon resections, like 
early discharge. Surprising was the tremendous variation in average total hospital 
costs between the clinical subgroups, ranging from €10,474 (≥75year ASA I-II lapa-
roscopic colon cancer patients) to €20,865 (<75year ASA III-IV laparoscopic rectal 
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cancer patients), which is a 99% difference. This significant variation between the 
subgroups should be an incentive for Dutch payers and/or healthcare providers to 
evaluate current reimbursement systems (see chapter 9 23).
Earlier studies analyzing differences in costs between open and laparoscopic 
procedures showed univocal outcomes. An important determinant in these stud-
ies might be that often no distinction between colon and rectal procedures was 
made 16,24,25. Probably this might be due to lower number of patients included in 
these studies making pooled analyses necessary. However, interpretation of those 
conclusions is difficult 16,24,25, because colon and rectal cancer are different disease 
entities in several aspects, and overall analysis does not give any insight into clini-
cally relevant risk groups.
Therefore, besides quality improvement, the availability of large number of pa-
tients in clinical registries underlines their importance as a robust source of data for 
research. The availability of large number of patients enables sub-group analyses, 
which - depending on the research question- might reveal better clinical insights 
as compared to multivariate analyses. Moreover, detailed data from nationwide 
covered clinical registries include information of patients often excluded from 
RCT’s, and therefore can address new research questions regarding patient care, 
new treatment modalities and the way it is financed.
Nowadays, more than 70% of all colon and 85% of all rectum cancer resections 
in the Netherlands are performed through laparoscopy 26. The vast majority of 
these laparoscopic procedures are performed using conventional laparoscopic 
techniques. A relatively new approach for operating colorectal cancer is the 
single-port laparoscopy (SPL). In 2010 the gastrointestinal surgeons of the Jeroen 
Bosch Hospital started with the introduction of SPL for less-complex abdominal 
procedures 27,28, resulting in the first SPL colorectal cancer resections in 2011. Since 
little is known about the costs of applying SPL, we performed a single-center cost-
analysis of SPL in 2011 and 2012 (chapter 6 29). Although average costs of SPL over 
two years were higher as compared to conventional laparoscopy, a 35% decrease 
in hospital costs was seen for single port procedures after the introduction year 
resulting in comparable costs as conventional laparoscopy. Moreover, although SPL 
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is a relatively new technique, this study showed that implementation of SPL could 
be save since there were no significant differences in mortality and/ or severe 
complications as compared to conventional laparoscopy. Advantages of single-port 
surgery include the use of a single incision. This single incision is larger than the 
incision of a conventional port (5 or 12mm), and one of the concerns after for ex-
ample cholecystectomies might be an increased rate of port side hernias 30. In the 
case of a colectomy, the affected bowel cannot be removed through a 12mm port 
and needs to be removed through a larger incision. Therefore during conventional 
procedures the 12mm sub-umbilical incision has to be extended (an alternative 
is the use of a Pfannenstiel incision). In SPL procedures the larger incision for the 
single port could be used for the removal of the bowel, minimizing the disadvan-
tage of this initial bigger incision.
This chapter used single center data, and the number of SPL procedures was 
relative small (analyzing 78 SPL procedures versus 189 conventional procedures). 
Therefore, conclusions of superiority and inferiority between the two procedures 
cannot be made. However, part of the evaluation of new surgical techniques is 
assessing its costs, and therefore this chapter should be seen as an impetus for 
further research in the field of laparoscopic advancements. 
High-risk patients and hospital costs
In order to facilitate the discussion of increasing healthcare costs when operating 
high-risk patients we analyzed the impact on hospitals costs of two specific sub-
groups suffering from high complications rates. In chapter 7 31 we describe that obe-
sity is associated with a significant increase in hospital costs, up to a 22% increase for 
obesity class ≥2 patients. Earlier studies describing such relationship were conducted 
in either the relatively obese populations of the United States and New Zeeland 32,33 
or the relatively none-obese population of Japan 34. Our report is the first to describe 
this relationship for an European country with an intermediate BMI distribution, and 
our findings should therefore be of use for other countries with an intermediate 
BMI distribution, like Sweden and France (Figure 2) 35. Moreover, we show that pre-
obesity is associated with a significant lower mortality rate after colorectal cancer 
188
Chapter 10
procedures. This so-called ‘obesity paradox’ was also identified in general surgery 36 
however has never been identified for surgical colorectal cancer patients. 
In conclusion, obese colorectal cancer patients have an increased risk for both minor 
and major complications, which highlight the need for targeted quality programs 
for these patients. Moreover, since obesity is becoming pandemic, obesity-related 
increase of healthcare costs could be expected worldwide when treating colorectal 
cancer patients. 
Operating oldest old colorectal cancer patients (≥85 year) has always been part 
of discussion between health care providers. A recent Dutch study showed a 12% 
excess mortality for the oldest old colorectal cancer patients in the first year after 
surgery 37, which is also seen after other major procedures like aorta aneurysm 
repair 38. In combination with an increased risk of post-operative complications, 
one might argue that operating the oldest old for colorectal cancer might result in 
an impermissible misbalance in hospitals’ resource utilization. In chapter 8 39 we 
describe that oldest old (≥85 year) suffered from higher complication and mortality 
rates as compared to their younger counterparts (Table 2, chapter 8 39). Although 
in the other chapters of this thesis higher complication rates were associated with 
higher costs, post-surgery hospital costs of the oldest old did not increase. These 
Figure 2. Pre-obese or obese popu-
lation by country (2012)
Data retrieved from OECD: pre-
obese [BMI 25-29,99 kg/m2] or 
obese population [BMI > 30 kg/m2] 
35. Percentage of population ≥15 
year is shown. Abbreviations: JPN, 
Japan. FRA, France. SWE, Sweden. 
NLD, the Netherlands. USA, United 
States of America. NZL, New Zea-
land.
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lower costs were probably due to faster deterioration or less aggressive treatment 
when complications occur (Table 3, chapter 8 39). This was indicated by less resource 
utilization and a higher failure to rescue rate when severe complications occur in 
the oldest old as compared to patients under 85 years. Since cases registered in 
the DSCA reflect ‘real world’ surgical selection, conclusions based on this study 
emphasizes that (short-term) financial arguments should not play a role in clinical 
decision making whether to operate the oldest old or not.
Reimbursement and hospital costs
The current Dutch reimbursement system is far from adding ‘value’ in colorectal 
cancer surgery 40. No differences in reimbursement for colorectal cancer surgery exist 
between tumor location, ASA classification or age. At the moment, differences in 
reimbursement are mainly based on length of hospitalization (up to 28 days vs more 
than 28 days, see Table 1) or the use of hyperthermic intraperitoneal chemoperfu-
sion (HIPEC), which is an intra-operative treatment with chemotherapy after cytore-
duction of peritoneal metastases in a selected group of patients. It seems fair that 
hospitals will financially be compensated for longer hospital admissions. Although 
unlikely, since it might affect the integrity of healthcare providers, this higher reward 
for longer admissions may also provide a strong perverse stimulus. This more or less 
applies for the United States of America as well, were Eappen et al. reported that 
some hospitals have the potential for adverse near-time financial consequences 
when reducing their post-surgical complications (depending on payer mix) 41. 
In chapter 9 23 we make a suggestion for a first step to a more sophisticated reim-
bursement system. The idea arose following the publication of chapter 5 22, where 
actual costs of patients in the different colorectal cancer subgroups differed up to 
99%. These differences were based on differences in tumor location, ASA classifica-
tion, age and operation technique (Figure 1, chapter 5 22). This means that health-
care providers serving relatively high number of frail colorectal cancer patients 
should be aware of the accompanying increased hospital costs without receiving a 
proper financially compensation (Table 1, chapter 9 23). The substantial differences 
in actual costs between the different risk groups, something a healthcare provider 
cannot influence, highlight the need for a better and fairer reimbursement system. 
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A new reimbursement system should not be introduced with a ‘big bang’. Instead, 
we propose in chapter 9 23 as a first step that colorectal cancer payments should be 
adjusted for patient and tumor characteristics (for example based on ASA classification, 
age and tumor location). Hospitals serving low-risk patients will receive a lower reward, 
therefore discouraging ‘cherry picking’ and pushing those hospitals to become more 
efficient. Hospitals serving high-risk patients will receive a higher reward, therefore 
giving those hospitals the opportunity to develop quality improvement initiatives in 
order to reduce complication rates. A better distribution of the reimbursement will 
give all hospitals the opportunity to deliver profitable care, regardless of their patients 
case-mix. A reasonable (and necessary) next step could be coupling the reward to 
outcomes of care, such as those available in the DSCA 2, in order to increase value 
of delivered care 42. This is also what the Dutch minister of Healthcare has in mind, 
proposing implementation of outcome reimbursement in 2020 43.
Analyzing hospital costs
Understanding hospital finances is complex and articles describing accurate 
translation of resource utilization into costs are scarce. In research, mostly proxies 
of costs are used, like insurance claim data or costs of drugs related diagnosis to 
indicate expenditures. One of the best methods to determine actual costs might be 
activity-based costing at patient level. As outlined by Kaplan, even better is using 
time-driven activity-based costing (TD-ABC), which is a bottom-up micro-costing 
method that consists of calculating two parameters per activity: the costs per 
time unit to perform each activity and the overall time units spent performing 
the activity 44. Compared with top-down costing methods, the TD-ABC is superior 
in terms of revealing patient-level resource-use variations and the prevention of 
cross-subsidizations 45. 
Earlier studies analyzing cost reduction of surgical auditing (chapter 2 4) were 
hampered by their use of ‘fixed’ costs of complications. In those studies a decline 
in complication rate was multiplied by a fixed price of those complications 46,47. Only 
Hollenbeak et al. used patient-level cost-calculations based on a standard ratio of cost-
to-charges methodology 48. For the cost-to-charges methodology, costs are estimated 
as a percentage of hospital charges. Since each hospital department estimated a 
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cost-to-charges on a yearly basis, the authors admitted that this approach is certainly 
imperfect for estimating hospital costs 48. Also multi-center studies analyzing cost 
differences between open or laparoscopic colorectal resections had their limitations, 
mainly because of a lack of uniform cost calculations between the individual centers 
49. Populations-based studies analyzing differences between open and laparoscopic 
colorectal procedures were performed in the United States of America and based on 
claim data from payers and therefore not reflecting actual hospital costs 19,50. 
In this thesis, translation of resource utilisation into costs was performed by Per-
formation, a healthcare consultancy firm providing patient level costing and bench-
marking services for more than 100 hospitals across Europe 51. Performation uses 
the activity-based costing methodology and where possible TD-ABC to determine 
actual hospital costs and benchmark products. All in-hospital resources used by 
the care of a patient (and therefore costs of those patients) are being tracked in 
the hospital information system and linked to the patients’ unique identification 
number. Since both the DSCA and Performation measure outcomes at patient level, 
combining these databases at patient level reveals detailed cost information of 
colorectal cancer treatment leading to compelling steering information (Figure 3). 
Figure 3. Illustrative picture: hospital costs of a patient with a complicated course 
Hospital costs of a 79-year, ASA III, female patient with a caecum cancer undergoing a laparoscopic ileo-
cecal resection (day 1) followed by an anastomotic leakage (day 8). Cost of primary admission (day 1 till 






From a macro-economic perspective healthcare has a bad track record when it 
comes to reducing costs. One of the future challenges will be determining through 
which system we are going to pay for our healthcare delivery in the next decades 52. 
Experts in the field agree that the current Dutch leading system with ‘fixed annual 
budgets’ for providers is outdated since budgets are disconnected from the actual 
patient need that arises during the year. This system also leads to waiting lists 
and creates pressure on both healthcare providers and payers at the end of the 
year when predetermined budgets are exceeded 53. Also the system in the United 
States, ‘fee for service’, is far from perfect. It fosters ‘eat what you kill’ mentality 
thereby fueling waste by rewarding quantity and not quality of care. 
None of the healthcare innovations during the last decades have led to considerable 
costs reductions, and therefore skepticism remains why a value based system will. 
For example, what if we are able to decrease failure to rescue rate for colorectal 
cancer patients by 50 percent? Although one might consider this as improvement 
in quality, this implies that more patients suffering from severe complications will 
survive and therefore generate more hospital costs. Eventually these patients will 
die from the same (or other diseases) in the future and therefore shifting present 
costs to costs in the future. This underlines that not all improvement in healthcare 
automatically leads to a reduction in costs, however when focused on the right 
outcomes it will, as seen in chapter 3 7 and 4 9. 
Two recent publications in the Harvard Business Review described two leading 
payment systems that might catalyze development of high-quality care: capita-
tion or bundled payments 42,54. Suggested by Michael Porter, ‘bundled payments’ 
might realign delivery of healthcare even more around value for patients. Bundled 
payments cover the full care cycle for acute medical conditions, the overall care 
for chronic conditions for a defined period, or primary and preventive care for a 
defined patient population. Besides case-mix correction they also have care guar-
antees that hold providers responsible for avoidable (long-term) complications 42. 
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As seen for hip and knee replacements in Sweden, bundled payments improved 
efficiency while improving outcomes for patients 55. Also incorporating the whole 
chain of care in the reimbursement could lead to more efficiencies while maintain-
ing quality, as seen in the Dutch ParkinsonNet 56. Although existing literature sounds 
promising, further studies are needed to identify if bundled payments will catalyze 
also further improvement of value in colorectal cancer care. For example, the con-
struction of a defunctioning stoma in rectal cancer surgery might be seen as a risk 
adverse strategy. However, a recent study showed that a high tendency towards 
stoma construction did not result in lower overall anastomotic leakage or mortality 
rates 57. Since construction of a defunctioning stoma introduces extra costs in the 
future (e.g. purchase of stoma bags, costs of treating stoma related complications, 
costs of a re-operation for removing the stoma), rewarding long-term outcomes in 
colorectal cancer surgery might provide more awareness whether to construct a 
stoma in the first place. 
The other leading model to pay for healthcare is capitation 54. With a population-
based capitated payment healthcare providers are paid a fixed amount for each 
enrolled person assigned to them, per period of time, whether or not that person 
seeks care. It should be adjusted for each patient’s expected needs and also held 
providers accountable for high-quality outcomes. Supporters of this system claim 
that this approach is the only one that would encourage healthcare to improve 
quality since it fundamentally shifts the role of managing care from insurers to care 
providers. A major driver behind this is system is that it should reduce all kinds of 
waste, which is claimed to eat up at least 35% of the healthcare budget 54. Since 
there is no robust nationwide evidence for either system yet, the big challenge for 
the future is to determine which system will support development of a high value 
care system the most.
Dealing with expensive medication
Another future challenge will be dealing with expensive medications. Recent 
developments in the field of oncology increased the number of indications for 
immunotherapy and so called ‘targeted therapies’. Immunotherapy is a type of 
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cancer treatment designed to boost the body’s natural defenses to fight the cancer. 
It uses substances either made by the body or in a laboratory (e.g. monoclonal 
antibodies, vaccines, T-cells) to improve or restore immune system function by 
stopping or slowing the growth and spread of cancer cells and help the immune 
system destroying cancer cells. Targeted therapies are either antibodies or drugs 
that work to inhibit specific proteins that are important for the growth and/or 
survival of cancer cells. Because targeted therapy agents do not directly interfere 
with rapidly dividing cells, they do not have the usual side effects of conventional 
chemotherapy (although they do have their own side effects) 58. The major concern 
is the exorbitantly high costs of these immuno- and targeted therapies and that 
they are often prescribed for patients with an end-stage disease. 
Back in 2006 the Dutch Council for Healthcare and Society proclaimed that the 
costs of an intervention per quality-adjusted life year should not exceed €80,000 
59. Therefore questions rise whether innovative therapies undermine the develop-
ment of a sustainable healthcare. For example, in 2012 Ipilimumab, an anti-CTLA4 
antibody, came available in the Netherlands and initially it could be used as a 
second line treatment for patients with unresectable or metastatic melanoma. It 
is administered in a dosage of 3mg/kg and repeated three times (four treatments 
in total, regardless of the appearance of new lesions or growth of existing lesions) 
60. Costs of 50mg Ipilimumab are €4,505. For a 60kg patient this means that total 
costs for four treatments exceed €60,000 61. For metastatic colorectal cancer, 
Ramucirumab (an antibody targeting the VEGF receptor 2) can be added to che-
motherapy (FOLFIRI) when there is still progression of the disease after failure of 
other targeted therapies (like Bevacizumab, Oxaliplatine and Fuoropyrimidine). For 
a patient of 60 kilograms, 480mg of Ramucirumab can be given every two weeks till 
progression of the disease or until unacceptable toxicity occurs 60. Costs of 100mg 
Ramucirumab are €572.40, resulting in almost €5,500 on a monthly basis 61. These 
striking high costs raise the question whether resources in healthcare are spend in 
the right manner and if these targeted therapies might even threat sustainability 
of healthcare in general. 
In 2013 the Dutch Melanoma Treatment Registry was founded in order to track 
the performance of Ipilimumab and B-RAF inhibitors 62. Perhaps for other targeted 
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therapies, and also for new surgical and/or radio-therapeutic therapies (like stapler 
material, implants, robotic surgery or proton therapy), implementation of clinical 
audits can fulfill an important role by tracking their performances in ‘real world’ 
clinical practice. As a result, such audits might identify patient groups that do ben-
efit most from these expensive therapies and patient groups that do not, leading to 
more appropriate care and a more sustainable healthcare system. 
Improving clinical audits’ value
Clinical audits traditionally cover clinical outcomes only and are most of the times 
focused on a single procedure or intervention2,3,63, rather than covering the full 
cycle of care. For colorectal cancer surgery, covering the full cycle of care would 
imply that also outcomes of colorectal cancer screening programs and related 
diagnostic procedures should be incorporated, as well as tracking long-term clini-
cal and/or financial outcomes (e.g. 5-year survival rates). In the Netherlands, this 
for example means that the Dutch Gastrointestinal Endoscopy Audit 64 should be 
merged with the Dutch Surgical Colorectal Audit 2 in order to cover both diagnostic 
and treatment processes.
The Dutch Parkinson’s Insight Audit is a good example of a trans-mural audit: clini-
cians, paramedics and general physicians contribute in order to register and im-
prove clinical outcomes and patient related outcome measures (PROMs) 65. In 2015 
the Dutch Society of Doctors for Lung Diseases and Tuberculosis, the Dutch Society 
for Radiotherapy and Oncology, the Dutch Association for Cardio-thoracic Surgeons 
and the Dutch Society for Lung Surgery have formed the Dutch Lung Cancer Audit 
66. This bundled audit covers the entire diagnostic and treatment program for all 
patients with lung cancer in the Netherlands. Currently it is further developed as 
a blue print for ‘whole care cycle’ audits in the Netherlands. Therefore, also the 
DSCA will be transformed in a patient-centered disease specific audit. After its 
multidisciplinary extension in 2017, this new audit will cover the full care cycle of 
colorectal cancer patients in the Netherlands (Dutch Colorectal Cancer Audit). 
Doctors think about colorectal cancer surgery in terms of anastomotic leakage. The 
average patient does not. This is also shown in recent literature describing that 
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patient related outcome measures (PROMs) are not correlated with early preop-
erative events in bariatric surgery, therefore adding new information in treatment 
evaluation 67. A systematic review showed that overall PROMs intervention effect 
sizes were small-to-moderate, however the routine use of PROMs might lead to 
improved symptom control and patient satisfaction, leading to more discussions 
of patient outcomes during consultation 68. This is why future registries should 
incorporate PROMs in order to provide meaningful data for patients 69. Although 
there are some initiatives pioneering integration of PROMs into daily practice 70, 
only a few have adopted it into nationwide programs 71. 
In 2012, a joint taskforce of the Karolinska Institute in Sweden, Harvard Business 
School and the Boston Consulting group initiated the International Consortium 
of Health Outcomes Measurement (ICHOM). The mission of ICHOM is to develop 
a new paradigm focused on health outcomes by defining global standard sets of 
outcome measures. Their aim is to have published standard sets covering more 
than half of the global disease burden by 2017 72. To make sure that outcomes that 
really matter to patients are measured, all their datasets cover besides clinical out-
comes, PROMs as well. The ICHOM colorectal cancer standard set was developed 
in close cooperation with the Dutch Institution for Clinical Auditing (DICA) and 
includes for example outcomes regarding depression, pain, sexual dysfunction and 
health-related quality of life through validated questionnaires 73. DICA has started 
with synchronizing its datasets with the ICHOM standard sets with incorporation of 
PROMs, that are already available for several of its clinical audits.
Finally, embedding costs to an audit will tremendously increase the audit’s value 
as shown in this thesis. The DVBHC-study was the first Dutch Institute of Clinical 
Auditng (DICA) database-based study to be linked in such manner. Performation 
51 and DICA are now making steps to set up more (pilot) costs studies for other 
audits, like the Dutch Upper GI Cancer Audit (DUCA) and the Dutch Audit for Treat-
ment of Obesity (DATO). Since accurate cost calculations are complex and should 
(nationwide) be performed in a uniformly manner, the question remains whether 
this is feasible. However, if healthcare providers can track down their expenses 
they can identify where their provided care is most costly and where it is not. This 
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might reveal the best opportunities for dedicated quality improvement programs 
leading to better outcomes for patients.
Implementation of undeveloped aspects of the ‘value agenda’
Several aspects of the ‘value agenda’ have not been addressed in this thesis. To en-
able the full power of the value agenda, health care providers should also embrace 
the other components as suggested by Michael Porter 40. 
For colorectal cancers we suggest the following items:
Organize into integrated practice units
Colorectal cancer surgeons might seek stronger collaboration with gastroenterolo-
gists, oncologist and radiotherapists and define their common goal: improving the 
outcomes for colorectal cancer patients. That means that, besides participation in 
weekly multidisciplinary meetings, each clinician should feel accountable for not 
only treating the disease, but also for treating the related complications and treat-
ing related circumstances that occur with it. For example, surgeons may choose to 
construct a diverting ileo-stoma (in order to protect the low anastomoses seen in 
rectal cancer 57), however they should be aware of the stoma related complications. 
For example, non-surgical stoma related complications are most of the times seen 
by the stoma care nurse (e.g. failure of appropriate stoma handling, superficial 
wound infections) and/or the internal medicine doctor (e.g. dehydration). Sharing 
information on long-term complications might also provide valuable insights for 
radiotherapist, since they are often not involved during the follow-up period and 
therefore not noticing the long-term toxicity of radiotherapy. Also sharing wards 
and/or out-clinic departments between surgeons and for example gastroenterolo-
gists might lead to a more direct treatment plan with fewer in-hospital referrals. 
Shared accountability might enhance direct feedback (short-loop communication) 
and stimulate relevant discussions between providers. In other hospitals where 
integrated practice units have been introduced, like the Martini Klinik in Hamburg 
74 and the Cleveland Clinic in Ohio75, specialists are aligned around the care of a 
single diagnosis leading to more satisfaction for both patients and doctors.
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Integrate care delivery across separate facilities
First colorectal cancer health care providers should define the scope of services for 
each hospital in a certain region. Community providers can usually work very effec-
tive, like shorter turnover times between surgeries or scheduling more out-clinic 
visits a day, and should ideally focus on less complex procedures/ proceedings. 
Academic centers have traditionally more heavily resourced facilities, therefore 
facilitating the infrastructure for more complex surgeries, like surgery for frail ASA 
III-IV patients. Second, care should be integrated across the different locations. For 
example, after a complex procedure is performed in an academic hospital, post-
operative physiotherapy or stoma care can be performed closer to home. Impor-
tant note is that the IPU still manages the full cycle of care and should for example 
be responsible for developing uniform protocols between the facilities. The Leiden 
University Medical Center is now teaming up with Haaglanden Medical Center 
(HMC), a major hospital in The Hague with multiple locations, in order to create the 
University Cancer Center Leiden|The Hague 76. In the near future, surgeons of both 
institutions will perform surgeries in one of the HMC locations, which will entirely 
focus on treating cancer. In addition, complex colorectal cancer patients (e.g. ASA 
IV patients) of the greater Leiden – The Hague area will be redirected to the Leiden 
University Medical Center. 
Build an enabling information technology platform
This component should powerfully enable all other components of the value 
agenda. Unfortunate information technology (IT) systems are lagging behind in 
most hospitals. In the greater Leiden area, almost all surrounding hospitals run on 
a different IT system, not even mentioning other health care providers like general 
practitioners or nursing facilities. Creating synergies between the different systems 
should catalyze efficient evaluation of treatments and optimize communication 
between different (located) health care providers. For example, treatment of 
colorectal cancer patients might improve when general physicians can easily reach 
out to specialist by leaving notes or pictures of wounds in the electronic patient 
record system in order to decide if a patient has to be redirected to the hospital 
again. 
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Also linking hospitals IT systems to audit IT systems (such as these of the DICA) 
could lead to easy accessible key information for healthcare providers on disease 
specific performances. Moreover, linking IT systems should enable data extraction 
for research and/ or audits. Since data extraction and verification for auditing is 
a time and cost consuming exercise 6,9 this certainly improve the usability of the 
audit. Although a lack of a perfect IT system is well recognized by most providers, 
there is no ideal IT system available in the market yet.
CONCLUSION
This thesis shows that quality of colorectal cancer care is irrevocably associated 
with hospital costs. Although surgical auditing is a cost and time-consuming exer-
cise, it has a strong potential to improve outcomes in healthcare and simultane-
ously reduce hospital costs. Comparing hospital performances on both quality and 
costs makes identification of ‘best practice’ hospitals possible. Moreover, providing 
combined quality-cost outcomes of frail patients or operation techniques provides 
valuable insights where to start quality improvement initiatives. Finally, rewarding 
healthcare providers based on operative risk could be a first step in developing 
powerful reimbursement systems. This all might catalyze the continuous improve-
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Nederland staat qua gezondheid systeem sinds 2008 onafgebroken op nummer 
één in de European Health Consumer Index, een index gericht op het vergelijken 
van Europese gezondheidszorg systemen. De keerzijde van de medaille is dat het 
Nederlandse systeem ook wordt gezien als één van de duurste in Europa. Ontwik-
kelingen omtrent beschikbaarheid van innovatieve geneesmiddelen en vergrijzing 
van de Nederlandse bevolking zullen de doelmatigheid van onze zorg nog verder op 
de proef stellen. Om te bepalen waar en/of welke zorg doelmatig wordt uitgevoerd 
is het bijhouden en analyseren van betrouwbare sturingsinformatie essentieel. 
De Dutch Institute for Clinical Auditing (DICA) is opgericht met als doel kwaliteit 
van zorg transparant te maken, te vergelijken en te verbeteren, door middel van 
metingen en analyses. In 2009 startte de eerste registratie gericht op patiënten 
die werden geopereerd aan een colorectaal carcinoom, de Dutch Surgical Colo-
rectal Audit (DSCA). In de eerste jaren na implementatie van deze registratie werd 
duidelijk dat landelijke richtlijnen omtrent colorectale ingrepen beter werden 
nageleefd en dat postoperatieve complicaties en mortaliteit daalden. Om de finan-
ciële gevolgen hiervan te analyseren werd de Dutch Value Based Healthcare study 
(DVBHC-study) gestart. Voor deze studie zijn van 29 Nederlandse ziekenhuizen de 
DSCA gegevens tussen 2010 en 2012 gekoppeld aan een financiële database. Deze 
database bevat de kostprijzen en alle verrichtingen die per patiënt zijn uitgevoerd 
vanaf de opname tot 90 dagen na ontslag. Doordat de kostprijzen op een uniforme 
manier in alle deelnemende ziekenhuizen zijn gemeten is een vergelijking tussen 
ziekenhuizen en patiënten goed uitvoerbaar. Data van de DVBHC-study is gebruikt 
voor hoofdstukken 3, 4, 5, 7, 8 en 9 van dit proefschrift. 
Chirurgische audits en ziekenhuiskosten
Hoofdstuk 2 van dit proefschrift beschrijft de resultaten van de literatuur studie 
(systematic review) waarbij gekeken is naar de relatie tussen chirurgische registra-
ties en kostenbesparing. Ondanks dat deze relatie vaak wordt aangenomen, waren 
van de meer dan 3.600 onderzochte artikelen slechts zes die deze relatie daadwer-




registreren en terugkoppelen van klinische uitkomsten leidt tot het verminderen 
van complicaties en een reductie in kosten. 
De conclusies van de literatuur studie werden bevestigd door de uitkomsten van de 
DVBHC-studie. Hoofdstuk 3 laat namelijk zien dat in drie jaar tijd (2010-2012) de 
klinische uitkomsten in de deelnemende ziekenhuizen verbeterden (reductie van 
20% in mortaliteit en 29% in gecompliceerd beloop) en dat de kosten in dezelfde 
periode met 9% afnamen (van 14.237 euro per patiënt naar 13.145 euro per pa-
tiënt). Ziekenhuizen die het percentage ernstige postoperatieve complicaties niet 
konden verminderen (n=7) waren in deze periode 390 euro per patiënt duurder uit. 
Ziekenhuizen die het percentage ernstige complicaties zagen afnemen met 0-10% 
(n=12) of meer dan 10% (n=10) waren respectievelijk 1.353 euro en 2.158 euro per 
patiënt goedkoper uit. Wanneer alle deelnemende ziekenhuizen zouden presteren 
als de ‘best practice groep’ zou er in drie jaar tijd meer dan 20 miljoen euro zijn be-
spaard. Deze potentiele besparing is gebaseerd op alleen het chirurgische gedeelte 
van de behandeling van het colorectaal carcinoom, mogelijk is de totale potentiele 
kostenbesparing nog hoger.
Aangezien registratie en verificatie van de klinische uitkomsten een dure en 
tijdrovende bezigheid is, geeft hoofdstuk 4 de business case weer. Hierin wordt 
aangetoond dat, ondanks de tijd en de kosten die gepaard gaan met de registratie 
voor de DSCA, deelname resulteert in een kostenbesparing van 80.393 euro per 
ziekenhuis in drie jaar tijd (voor een ziekenhuis met een gemiddelde van 100 
colorectale resecties). Bovendien gaat dit hoofdstuk in op de enorme financiële 
impact van ernstige complicaties: de 5% duurste patiënten waren verantwoordelijk 
voor 23% van de totale kosten. Daarnaast bedroegen de additionele kosten van 
patiënten met complicaties 30% van het totale budget.
Chirurgische technieken en ziekenhuiskosten
In de laatste twee decennia heeft laparoscopie zich bewezen als een algemeen 
geaccepteerde chirurgische techniek voor de behandeling van het colorectaal 
carcinoom. Recente literatuur laat zien dat laparoscopie gepaard gaat met sneller 
postoperatief herstel en overeenkomstige (lange termijn) oncologische resul-
taten in vergelijking tot open chirurgie. Verrassend genoeg is het kostenverschil 
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tussen deze twee technieken minder vaak en minder goed onderzocht. Meestal 
zijn kostenstudies naar deze twee operatietechnieken verricht als onderdeel van 
een gerandomiseerde klinische studie met een andere primaire onderzoeksvraag. 
Bovendien gaat het vaak om geselecteerde patiëntengroepen bestaande uit pati-
enten die meestal geopereerd zijn door een gespecialiseerd team. Dit maakt dat 
de resultaten moeilijk te extrapoleren zijn naar andere ziekenhuizen. Bovendien 
is onderzoek naar zorgkosten op nationaal niveau uitdagend omdat uniformiteit 
(en transparantie) van kostprijsberekening tussen verschillende ziekenhuizen vaak 
ontbreekt. 
In hoofdstuk 5 zijn de kosten voor electieve chirurgie van niet op afstand gemeta-
staseerde patiënten met een colorectaal carcinoom beschreven (tumor stadium 
T1-3N0-2M0). Om inzicht te krijgen in verschillen tussen de risicogroepen werd 
naast stratificatie voor operatietechniek (open versus laparoscopisch) ook gekeken 
naar tumorlocatie (colon versus rectum), leeftijd (<75jaar versus ≥75jaar) en ASA 
classificatie (ASA I-II versus ASA III-IV). Verschil in ziekenhuiskosten tussen de sub-
groepen varieerde van €10.474 tot €20.865 afhankelijk van het risico profiel van de 
groep. Daarnaast was een laparoscopische operatie goedkoper dan de open chi-
rurgische techniek bij patiënten met een coloncarcinoom. Dit is te verklaren door 
minder complicaties en kortere opnameduur in de laparoscopisch geopereerde 
patiëntengroepen. Laparoscopische ingrepen bij rectum chirurgie resulteerden 
juist in hogere kosten dan de open chirurgische techniek. Een mogelijke verklaring 
hiervoor is dat bij rectumchirurgie in ongeveer 80% van de gevallen een stoma 
werd aangelegd. Waarschijnlijk interfereert het aanleggen van een stoma met de 
voordelen die worden gezien bij laparoscopische colon chirurgie, zoals een kortere 
opnameduur.
Tegenwoordig wordt 70% van de coloncarcinoom resecties en 85% van de rectum-
carcinoom resecties laparoscopisch uitgevoerd. Een relatief nieuwe laparoscopi-
sche techniek is de ‘single port laparoscopy’ (SPL), waarbij de gehele procedure 
via één incisie wordt uitgevoerd. Aangezien er weinig bekend is over de kosten van 
het gebruik van SPL is in hoofdstuk 6 een kostenanalyse beschreven voor SPL en de 




voerd in het Jeroen Bosch Ziekenhuis in ’s-Hertogenbosch. De kosten per patiënt 
van SPL waren over de twee geanalyseerde jaren hoger dan die van conventionele 
laparoscopie. Echter, in het tweede jaar daalden de kosten van SPL, waarmee de 
kosten vergelijkbaar werden met die van de conventionele laparoscopie. Tot slot 
werden er geen significante verschillen gezien betreffende de klinische uitkomsten 
tussen beide groepen. De resultaten in dit hoofdstuk waren gebaseerd op een 
relatieve kleine groep (78 SPL en 189 conventionele laparoscopische procedures) 
en moeten daarom dienen als een stimulans voor nader onderzoek.
Hoog-risico patiënten en ziekenhuiskosten
Het opereren van hoog-risico patiënten gaat vaak gepaard met hoge ziekenhuis-
kosten. In hoofdstuk 7 en hoofdstuk 8 wordt de financiële impact van de twee 
veel voorkomende risicofactoren op een gecompliceerd postoperatief beloop 
geanalyseerd. 
Hoofdstuk 7 beschrijft de impact van obesitas op ziekenhuis kosten van geope-
reerde patiënten met een colorectaal carcinoom. Patiënten met een Body Mass 
Index (BMI) 35 kg/m2 en hoger zijn geassocieerd met significant hogere ziekenhuis 
kosten, tot wel 22 procent, ten opzichte van patiënten met een normaal gewicht. 
Aangezien in de toekomst steeds meer patiënten aan obesitas zullen lijden, bete-
kent dit dat de kosten voor behandeling van colorectale carcinoom patiënten ook 
steeds meer zullen toenemen. Daarnaast beschrijft dit hoofdstuk voor het eerst 
een beschermend effect van pre-obesitas op mortaliteit binnen de colorectale 
chirurgie. Dit wordt de ‘obesitas-paradox’ genoemd waarbij patiënten met een 
BMI tussen de 25 kg/m2 en 30 kg/m2 een lager risico op overlijden hebben dan 
patiënten met een BMI < 25 kg/m2. 
Hoofdstuk 8 beschrijft dat de behandeling van de oudste patiëntengroep (85 jaar 
en ouder) met een colorectaal carcinoom geassocieerd is met een hogere mor-
biditeit en mortaliteit. Echter, de behandeling van deze groep patiënten is niet 
geassocieerd met een stijging in ziekenhuiskosten. Dit is te verklaren doordat er 
voor de oudste patiënten minder middelen werden verbruikt bij het behandelen 
van complicaties (bijvoorbeeld minder ICU ligdagen en kortere re-operatietijden). 
Bovendien bleek er sprake te zijn van een hogere mortaliteit na het optreden van 
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complicaties (‘failure to rescue’) in vergelijking met patiënten jonger dan 85 jaar. 
Een duidelijke verklaring hiervoor is niet uit de DSCA database te halen, maar 
meest waarschijnlijk komt dit doordat de oudste patiënten een beperkte fysieke 
reserve hebben waardoor ze bij complicaties sneller komen te overlijden. Een 
andere verklaring is dat bij deze patiëntengroep vaak gekozen wordt voor een 
minder agressieve behandeling in het geval van complicaties. Omdat de DSCA 
de dagelijkse praktijk reflecteert geven deze conclusies aan dat op korte termijn 
financiële argumenten niet van belang zijn voor de chirurgische behandeling van 
oudere patiënten met colorectaal carcinoom. 
Declaraties en kwaliteitsverbetering
Het huidige Nederlandse declaratiesysteem draagt niet bij aan verbetering van 
kwaliteit van zorg voor de patiënt met een colorectaal carcinoom. Zo wordt bij-
voorbeeld de beloning voor colorectale chirurgische zorg met name bepaald door 
de ligduur van patiënten (langer of korter dan 28 dagen opname) en niet op basis 
van geleverde uitkomsten. 
Naar aanleiding van de grote verschillen in kosten tussen verschillende risico 
groepen (hoofdstuk 5) worden in hoofdstuk 9 twee belangrijke tekortkomingen 
van dit systeem toegelicht. De eerste tekortkoming is dat het huidige systeem 
geen onderscheid maakt tussen hoog dan wel laag risico subgroepen. Hierdoor 
zijn er ziekenhuizen die goedkoper zijn, omdat ze voornamelijk (of uitsluitend) laag 
complexe patiënten behandelen. Daarnaast zijn de ziekenhuizen die zich focussen 
op complexe patiënten en/of complexe ingrepen duurder uit. Dit verschil wordt 
onder andere veroorzaakt door de zogenaamde volumenormen voor bijvoorbeeld 
de rectum chirurgie. Op zichzelf geen slechte ontwikkeling, alleen de beloning is 
hier momenteel niet op afgestemd. De tweede tekortkoming bestaat uit het feit 
dat het huidige systeem ingaat tegen het belonen van kwaliteit. Dit komt doordat 
het huidige systeem perverse prikkels bevat. Immers, op basis van de ‘28 dagen 
regel’ kunnen gecompliceerde patiënten een 200% hoger bedrag opleveren indien 
ze langer dan 28 dagen opgenomen blijven. Daarnaast mag 42 dagen na ontslag 
een nieuw financieel product worden geopend, hetgeen korte termijn denken in 




Een volgende stap naar verdere kwaliteitsverbetering in de gezondheidszorg zou 
het belonen op basis van kwaliteit zijn. Aangezien dit niet met een ‘big bang’ dient 
te gebeuren stellen wij in hoofdstuk 9 als eerste stap het gedifferentieerd belonen 
voor. Hierbij zal dan onderscheid moeten worden gemaakt tussen de verschillende 
risico profielen van patiënten. Zo kan de winstmarge van het ziekenhuis bepaald 
worden door het leveren van superieure kwaliteit, ongeacht de zorgzwaarte van de 
patiënt, hetgeen ziekenhuizen direct stimuleert tot het behalen van hoogwaardige 
uitkomsten. Bovendien zou de eerste stap naar gedifferentieerd belonen eenvou-
dig gemaakt kunnen worden omdat de huidige klinische registraties de benodigde 
patiëntkarakteristieken kunnen aanleveren voor risico profilering. Tot slot kan de 
klinische registratie bijdragen aan het uiteindelijke doel: belonen op basis van 
geleverde kwaliteit.
CONCLUSIE
Dit proefschrift laat zien dat kosten van medische zorg onherroepelijk verbonden 
zijn aan behaalde uitkomsten. Waar ziekenhuizen zich focussen op kwaliteit wor-
den kosten bespaard. Daarnaast ondersteund dit proefschrift dat het gekoppeld 
rapporteren van klinische en financiële uitkomsten krachtige informatie geeft voor 
het starten van initiatieven om de kwaliteit te verbeteren. Het maakt inzichtelijk 
waar en op welke manier zorg het beste kan worden geleverd. Een logisch gevolg 
is dat ook overheid en zorgverzekeraar over gaan tot het belonen van behaalde 
uitkomsten hetgeen als een katalysator voor verder kwaliteitsverbetering zou 
moeten werken.
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